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Abstract 
A GGGGCC repeat expansion in the first intron of chromosome 9 open reading fame 72 
(C9orf72) is the most common known genetic cause of both frontotemporal dementia 
(FTD) and amyotrophic lateral sclerosis (ALS). The repeats are transcribed into RNA in both 
sense and antisense orientations, which aggregates to form RNA foci in cells. Additionally, 
repeat RNA undergoes repeat-associated non-ATG initiated (RAN) translation producing 
dipeptide repeat (DPR) proteins in all six sense and antisense reading frames. This thesis 
aims to dissect RNA and DPR protein gain-of-function mechanisms operating in C9orf72 
FTD/ALS to study their effects in isolation. To achieve this, three classes of DNA constructs 
were generated: 1) pure GGGGCC repeats that produce RNA foci and DPR proteins, 2) 
‘RNA-only’ constructs designed to preclude RAN translation, and 3) ‘protein-only’ 
constructs coding for all five DPR proteins that do not produce GGGGCC repeat RNA. 
Cultured cells transfected with pure and RNA-only repeat constructs exhibited a positive 
correlation between repeat length and both sense and antisense RNA foci formation. 
Additionally, DPR protein subcellular localisation was examined in protein-only repeat 
construct transfected cells and compared to the pathology found in patient brain. A 
collaborative project expressing these constructs in Drosophila showed that arginine-
containing DPR proteins were responsible for C9orf72 repeat toxicity in flies. To determine 
the relevance of the different DPR proteins to human disease, the frequency and 
distribution of DPR protein inclusions was studied in C9orf72 FTD patient brain, using a 
novel automated image analysis protocol. Poly(glycine-arginine) DPR protein inclusion-
bearing neurons also exhibited an increased nucleolar volume compared to inclusion-
negative neurons, confirming recent speculation implicating nucleolar stress in disease 
pathogenesis. These studies in cell culture, Drosophila and human post-mortem brain 
implicate poly(glycine-arginine) as a toxic species within C9orf72 FTD, which may aid in the 
targeting of future treatments for this condition.  
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Chapter 1:  Introduction 
1.1  Overview 
Neurodegeneration has a major impact on quality of life for both patients and those 
around them, and additionally presents an immense economic cost to society in terms of 
health and social care. Advancing age is the biggest risk factor for neurodegenerative 
disease, therefore as the global population grows and the proportion of older individuals 
increases, the number of patients suffering from neurodegenerative diseases is predicted 
to dramatically rise in the coming decades, with dementia cases in the UK predicted to 
double by 2050 (Lewis et al., 2014).  
Our understanding of the genetics and molecular mechanisms behind neurodegeneration 
has greatly increased over the last 25 years. However, available treatment options remain 
limited: current therapies may offer some alleviation of symptoms, but do very little to 
delay disease progression. A more detailed knowledge of pathological mechanisms 
involved in neurodegeneration is therefore necessary to develop more effective therapies. 
In 2011, two international collaborations resulted in the identification of a mutation in the 
gene C9orf72 that causes two neurodegenerative disorders: frontotemporal dementia 
(FTD) and amyotrophic lateral sclerosis (ALS) (DeJesus-Hernandez et al., 2011; Renton et 
al., 2011b). This genetic defect is now considered to be the most common known cause of 
both FTD and ALS in most European and North American populations (Majounie et al., 
2012b), however, how it gives rise to these diseases is not yet fully understood. The work in 
this thesis therefore explores the molecular mechanisms underlying C9orf72 FTD/ALS to 
better understand the disease processes operating in these patients, which may also aid in 
our understanding of neurodegeneration as a whole. 
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1.2  Clinical features of frontotemporal lobar degeneration and 
amyotrophic lateral sclerosis 
1.2.1 Frontotemporal dementia 
Frontotemporal dementia is the most common clinical presentation of a 
neurodegenerative pathology termed frontotemporal lobar degeneration (FTLD), which is 
characterised by the progressive atrophy of the frontal and temporal cortices. The 
prevalence of FTD is estimated to be 15 cases per 100,000 in patients between 45 and 64 
years of age, accounting for between 5 and 15 % of all dementia onset in patients younger 
than 65, rendering it the second most common form of pre-senile dementia after 
Alzheimer’s disease (Rademakers et al., 2012; Ratnavalli et al., 2002). Incidence is equally 
distributed between men and women (Neary et al., 2005). Disease onset most often occurs 
between 45 and 65 years of age, with a median duration of 6-8 years, but can range from 2 
to 20 years (Neary et al., 2005). Genetic factors can play a strong role in the disease, with a 
familial history of FTD or a related disorder present in 25 to 50 % of cases, while the 
remainder of cases are classed as sporadic (Rohrer et al., 2009; Seelaar et al., 2008). FTD 
can be subdivided into several clinical subgroups (Figure 1.1) including behavioural variant 
frontotemporal dementia (bvFTD) and two forms of language variants collectively known as 
primary progressive aphasia (PPA): semantic dementia (SD) and progressive non-fluent 
aphasia (PNFA) (Neary et al., 1998; Sieben et al., 2012). bvFTD is characterised by 
pronounced degeneration in the orbital and mesial frontal lobes, leading to changes in 
personality and social behaviour, loss of empathy, stereotyped behaviour and a lack of 
insight. Patients can present as socially disinhibited and inappropriate, but also as apathetic 
and unemotional. SD results from degeneration of the anterior temporal lobes, and results 
in a loss of conceptual knowledge and impaired comprehension and recollection of words, 
names, objects and faces. Patients increasingly substitute more general terms such as 
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“thing” in place of specific concepts. PNFA also results in a loss of language abilities, arising 
from degeneration of the inferior and insular frontal cortex, but while conceptual 
understanding of words and objects is retained, grammar and speech articulation is 
disrupted, leading to mispronunciation of words and disruption of sentence structure. 
Patients can also present with a mixed clinical syndrome of these subtypes, and aspects of 
both behavioural and language deficits often occur in the advanced stages of disease 
(Neary et al., 1998; Sieben et al., 2012). In addition, some overlap with corticobasal 
syndrome (CBS) and progressive supranuclear palsy (PSP) has been noted in FTD, resulting 
in a presentation of parkinsonism in some patients (Kertesz and Munoz, 2004). However, 
unlike the dementia exhibited in Alzheimer’s disease, memory functions in FTD cases are 
usually left intact.  
1.2.2 Amyotrophic lateral sclerosis 
Motor neuron disease (MND) is a group of conditions involving progressive motor neuron 
loss, the most prevalent of which is amyotrophic lateral sclerosis (ALS), which accounts for 
more than 75 % of all MND cases (Figure 1.1). Prevalence is approximately 5.2 cases per 
100,000, with men 1.2 to 1.5 times more likely than women to be diagnosed (Logroscino et 
al., 2010). ALS is characterised by the degeneration of both the upper motor neurons 
within layer V of the motor cortex, and lower motor neurons in the brainstem and anterior 
horn of the spinal cord. Clinically, this manifests as fasciculations, spasticity, and 
progressive wasting and weakness within voluntary muscles, most frequently beginning 
with symptoms in the limb muscles (65 %), but can also present with bulbar dysfunction (30 
%), while a minority of cases experience respiratory onset (5%) (Logroscino et al., 2010). 
Other forms of MND include progressive muscular atrophy (PMA), in which degeneration 
occurs solely in the lower motor neurons, primary lateral schlerosis (PLS) in which only the 
upper motor neurons are affected, and progressive bulbar palsy (PBP) which principally 
affects the bulbar nuclei. 
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ALS disease course is frequently very rapid, but can vary considerably. Disease duration is 
less than 3 years in over 60 % of patients, while 10 % of patients survive more than 8 years, 
and rare cases have survived 40 years (Kiernan et al., 2011). 5 to 10 % of patients have a 
familial history of the disease, with the remaining cases arising sporadically. The average 
age of disease onset is between 47 to 52 years for familial ALS and 58 to 63 years for 
sporadic ALS (Kiernan et al., 2011). A number of environmental factors have been 
implicated in a higher risk of ALS onset, including smoking, high levels of physical activity, 
and exposure to pesticides and electromagnetic radiation (Alonso et al., 2010; Sutedja et 
al., 2009b), Additionally, a neurotoxic amino acid beta-methylamino-L-alanine (BMAA) 
produced by cyanobacteria is hypothesised to cause ALS when ingested in high quantities, 
leading to a high incidence of ALS in parts of the world where it enters the food chain 
(Bradley and Mash, 2009). A higher incidence of ALS has also been noted in certain 
professions including military workers, soccer players and health workers (Sutedja et al., 
2009a), however larger population based studies are required to confirm these 
associations.       
 
Figure 1.1 Clinical subtypes of frontotemporal lobar degeneration and motor neuron disease 
FTD: frontotemporal dementia, MND: motor neuron disease, ALS: amyotrophic lateral sclerosis, PMA: 
progressive muscular atrophy, PLS: primary lateral sclerosis, PBP: progressive bulbar atrophy, bvFTD: 
behavioural variant frontotemporal dementia, PPA: primary progressive aphasia, SD: semantic dementia, PNFA: 
progressive non-fluent aphasia 
MND 
ALS PMA PLS PBP 
FTD 
bvFTD PPA 
SD PNFA 
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1.2.3 Clinical overlap 
While FTD and ALS were historically considered as separate entities, it has been 
increasingly recognised that these two neurodegenerative disorders are related, and in fact 
form part of a single pathological continuum (Lillo and Hodges, 2009). As many as half of all 
ALS patients exhibit some degree of behavioural or cognitive impairment, while the 
severity of these symptoms is severe enough to warrant a classification of FTD in 15 to 18 % 
of patients (Lomen-Hoerth et al., 2003; Ringholz et al., 2005). Additionally, around 40 % of 
FTD patients exhibit mild motor system dysfunction such as muscle wasting, muscle 
weakness and infrequent fasciculations, with 12 to 15 % of FTD patients exhibiting motor 
dysfunction that meets the criteria for a diagnosis of ALS (Burrell et al., 2011; Lomen-
Hoerth et al., 2002). Motor neuron deficits observed in combined FTD-ALS most often 
resemble classical ALS, while cognitive changes observed in FTD-ALS are typically akin to 
bvFTD, with rare cases of SD or PNFA with ALS also reported (Van Langenhove et al., 2012). 
FTD-ALS patients often have a poor prognosis, with an average survival 2-3 years following 
symptom onset (Sieben et al., 2012). Heritability of  FTD-ALS is also high, with 50 % 
considered familial, suggesting a strong genetic component (Sieben et al., 2012). In 
accordance with this clinical overlap, recent studies have increasingly uncovered common 
neuropathology (Section 1.3) and genetics (Section 1.4) underlying the coincidence of these 
disorders. 
1.2.4 Treatment 
Currently, the only treatment for ALS is riluzole, an inhibitor of presynaptic glutamate 
release, which prolongs median survival in patients by a modest two to three months and 
yields a 9 % increase in patient survival for one year (Miller et al., 2007). Regrettably, there 
are presently no disease modifying therapies available for FTD. Disease management 
usually consists of symptom treatment only, with a focus on palliative care, building 
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support networks and psychiatric services. Some Alzheimer’s disease treatments for 
improving cognitive impairment have been tested in FTD patients, but little benefit has 
been observed so far, with some interventions even observed to worsen behavioural 
symptoms (Vossel and Miller, 2008). 
1.3  Pathological features of FTLD and ALS 
FTLD refers to the pathological processes that underlie the clinical presentation of FTD. 
Both FTLD and ALS pathologies are characterised by the formation of aberrant protein 
aggregates within neurons and glia, and pathological subtypes can be classified according 
to the primary protein components present within these aggregates. FTLD cases can be 
classified under four main categories: FTLD-tau, FTLD-TDP, FTLD-FUS and FTLD-UPS, while 
ALS cases can be classified under three main categories: ALS-TDP, ALS-SOD1 and ALS-FUS.  
1.3.1 FTLD-TDP and ALS-TDP 
In 2006, transactive response (TAR) DNA-binding protein 43 (TDP-43) was discovered to be 
the major pathological protein in the majority of tau-negative, SOD1-negative, ubiquitin-
positive inclusions in both FTLD and ALS, accounting for approximately 50 % of all FTLD 
cases and over 95 % of all ALS cases (Mackenzie et al., 2007; Neumann et al., 2006). In 
addition, mutations in the TARDBP gene cause approximately 3 % of familial ALS and rare 
cases of FTD (Lattante et al., 2013).  TDP-43 is a highly evolutionarily conserved member of 
the heterogeneous ribonucleoprotein (hnRNP) family, with roles in splicing regulation and 
transcription, which it mediates via its two RNA recognition motifs (RRMs) and its glycine-
rich low-complexity c-terminal region (Mackenzie et al., 2010b). TDP-43 has been reported 
to bind over 6000 RNA targets in the brain, often targeting transcripts with very long 
introns and GU enriched sequences (Polymenidou et al., 2011). Under normal conditions, 
TDP-43 is primarily localised to the nucleus, but shuttles between the nucleus and the 
cytoplasm. However, in some forms of ALS and FTLD, TDP-43 is depleted from the nucleus 
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and forms abnormally phosphorylated and ubiquitylated aggregates in the cytoplasm, with 
truncated C-terminal fragments of the protein also observed (Mackenzie et al., 2010b). It is 
not yet clear how TDP-43 mislocalisation might lead to neurodegeneration, but it is thought 
to be due to a combination of loss of protein function in the nucleus, and gain of toxic 
function of the cytoplasmic aggregates. A loss of function mechanism is supported by 
studies in human cell lines in which a loss of viability was observed following knock-down of 
TDP-43 (Ayala et al., 2008; Iguchi et al., 2009), as well as in Drosophila and mouse models, 
in which motor defects were reported in response to reduced TDP-43 expression (Feiguin 
et al., 2009; Kraemer et al., 2010). Over expression of human TDP-43 was also shown to 
result in TDP-43 cytoplasmic inclusions and neurodegeneration in Drosophila, mouse and 
rat models (Li et al., 2010; Tatom et al., 2009; Wils et al., 2010).  
In ALS cases, neuronal cytoplasmic inclusions of TDP-43 are observed primarily within 
neurons and glia within the motor cortex, spinal cord, and brainstem motor nuclei, as well 
as the white matter tracts associated with these areas (Mackenzie et al., 2007). Within 
FTLD, the distribution of TDP-43 pathology differs between patients and between different 
clinical or genetic subtypes. FTLD-TDP pathology can be categorised into four broad 
profiles: A, B, C and D (Mackenzie et al., 2011). Type A is characterised by frequent 
neuronal cytoplasmic inclusions and short dystrophic neurites positive for TDP-43, primarily 
within layer 2 of the neocortex. Type B TDP-43 pathology is exemplified by moderate 
neuronal cytoplasmic inclusions across all cortical layers, with rare dystrophic neurites. 
TDP-43 type C pathology is characterised by frequent long dystrophic neurites with 
infrequent neuronal cytoplasmic inclusions, predominantly within layer 2 of the neocortex. 
Finally, type D pathology is exhibited by patients with inclusion body myopathy with 
Paget’s disease of bone and frontotemporal dementia (IBMPFD), presenting as frequent 
short dystrophic neurites, frequent neuronal intranuclear inclusions, and rare neuronal 
cytoplasmic inclusions, throughout all cortical layers. 
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1.3.2 FTLD-FUS and ALS-FUS 
Fused in sarcoma (FUS) was identified as the primary component of the majority of non-
TDP-43, ubiquitinated inclusions in FTLD and ALS, accounting for approximately 9 % of all 
cases of FTLD, and rare cases (less than 1 %) of ALS (Kwiatkowski et al., 2009; Vance et al., 
2009). Conversely, mutations in FUS are observed to cause around 4 % of familial ALS cases, 
and rare cases of FTLD (Van Langenhove et al., 2010). Previously identified as a fusion 
oncogene, FUS is a highly conserved RNA and DNA binding protein with multiple binding 
domains including an RNA recognition motif, a transcriptional activation domain, a zinc 
finger motif and several glycine-arginine-rich “RGG” nucleic acid-binding domains (Deng et 
al., 2014). While the precise function of FUS has not been elucidated, it is known to be 
involved in transcriptional regulation, and has also been implicated in DNA damage repair 
(Deng et al., 2014). In a similar manner to TDP-43, FUS predominantly localises to the 
nucleus under normal conditions and shuttles between the nucleus and the cytoplasm, but 
forms frequent cytoplasmic and infrequent intranuclear inclusions under pathological 
conditions (Deng et al., 2014). Unlike TDP-43, aberrant phosphorylation or cleavage of FUS 
is not observed. FUS pathology has additionally been reported in other neurodegenerative 
disorders including many forms of polyglutamine disease (Doi et al., 2008).  
1.3.3 ALS-SOD1 
Superoxide dismutase 1 (SOD1) is an anti-oxidant enzyme whose principal function is the 
conversion of reactive oxygen species to hydrogen peroxide and oxygen, protecting the cell 
against oxidative stress. Mutations in SOD1 were first reported to cause ALS in 1993 (Rosen 
et al., 1993), and it was later found that misfolded SOD1 forms cytoplasmic aggregates in 
these patients (Kato et al., 2000). Patients with SOD1 mutations are now known to account 
for around 20 % of familial ALS cases around 1 % of sporadic ALS cases (Pasinelli and 
Brown, 2006). For over a decade, mutations in SOD1 remained the only known cause of 
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ALS, and were therefore studied intensely, with numerous transgenic mouse models 
generated, however the mechanism by which SOD1 causes ALS still remains elusive 
(McGoldrick et al., 2013). SOD1 aggregate formation is not ordinarily observed in other 
forms of ALS, and the TDP-43 inclusions observed in the majority of other familial and 
sporadic ALS are not observed in SOD1 patients (Mackenzie et al., 2007), suggesting that an 
atypical molecular mechanism may be operating in these patients. 
1.3.4 FTLD-tau 
The microtubule associated protein tau ordinarily exists in a monomeric, soluble form 
within cells, and is thought to play a vital role in the assembly and stabilisation of 
microtubules (Spillantini and Goedert, 2013). Tau has been observed to localise to neuronal 
axons, and is thought to play a regulatory role in vesicular transport along microtubules 
(Spillantini and Goedert, 2013). In just under half of all FTLD cases, tau protein accumulates 
in an insoluble, hyperphosphorylated, filamentous form within neurons (Sieben et al., 
2012). Aggregation of the tau repeat domain has been observed to be toxic to cultured 
cells (Khlistunova et al., 2006), however the mechanism by which this occurs has not been 
fully characterised. Mutations in the MAPT gene that encodes tau have also been observed 
to cause between 8 and 43 % of familial FTLD, depending on the population examined  
(Rademakers et al., 2004). Collectively, diseases involving tau neuropathology, including 
FTLD and Alzheimer’s disease, are termed tauopathies. FTLD-tau disease subtypes include 
Pick’s disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and 
argyrophilic grain disease (AGD). A number of differentially spliced isoforms of the MAPT 
gene encoding tau exist, which can contain either three (3R) or four (4R) repeating 
microtubule-binding domains, and either zero (0N), one (1N) or two (2N) N-terminal 
inserts, which mediate interaction of tau protein with the plasma membrane. Insoluble tau 
in different tauopathies may have a differing composition of tau isoforms, and can differ 
between patients in FTLD (Spillantini and Goedert, 2013). 
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1.3.5 FTLD-UPS 
Prior to the identification of TDP-43 and FUS as major inclusion components in some FTLD 
cases, all patients exhibiting ubiquitinated inclusions were classified in a single “FTLD-U” 
category. While most FTLD-U cases are now reclassified as FTLD-TDP or FTLD-FUS, a 
number of cases remain for which other components of the ubiquitinated inclusions have 
not been identified, including cases with familial FTD linked to mutations in the CHMP2B 
gene, which were observed to be negative for both TDP-43 and FUS (Holm et al., 2009, 
2007). These cases are now re-classified as FTLD-UPS (Mackenzie et al., 2010a). 
1.4  Genetics 
Mutations within a number of genes have been found to cause familial forms of ALS, FTLD 
or both of these pathologies, summarised in Table 1.1 and Figure 1.2. As detailed in the 
previous section (1.3), mutations in all of the genes that encode the major aggregating 
proteins in ALS and FTLD, including MAPT, TARDBP, FUS and SOD1 cause a subset of familial 
ALS and FTD cases. In addition, a number of mutations in other genes have also been found 
 
Figure 1.2 Genetic causes of familial FTD and familial ALS 
 
Charts represent the approximate proportion of total familial FTD and familial ALS cases caused by mutations in 
individual genes. Familial FTD data was derived from: (Rademakers et al., 2012). Familial ALS data was derived 
from: (Renton et al., 2014). 
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to cause these pathologies, the most prevalent of which include C9orf72 (which will be 
discussed in detail from section 1.5 onwards), and GRN.  
GRN encodes progranulin, a growth factor precursor implicated in the promotion of 
neuronal growth and survival, as well as processes such as inflammation and wound repair 
(Ahmed et al., 2007). Mutations in GRN result in a loss of protein function, frequently by 
premature termination of the protein sequence (Gass et al., 2006), which causes between 3 
and 26 % of all familial FTLD cases, depending on the population examined (Gijselinck et al., 
2008). GRN mutations result in an FTLD-TDP type A pathology, and either bvFTD or PNFA 
(Sieben et al., 2012). However it is not yet fully understood how loss of progranulin 
function leads to the onset of FTLD. 
The remaining genes are mutated in small numbers of ALS and FTLD patients, but share 
common themes that underline potentially important mechanisms within these disorders. 
Several genes play a role in autophagy and protein clearance, including VCP, CHMP2B, 
UBQLN2, SQSTM1, and OPTN, emphasising the importance of protein homeostasis and 
degradation in ALS and FTLD. A number of the mutated genes also play a role in RNA 
and/or DNA metabolism, including HNRNPA1, TAF15, SPG11 and SETX, a function also 
played by aggregating proteins FUS and TDP-43, highlighting an important role for 
transcriptome changes in ALS and FTLD. 
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Gene symbol Gene name Protein function 
Approx. 
frequency in 
familial ALS % 
Approx. 
frequency in 
familial FTD % 
Aggregating 
protein 
Reference 
FTD only 
MAPT Microtubule associated protein tau Cytoskeleton - 8 - 43 % Tau 
(Hutton et al., 1998) 
(Rademakers et al., 2004) 
GRN Progranulin 
Trophic factor 
Inflammation 
- 3 – 26 % TDP-43 
(Cruts et al., 2006) 
(Baker et al., 2006) 
(Gijselinck et al., 2008) 
Predominantly FTD 
VCP Valosin-containing protein Autophagy Rare Rare TDP-43 
(Watts et al., 2004) 
(Johnson et al., 2010) 
CHMP2B Charged multivesicular body protein 2B 
Endosomal trafficking 
Autophagy 
Rare Rare p62 
(Skibinski et al., 2005) 
(Parkinson et al., 2006) 
FTD / ALS 
C9orf72 Chromosome 9 open reading frame 72 
Unknown (implicated 
in vesicular trafficking) 
21 – 56 % 14 – 48 % TDP-43 
(DeJesus-Hernandez et al., 2011) 
(Renton et al., 2011a) 
(Majounie et al., 2012b) 
UBQLN2 Ubiquilin 2 Autophagy Rare Rare TDP-43, FUS (Deng et al., 2011) 
HNRNPA1 Heterogenous nuclear ribonucleoprotein A1 RNA metabolism Rare Rare  (Kim et al., 2013) 
HNRNPA2B1 
Heterogenous nuclear ribonucleoprotein 
A2/B1 
RNA metabolism Rare Rare  (Kim et al., 2013) 
SQSTM1 Sequestosome 1 (p62) Autophagy Rare Rare  
(Fecto, 2011) 
(Le Ber et al., 2013) 
SIGMAR1 Sigma non-opioid intracellular receptor 1 
Endoplasmic reticulum 
lipid rafts 
Rare Rare  (Luty et al., 2010) 
 
Table 1.1 Details of genetic mutations found in FTD and ALS (continued overleaf)  
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Gene symbol Gene name Protein function 
Approx. 
frequency in 
familial ALS % 
Approx. 
frequency in 
familial FTD 
Aggregating 
protein 
Reference 
Predominantly ALS 
FUS Fused in sarcoma DNA/RNA metabolism 4 % Rare FUS 
(Vance et al., 2009) 
(Kwiatkowski et al., 2009) 
(Van Langenhove et al., 2010) 
TARDBP TAR DNA binding protein DNA/RNA metabolism  3 % Rare TDP-43 
(Neumann et al., 2006) 
(Lattante et al., 2013) 
ALS only 
SOD1 Superoxide dismutase 1 Antioxidant 20 % - SOD1 
(Rosen et al., 1993), 
(Pasinelli and Brown, 2006) 
OPTN Optineurin Autophagy Rare - TDP-43 (Maruyama et al., 2010) 
ANG Angiogenin 
Blood vessel 
formation 
Rare - TDP-43 (Greenway et al., 2006) 
VAPB 
VAMP (vesicle-associated membrane 
protein)-associated protein B 
Vesicular trafficking Rare - TDP-43 (Nishimura et al., 2004), 
PFN1 Profillin 1 Actin dynamics Rare -  (Wu et al., 2012) 
TAF15 
TATA box binding protein (TBP)- 
associated factor 15 
RNA metabolism Rare -  (Couthouis et al., 2011) 
DAO D-amino-acid oxidase Peroxisomal enzyme Rare -  (Mitchell et al., 2010) 
ALS2 Amyotrophic lateral sclerosis 2 Endosomal trafficking Rare -  (Hadano et al., 2001) 
SPG11 Spastic paraplegia 11 DNA damage repair Rare -  (Daoud et al., 2012) 
SETX Senataxin DNA/RNA metabolism Rare -  (Chen et al., 2004), 
FIG4 Phosphoinositide 5-phosphatase Lipid metabolism Rare -  (Chow et al., 2009) 
 
Table 1.2 Details of genetic mutations found in FTD and ALS (continued from previous page)
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1.5  The C9orf72 repeat expansion mutation 
1.5.1  Identification of a hexanucleotide repeat expansion mutation in C9orf72 
In order to understand more about the genetic basis for the observed association between 
ALS and FTD, genome-wide linkage analysis studies were carried out by several groups on 
kindreds who exhibited concomitant ALS and FTD within single individuals or within 
different individuals in the same family. Collectively, these reports identified a minimum 
linkage region of 3.7 Mb on chromosome 9p21 conferring FTD/ALS susceptibility to 
individuals within these families (Boxer et al., 2011; Gijselinck et al., 2010; Le Ber et al., 
2009; Luty et al., 2008; Morita et al., 2006; Pearson et al., 2011; Valdmanis et al., 2007; 
Vance et al., 2006). Concurrently, several independent genome-wide association studies 
(GWAS) performed on both ALS patients (Laaksovirta et al., 2010; Shatunov et al., 2010; 
van Es et al., 2009) and FTD patients (Van Deerlin et al., 2010) highlighted a risk haplotype 
in the same linkage region and narrowed the area of interest to a 232 Kb linkage 
disequilibrium block containing three genes: MOBKL2B, INFK and C9orf72. Initial 
sequencing of the protein coding regions of these genes found no evidence for exonic 
mutations linked to the pathology (Pearson et al., 2011), implicating non-coding DNA 
within this region in FTD/ALS susceptibility. Several large-scale international collaborations 
finally resulted in the identification of a GGGGCC hexanucleotide repeat expansion within 
the first intron of C9orf72 (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; Renton et 
al., 2011a), which initially evaded detection in part due to the difficulty in sequencing this 
repetitive, GC-rich sequence. 
1.5.2 Genetic characteristics of the C9orf72 repeat expansion 
Three transcript variants are generated from the C9orf72 gene: variants 1 and 3 encode a 
481 amino acid long protein isoform C9orf72a, while variant 2 encodes a shorter 222 amino 
acid isoform C9orf72b (Figure 1.3a). The repeat expansion is present within the promotor  
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Figure 1.3 The C9orf72 repeat expansion 
 
A) The C9orf72 gene locus and transcript variants. Red star represents the locus of the GGGGCC repeat 
expansion. Numbered rectangles represent coding (white) and non-coding (blue) exons in the C9orf72 gene.  
Adapted from (Woollacott and Mead, 2014). B) Example electropherograms of repeat-primed PCR reactions of 
expanded and normal C9orf72 repeats. Adapted from (Rademakers et al., 2012). 
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region of variant 1, but falls within the first intron of variants 2 and 3, between non-coding 
exons 1a and 1b, permitting the transcription of the repeat expansion itself into RNA in 
these transcripts. 
Normal individuals exhibit a non-expanded repeat size of between 2 and around 30 
GGGGCC units in C9orf72, with two repeats most frequently observed (DeJesus-Hernandez 
et al., 2011; Ratti et al., 2012), while repeat expansion carriers most often exhibit between 
800 and 4400 repeats (Beck et al., 2013). However, the lower limit of pathogenic repeat 
lengths has not been definitively determined, with some mild cognitive dysfunction 
reported in patients with intermediate length repeats (Byrne et al., 2014; van der Zee et al., 
2013). Expanded repeats are also subject to extreme somatic instability and differ in length 
between different patient tissues, and from generation to generation, with some recent 
evidence suggesting increased repeat length and disease anticipation in parent to child 
transmission (Gijselinck et al., 2015).  
Due to the repetitive and GC-rich nature of the repeat expansion, sequencing an expansion 
comprised of thousands of thousands of repeats in its entirety is unfeasible. Presence of 
the repeat expansion is therefore commonly determined using repeat-primed PCR, which 
uses three primers: a forward and a reverse primer targeted to the sequences flanking the 
repeats, plus an additional reverse primer complimentary to the repeat sequence itself. In a 
large GGGGCC repeat expansion, the repeat primer can bind at numerous positions, and so 
yields an array of different length amplification products that diminish in concentration 
with increasing length to give a characteristic saw-tooth amplification pattern indicating 
the presence of a repeat (Figure 1.3b). However, repeat sequences can only be successfully 
amplified up to a maximum of approximately 60 repeats, meaning that while the presence 
or absence of a large expansion can be determined, other techniques are necessary to 
determine its length. To achieve this, Southern blotting can be carried out to approximate 
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the repeat size or range of repeat sizes present in patient tissue. This can be accomplished 
by rigorous restriction enzyme digestion of genomic patient DNA, followed by 
electrophoretic resolution and transfer of the digested DNA and subsequent hybridisation 
with a labelled DNA probe complimentary to the repeat expansion (Beck et al., 2013).  
1.5.3 Epidemiology of C9orf72 FTD/ALS 
The hexanucleotide repeat expansion in C9orf72 is presently the most prevalent known 
cause of ALS, FTD, or combined FTD/ALS, exceeding the incidence of any other pathological 
mutation. The expansion is most frequently found in European and North American 
Caucasian populations, with a particularly high frequency in certain Nordic populations 
such as Finland, Sweden and Denmark, with 28 % of FTD and 29 % of ALS patients in 
Finland found to be positive for the expansion (Renton et al., 2011a; van der Zee et al., 
2013). In the UK, 11 % of FTD and 8 % of ALS patients have been found to be positive for 
the expansion (Majounie et al., 2012b). Conversely, the expansion is rare within East Asian 
populations, with the exception of infrequent hubs of high prevalence such as in the Kii 
peninsula in Japan (Ishiura et al., 2012). Information about prevalence in South Asian, 
South American, African and Middle Eastern populations is currently lacking (Woollacott 
and Mead, 2014). The high prevalence of the repeat expansion in specific Northern 
European populations combined with the fact that patients with the repeat expansion 
share a common risk haplotype on adjacent regions of chromosome 9 has led some groups 
to hypothesise that the mutation arose from a single expansion event in a European 
ancestor six thousand years ago (Smith et al., 2013). However, other studies have disputed 
the existence of a single common ancestor, instead suggesting that de novo expansion of 
the repeats is more favourable on the risk haplotype, resulting in multiple expansion events 
in unrelated individuals throughout history (Beck et al., 2013; Dobson-Stone et al., 2013)   
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1.5.4 Clinical features of C9orf72 FTD/ALS 
A large degree of clinical diversity is observed in individuals bearing the C9orf72 repeat 
expansion, and patients can develop ALS, FTD or combined FTD/ALS. Patient series with 
mixed FTD/ALS disease course exhibit a notably high C9orf72 mutation frequency of up to 
88 %, depending on the cohort (Cruts et al., 2013). While the C9orf72 repeat expansion is 
present in a higher proportion of familial cases of ALS and FTD, it is also found in some 
sporadic cases, which is of particular importance in ALS wherein 90 % of all cases are in 
patients lacking a family history of the disease. These non-familial cases may be due to de 
novo expansion of the unstable repeats between generations, however many apparently 
sporadic cases may be explained by the fact that the pathology does not manifest in all 
individuals with the mutation, and therefore the presence of the expansion in previous 
generations can be masked. Disease penetrance in patients with the C9orf72 repeat 
expansion is  almost complete, with 50 % penetrance in ALS and FTD patients at 58 years of 
age, and almost full penetrance by 80 years of age (Majounie et al., 2012b). However, 
disease onset has been observed in patients in their ninth decade, and healthy elderly 
individuals have been found to carry the expansion (Majounie et al., 2012b). Conversely, 
disease onset has also been observed in patients as young as 27 years old (Majounie et al., 
2012b). Disease duration is heavily dependent on the manifestation of disease subtype in 
each patient. C9orf72 ALS patients were found to have an average duration of 33 ± 2 
months (mean ± standard error) by one study (Millecamps et al., 2012), while C9orf72 FTD 
patients characteristically experience a much longer disease course similar to other 
inherited forms of FTD, with an average duration of 74 ± 11 months (mean ± standard 
error) observed by another report (Van Langenhove et al., 2013).  
Motor neuron disease exhibited by patients with the C9orf72 repeat expansion is almost 
exclusively ALS, with rare incidences of PMA, PLS or PBP (Snowden et al., 2012; Stewart et 
al., 2012). While most C9orf72 ALS cases exhibit limb-onset, a higher proportion of bulbar-
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onset is observed in patients with the repeat expansion compared to those without 
(Majounie et al., 2012b). Minor cognitive dysfunction not sufficiently severe to be classed 
as FTD is also more common in C9orf72 ALS patients compared to those without the repeat 
expansion (Byrne et al., 2012).  
C9orf72 FTD cases present with bvFTD in 87 % of cases, with a minority of patients 
presenting with PNFA and rare incidences of SD reported (Boeve et al., 2012; Van 
Langenhove et al., 2012). Psychiatric symptoms such as anxiety, agitation and psychosis are  
more frequently observed in C9orf72 FTD patients compared to patients without the 
repeat expansion (Mahoney et al., 2012; Snowden et al., 2012), and a proportion of 
C9orf72 FTD patients additionally present with some Parkinsonism, with an akinetic-rigid 
syndrome or tremor observed (Boeve et al., 2012).  
Rarely, C9orf72 repeat expansions have been observed in patients with Parkinson’s disease 
and Alzheimer’s disease: in a study examining a large Parkinson’s Disease cohort, 0.055 % 
of patients were found to carry the expansion, all of whom presented with atypical 
Parkinson’s Disease with elements of cognitive decline (Theuns et al., 2014). In a cohort of 
patients diagnosed with Alzheimer’s Disease, less than 1 % of patients carried the C9orf72 
repeat expansion, and several of the patients presented with ubiquitin-positive inclusions 
characteristic of FTD when subsequent post-mortem examination was carried out 
(Majounie et al., 2012a). These results suggest that Parkinson’s disease and Alzheimer’s 
disease do not represent major manifestations of the C9orf72 repeat expansion, and some 
of the reported cases may be attributable to misdiagnosis of FTD presenting with atypical 
symptoms. 
1.5.5 Neuroanatomical features of C9orf72 FTD/ALS 
Neuroimaging studies have revealed some characteristic differences in the distribution of 
brain atrophy in patients with the C9orf72 repeat expansion compared to patients with 
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other forms of FTD and ALS. Magnetic Resonance Imaging (MRI) studies of FTD patients 
found that C9orf72 FTD patients were associated with a symmetric pattern of frontal, 
temporal and parietal cortical atrophy in contrast to the asymmetric atrophy exhibited by 
patients with GRN mutations (Mahoney et al., 2012; Whitwell et al., 2012). C9orf72 FTD 
patients also exhibited an unusual degree of cerebellar and thalamic atrophy compared to 
other FTD subtypes, with less temporal lobe involvement observed compared to MAPT 
mutation bearing patients (Mahoney et al., 2012; Whitwell et al., 2012). ALS patients with 
the C9orf72 repeat expansion were also observed to exhibit a distinct pattern of atrophy 
compared to other ALS patients, with C9orf72 ALS patients exhibiting a greater degree of 
extramotor abnormality within frontal cortical, temporal cortical and thalamic regions, in 
accord with the higher incidence of cognitive dysfunction observed in these patients 
compared to other types of ALS (Bede et al., 2013; Byrne et al., 2012).    
1.5.6 Neuropathology in C9orf72 FTD/ALS 
Cases with the C9orf72 repeat expansion typically exhibit TDP-43 pathology, including 
neuronal and glial cytoplasmic inclusions, diffuse cytoplasmic TDP-43, dystrophic neurites 
and infrequent neuronal intranuclear inclusions (Mackenzie et al., 2014). In patients with 
pure ALS, prominent TDP-43 pathology is found in upper motor neurons, brainstem and 
spinal cord, while patients with pure FTLD show abundant TDP-43 pathology in the frontal 
and temporal cortex, and patients with combined FTLD-ALS exhibit a degree of pathology in 
both of these areas. A good correlation is usually observed between TDP-43 inclusion 
burden and the degree of degeneration in each brain region (Mackenzie et al., 2013). 
In cases that exhibit some degree of cortical TDP-43 pathology, an FTLD-TDP type B 
pathology is most often observed, with neuronal cytoplasmic inclusions present throughout 
the cortex and infrequent neuronal intranuclear inclusions and dystrophic neurites. A 
smaller subset of patients also present with FTLD-TDP type A pathology, which is typified by 
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small neuronal cytoplasmic inclusions and frequent, short dystrophic neurites 
predominantly in layer II of the neocortex, with some neuronal intranuclear inclusions. 
FTLD-TDP type A pathology is more frequently found in patients with a pure FTLD 
pathology, while type B is frequently associated with a mixed FTLD-ALS pathology. Rare 
C9orf72 repeat expansion cases have been found that lack TDP-43 pathology: one C9orf72 
FTLD case from a Belgian cohort was found to be absent for TDP-43 inclusions (Gijselinck et 
al., 2012), while another patient in the UK exhibited FTLD-tau pathology with no TDP-43 
inclusions (Snowden et al., 2012). Additionally, several C9orf72 repeat expansion bearing 
patients who died prematurely have been studied, and have been observed to exhibit very 
sparse or no TDP-43 pathology (Baborie et al., 2014; Proudfoot et al., 2014)    
In addition to TDP-43 inclusions, C9orf72 FTD/ALS patients also exhibit characteristic TDP-
43 negative, p62 positive inclusions, which can take the form of “star-like” cytoplasmic 
inclusions or “dot-like” intranuclear inclusions (Al-Sarraj et al., 2011). These inclusions are 
present in most brain regions and in the spinal cord, with particularly high abundance 
throughout the cortex, cerebellum and hippocampus (Schludi et al., 2015). In particular, 
cerebellar p62 positive inclusions are a defining hallmark of C9orf72 pathology that are 
rarely observed in any other FTD or ALS disease subtypes (Al-Sarraj et al., 2011). In 2013, it 
was found that these inclusions also contain five different proteins consisting of repeating 
dipeptide units, translated from the repeat expansion itself by a novel process called 
repeat-associated, non-ATG initiated (RAN) translation, which will be discussed in more 
detail in section 1.6.3. A subset of these aggregates have additionally been found to 
contain the RNA binding protein hnRNP A3 (Mori et al., 2013b). 
C9orf72 FTD/ALS patient neurons also exhibit aggregates of RNA termed RNA foci 
comprised of sense GGGGCC and antisense CCCCGG RNA repeats transcribed from the 
expansion (Cooper-Knock et al., 2015b, 2014; Donnelly et al., 2013; Gendron et al., 2013; 
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Lagier-Tourenne et al., 2013; Lee et al., 2013; Mizielinska et al., 2013; Zu et al., 2013), 
which accumulate within the nucleus and to a lesser extent in the cytoplasm (Mizielinska et 
al., 2013). The role of RNA foci in C9orf72 FTD/ALS will be discussed more in section 1.6.2.   
1.6  Potential disease mechanisms in C9orf72 FTD/ALS 
Three main mechanisms of toxicity have been implicated in C9orf72 FTD/ALS pathology 
(Figure1.4): 1) a loss of C9orf72 protein function due to disruption of gene transcription by 
the repeats (section 1.6.1), 2) a gain-of-RNA function as a result of transcription of the 
repeat DNA into repetitive RNA in the sense and antisense orientations, which 
subsequently aggregate within the cell to form RNA foci (section 1.6.2) and 3) a gain-of-  
 
Figure 1.4 Potential disease mechanisms in C9orf72 FTD/ALS. 
Illustration summarises the three main loss and gain-of-function mechanisms that may contribute to 
pathogenesis in C9orf72 FTD/ALS. Loss-of-function may arise from a reduction of C9orf72 transcripts, depicted 
here by an RNA molecule under a cancel sign, leading to a potential reduction in normal C9orf72 protein 
function. Gain of RNA function may occur as a result of the sequestration of vital RNA binding proteins into RNA 
foci, depicted here by sense (red circles) and antisense (green circles) foci within a cell nucleus (blue circle) as 
seen in fluorescence in situ hybridisation experiments. Gain of peptide function may arise from the translation 
of sense and antisense RNA repeat transcripts into five different repeating dipeptides, with the proteins 
produced depicted here using their respective three letter amino acid codes: gly  = glycine, pro = proline, ala = 
alanine, arg = arginine. 
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peptide function due to the translation of repeat RNA into proteins in all sense and 
antisense frames, forming five different dipeptide repeat proteins that aggregate within 
neurons (section 1.6.3). 
1.6.1 Loss of C9orf72 protein function 
The loss of a protein resulting in the disruption of a vital biological process is a common 
disease mechanism, and is observed in a number of repeat expansion disorders including 
fragile X syndrome, in which a CGG repeat expansion in the 5’ untranslated region of FMR1 
causes a loss of fragile X mental retardation protein (FMRP)(Penagarikano et al., 2007), and 
Friedreich’s ataxia, in which a GAA repeat expansion in the first intron of FXN causes a loss 
of frataxin protein (Delatycki et al., 2000). A number of studies have therefore investigated 
whether a loss of normal C9orf72 protein function could contribute to C9orf72 FTD/ALS. 
While the exact function of C9orf72 protein remains to be determined, it is known to share 
homology with the differentially expressed in normal and neoplasia (DENN) family of 
GDP/GTP exchange factors (GEFs) which activate Rab-GTPases and modulate vesicular 
trafficking (Levine et al., 2013; Zhang et al., 2012). In support of this function, siRNA 
knockdown of C9orf72 protein was found to disrupt transport of shiga toxin, the receptor 
TrkB and autophagosome marker light chain 3 (LC3), implicating C9orf72 protein in the 
modulation of autophagy and endocytosis (Farg et al., 2014). C9orf72 protein was also 
found to colocalise with Rab proteins in neuronal cell lines, primary rat cortical neurons and 
in human post-mortem spinal cord sections (Farg et al., 2014). However, study of C9orf72 
localisation is presently limited by the currently available antibodies, which exhibit non-
specific staining. Some of the reports published using commercially available anti-C9orf72 
antibodies give divergent observations of C9orf72 localisation, and lack negative controls 
(Cooper-Knock et al., 2012; DeJesus-Hernandez et al., 2011; Farg et al., 2014; Gijselinck et 
al., 2012; Hsiung et al., 2012; Snowden et al., 2012; Stewart et al., 2012). New antibodies 
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were more recently generated that are reported to differentially recognise the two C9orf72 
protein isoforms. Using these antibodies, the long C9orf72 isoform was observed to exhibit 
diffuse cytoplasmic localisation, meanwhile the short C9orf72 isoform was found to localise 
to the nuclear membrane in neurons from non-neurodegenerative control patients, 
suggesting a differential localisation of the two isoforms. Both long and short C9orf72 
isoforms were reported to interact with components of the nuclear pore complex including 
Ran-GTPase and Importin β1 (Xiao et al., 2015), suggesting a possible function in nuclear 
transport. However, in motor neurons of ALS patients both with and without the repeat 
expansion, the short isoform was not observed at the nuclear membrane and instead 
localised to the plasma membrane (Xiao et al., 2015), suggesting a disruption in short-
isoform C9orf72 protein localisation in disease. However further antibody characterisation 
and staining of C9orf72 protein deficient tissue as a negative control is needed to confirm 
these observations.  
Several studies have observed a significant reduction in total C9orf72 RNA (Belzil et al., 
2013; Fratta et al., 2013; van Blitterswijk et al., 2015; Waite et al., 2014), as well as a 
specific reduction in transcript variant 1 (Belzil et al., 2013; DeJesus-Hernandez et al., 2011; 
Fratta et al., 2013; van Blitterswijk et al., 2015), the promotor region of which is disrupted 
by the presence of the repeat expansion. One report additionally observed a specific 
reduction in transcript variant 2 (van Blitterswijk et al., 2015), but a significant reduction in 
variant 3 has not been observed (Belzil et al., 2013; DeJesus-Hernandez et al., 2011; Fratta 
et al., 2013; van Blitterswijk et al., 2015; Waite et al., 2014). A decrease in C9orf72 protein 
level has also been reported in C9orf72 FTD post-mortem frontal cortex (Waite et al., 
2014). A study examining an FTD patient homozygous for the C9orf72 repeat expansion 
additionally found that the presence of two expanded C9orf72 repeat alleles in this patient 
is associated with a decrease in the levels of variant 1 and variant 2 RNA transcripts 
compared to heterozygous C9orf72 expansion patients and control patients, however 
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transcripts of all variants were still present within the homozygous patient, suggesting an 
incomplete loss of C9orf72 protein even in the presence of double repeat expansions 
(Fratta et al., 2013).  
The reduction in C9orf72 transcription is thought to be due to epigenetic silencing. 
Methylation of cytosine-phosphate-guanine (CpG) dinucleotides is an important 
mechanism in inhibiting gene expression, and is associated with the induction of a 
repressed chromatin state. Hypermethylation of CpG sites adjacent to a repeat expansion 
has been observed in several other disorders including Friedreich’s ataxia (Al-Mahdawi et 
al., 2008; Evans-Galea et al., 2012; Greene et al., 2007), fragile X syndrome (Bell et al., 
1991; Pieretti et al., 1991; Sutcliffe et al., 1992) and myotonic dystrophy (Klesert et al., 
1997; Korade-Mirnics, 1999; Thornton et al., 1997). Two CpG islands are present upstream 
of the C9orf72 repeat expansion, and were found to be hypermethylated in up to 36 % of 
repeat expansion carriers, with a similar level of methylation seen in both ALS and FTD 
patients (Liu et al., 2014; Russ et al., 2015; Xi et al., 2014, 2013). Furthermore, CpG 
sequences within the repeat itself are also methylated in 97 % of patients with over 50 
repeats (Xi et al., 2015b). The degree of methylation in the C9orf72 promotor was found to 
be associated with a reduction in C9orf72 RNA transcript levels in patient derived 
lymphoblast lines but was reversed following treatment with the DNA methyltransferase 
inhibitor 5-aza-2′-deoxycytidine (Liu et al., 2014). Trimethylated histone residues, which are 
also known to inhibit gene expression, were additionally found to bind to the C9orf72 
repeat expansion in patient derived fibroblast lines (Belzil et al., 2013). 
A number of studies have been published that support a role for loss of C9orf72 protein 
function in C9orf72 FTD/ALS. Knockdown of the zebrafish C9orf72 homolog (zC9orf72) 
using antisense morpholino oligonucleotides to block translation of zC9orf72 RNA 
transcripts resulted in axonal degeneration in motor neurons and defective locomotion in 
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swimming tasks (Ciura et al., 2013). Deletion of Caenorhabditis elegans C9orf72 homolog 
alfa-1 resulted in a progressive paralysis phenotype in the worms and the degeneration of 
motor neurons (Therrien et al., 2013). Furthermore, one study found that patients with the 
lowest 25th percentile of C9orf72 variant 1 expression had a significantly shorter disease 
duration than the top 75th percentile of patients, indicating a more aggressive disease 
course in patients with low C9orf72 transcripts (van Blitterswijk et al., 2013), while the 
degree of C9orf72 promoter methylation also correlated with a lower age of onset and a 
higher repeat length (Gijselinck et al., 2015).  
However, other evidence suggests that loss of C9orf72 protein function does not represent 
the primary pathological mechanism in C9orf72 FTD/ALS. Firstly, no cases of ALS or FTD 
have been found that are caused by loss-of-function mutations in the coding region of 
C9orf72 (Harms et al., 2013), suggesting that the repeat expansion itself is important in 
pathogenesis.  Knockdown of C9orf72  was additionally found not to be toxic in C9orf72 ALS 
patient derived iPSCs (Sareen et al., 2013). Several C9orf72 loss-of-function mouse models 
have also failed to induce a neurodegenerative phenotype: mice treated with antisense 
oligonucleotides against C9orf72 did not exhibit any behavioural or pathological 
neurodegenerative features (Lagier-Tourenne et al., 2013), and conditional knock-out of 
C9orf72 in neurons and glia of Nestin-Cre+/−;C9orf72fl/fl mice resulted in decreased body 
weight, but no neurodegeneration, motor defects or reduction in viability (Koppers et al., 
2015).  
Silencing of the C9orf72 locus may even serve a protective role in patients due to the 
attenuation of downstream gain-of-function disease mechanisms. Hypermethylation of the 
C9orf72 promoter in post-mortem FTD/ALS patient brain was associated with a reduction in 
the percentage of cells exhibiting RNA foci or DPR protein aggregates (Liu et al., 2014), and 
was additionally associated with a reduction in the loss of grey matter density (McMillan et 
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al., 2015). One study also observed that C9orf72 promotor methylation in the brain and 
blood is correlated with a later age of death, with methylation in the blood found to be 
associated with a longer disease duration in FTD patients (Russ et al., 2015).  
These data therefore suggest that while loss of C9orf72 protein function may exacerbate 
disease progression, it does not represent the major pathological pathway, and reduction 
of harmful repeat RNA and DPR proteins through silencing of the C9orf72 gene locus at the 
cost of a reduction in C9orf72 protein levels may therefore still exhibit a beneficial net 
effect. 
1.6.2 RNA gain-of-function mechanisms 
An RNA gain-of-function disease mechanism has been proposed in a number of non-coding 
repeat expansion diseases and is best characterised in myotonic dystrophy type 1 (DM1), in 
which a CTG repeat in the 3’ untranslated region (UTR) of the human DMPK gene is 
expanded from 5-38 repeats in control patients, to between 50 and several thousands of 
repeats in length (Brook et al., 1992; Fu et al., 1992; Mahadevan et al., 1992). Following 
transcription into RNA, the CUG repeats form a hairpin secondary structure, and aggregate 
to form RNA foci in the cell nucleus (Koch and Leffert, 1998; Taneja, 1995). These foci 
sequester a number of RNA-binding proteins including the splicing protein muscleblind-like 
protein 1 (MBNL1), leading to a loss of normal splicing function (Mankodi, 2001; Miller et 
al., 2000). This results in the aberrant splicing of chloride channel ClC-1, a vital component 
in normal muscle function, and the expression of embryonic as opposed to the adult splice 
variant in adult muscles (Mankodi et al., 2002). This dysregulated expression gives rise to 
the hyperexcitability of muscle fibre membranes, resulting in the symptoms of myotonia 
(Mankodi et al., 2002). Therefore, a clear molecular cascade can be observed leading from 
the expression of the repeats to the disease phenotype seen in patients.  
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A similar mechanism has been proposed to operate in C9orf72 FTD/ALS. Studies using RNA 
fluorescence in-situ hybridisation have shown that both sense (GGGGCC) and antisense 
(CCCCGG) repeat transcripts form RNA foci in human brain (Cooper-Knock et al., 2015b, 
2014; Donnelly et al., 2013; Gendron et al., 2013; Lagier-Tourenne et al., 2013; Lee et al., 
2013; Mizielinska et al., 2013; Zu et al., 2013) (Figure 1.5a). Sense and antisense foci have 
been observed in neurons throughout the CNS including the frontal cortex, motor cortex, 
cerebellum, spinal cord and hippocampus (Cooper-Knock et al., 2015b, 2014; DeJesus-
Hernandez et al., 2011; Donnelly et al., 2013; Gendron et al., 2013; Lagier-Tourenne et al., 
2013; Lee et al., 2013; Mizielinska et al., 2013; Zu et al., 2013), and are primarily localised 
within the cell nucleus, with a minority found in the cytoplasm (Lagier-Tourenne et al., 
2013; Mizielinska et al., 2013). RNA foci are additionally found in glial cells, but to a lesser 
extent (Gendron et al., 2013; Lagier-Tourenne et al., 2013; Mizielinska et al., 2013) and 
have also been detected in cell cultures derived from tissues outside of the CNS such as 
fibroblasts and lymphoblasts (Cooper-Knock et al., 2014; Zu et al., 2013). Sense RNA foci 
formation has been observed in a mouse model expressing 66 GGGGCC repeats in the CNS 
(Chew et al., 2015), while both sense and antisense foci formation have been observed in 
C9orf72 patient derived iPSCs, and neurons differentiated from these iPSCs (Almeida et al., 
2013; Donnelly et al., 2013; Sareen et al., 2013), as well as in a number of transgenic cell 
lines overexpressing the repeats (Gendron et al., 2013; Lee et al., 2013; Mizielinska et al., 
2014; Rossi et al., 2015)  
In C9orf72 FTD patients, RNA foci were observed to be most abundant in the frontal cortex, 
the brain region most affected in FTD, with an inverse correlation between the frequency 
of cortical sense foci and the age of disease onset (Mizielinska et al., 2013), while the 
presence of antisense foci was observed to correlate with TDP-43 mislocalisation in C9-ALS 
motor neurons (Cooper-Knock et al., 2015b), consistent with a role for RNA mediated 
toxicity.  
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Figure 1.5 RNA foci and G-quadruplex formation 
 
A) Confocal fluorescence microscopy image taken of RNA fluorescence in-situ hybridisation in C9orf72 FTD 
patient frontal cortex, showing DAPI stained nuclei (blue), sense RNA foci (red) and antisense RNA foci (green). 
Cell 1 exhibits only antisense foci, cell 2 exhibits only sense foci, and cell 3 exhibits a mixture of both sense and 
antisense foci. Figure taken from (Mizielinska et al., 2013). B) Schematic of G-quadruplex secondary structure 
formed by C9orf72 repeat RNA. Left hand image shows a single G quartet comprised of guanine residues (grey) 
stabilised by hydrogen bonds (black) around a central metal ion (orange), with surrounding phosphate 
backbone (blue). Right hand image shows four stacked G-quartets with anti glycosidic bonds in a parallel 
conformation. Figure taken from (Fratta et al., 2012). 
 
GGGGCC repeat RNA and DNA form a stable secondary structure common to repetitive 
guanine rich sequences called a G-quadruplex (Fratta et al., 2012; Haeusler et al., 2014; 
Reddy et al., 2013). Sets of four guanine nucleotides form hydrogen bonds in a planar 
structure around a monovalent cation to form G-quartets, which stack together to form a 
G-quadruplex (Bochman et al., 2012)(Figure 1.5b). G-quadruplexes have been implicated in 
a range of different biological processes, such as transcriptional regulation, maintenance of 
telomeres, splicing and RNA transport (Millevoi et al., 2012). GGGGCC RNA repeats were 
shown to form a parallel G-quadruplex structure (Fratta et al., 2012; Reddy et al., 2013), 
while DNA repeats predominantly form an anti-parallel structure (Haeusler et al., 2014).  
These structures can be either unimolecular, with one RNA or DNA molecule folding upon 
itself, or multimolecular, in which several RNA and DNA molecules form the structure 
together (Reddy et al., 2013). It has been observed that the formation of G-quadruplexes in 
GGGGCC repeat DNA contributes to decreased RNA polymerase processivity (Haeusler et 
al., 2014). Additionally, repeat RNA was found to associate with repeat DNA after 
B A 
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transcription, forming a structure termed an R-loop, which further contributes to the 
abortion of transcripts (Haeusler et al., 2014). When transfected into cells, these truncated 
transcripts were observed to reduce cell viability (Haeusler et al., 2014), suggesting that G-
quadruplexes and other secondary nucleic acid structures could play an important role in 
disease pathology. Furthermore, the prolonged interaction of RNA and DNA repeats in R-
loops is hypothesised to contribute to DNA slippage and repeat instability due to the 
prolonged disassociation of the sense and antisense DNA strands (Haeusler et al., 2014). 
A number of proteins have been proposed to recognise and interact with sense repeat 
RNA, antisense repeat RNA and the G-quadruplex motif, and may therefore be sequestered 
by the repeats. Common themes in the function of these interacting proteins include 
splicing, RNA trafficking, and nuclear import and export. Several heterogeneous nuclear 
ribonucleoproteins (hnRNPs), a class of proteins abundant in the nucleus with diverse RNA 
processing roles (Krecic and Swanson, 1999), have been observed to co-localise with both 
sense and antisense foci in human patient brain; these include hnRNP A1, hnRNP H and 
hnRNP F (Cooper-Knock et al., 2015b, 2014; Donnelly et al., 2013; Lee et al., 2013), factors 
which are known to play an important role in mRNA splicing (Krecic and Swanson, 1999). 
However not all studies were able to observe the sequestration of these proteins, with the 
absence of hnRNP A1 sequestration noted in sense RNA foci in C9orf72 ALS patient 
cerebellum tissue (Donnelly et al., 2013), and no sequestration of hnRNP H or hnRNP F 
observed in a study in C9orf72 FTD patient derived iPSCs (Almeida et al., 2013). hnRNP K, a 
protein known to bind cytosine-rich sequences with multiple functions in splicing, 
transcription and translation (Bomsztyk et al., 2004), was shown to bind preferentially to 
GGCCCC antisense repeat RNA (Haeusler et al., 2014), and co-localised with antisense RNA 
foci in C9orf72 ALS patient cerebellum (Cooper-Knock et al., 2015b). However a crosslinking 
assay failed to show a direct interaction between hnRNP K and repeats in patient tissue 
(Cooper-Knock et al., 2015b). Additionally, hnRNP A3, which plays a role in cytoplasmic RNA 
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trafficking (Ma et al., 2002), was also observed to bind GGGGCC repeats in vitro (Mori et al., 
2013b) but was not observed to co-localise with sense RNA foci in C9orf72 FTD/ALS patient 
cerebellum (Lee et al., 2013). The degree to which sequestration of hnRNPs impacts on 
splicing and other RNA processing activities, is therefore yet to be determined.   
A number of other RNA processing factors have also been observed to interact with repeat 
RNA under certain conditions. The mRNA nuclear export factor Aly/REF, which belongs to a 
family of hnRNP-like proteins (Stutz et al., 2000), was observed to co-localise with both 
sense and antisense RNA foci in C9orf72 ALS patient brain (Cooper-Knock et al., 2015b, 
2014), as was serine/arginine-rich splicing factor 2 (SRSF2), a component of the 
spliceosome, (Cooper-Knock et al., 2015b, 2014; Lee et al., 2013). Adenosine deaminase 
RNA specific B2 (ADARB2), one of a family of ADAR RNA editing proteins that are enriched 
in the CNS, was also observed to co-localise with sense RNA foci (Donnelly et al., 2013). The 
ADAR proteins convert adenosine to inosine, which is an important step in the production 
of the AMPA receptor subunit gluA2, and the downregulation of this protein has been 
implicated in sporadic ALS (Hideyama et al., 2012). However, ADARB2 is thought to lack this 
activity, although it has been hypothesised to play a complimentary role (Chen et al., 2000). 
Pur-alpha, a protein known to bind and transport purine rich RNA and DNA, was observed 
to interact with GGGGCC repeats in a pull down assay from human brain lysate (Xu et al., 
2013), and co-localised with sense RNA foci in neurons derived from C9orf72 patient iPSCs 
(Sareen et al., 2013). It has also previously been shown that pur-alpha binds to the CGG 
repeats found in fragile X tremor/ataxia syndrome (FXTAS) in a CCG repeat expressing fly 
model as well as CCG RNA foci in FXTAS patient brain (Jin et al., 2007). However, several 
other studies were unable to replicate the interaction of pur-alpha with GGGGCC repeat 
RNA foci in C9orf72 ALS patient cerebellum or in C9orf72 ALS patient derived iPSCs 
(Donnelly et al., 2013; Lee et al., 2013). It is therefore currently unclear to what degree 
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sequestration of RNA binding proteins plays a role in C9orf72 RNA gain-of-function 
pathology. 
1.6.3  Gain of peptide function 
In 2011 it was discovered that the non-coding CAG repeat expansions in myotonic 
dystrophy and spinocerebellar ataxia type 8 (SCA8) are translated in the absence of an ATG 
methionine start codon by an non-canonical process called repeat associated non-ATG 
initiated (RAN) translation (Zu et al., 2011). This translation occurs in all reading frames, 
yielding three different homopolymeric proteins: polyglutamine, polyalanine and 
polyserine  (Zu et al., 2011). Expression of these homopolymeric proteins was detected in 
CAG repeat expressing cell models, in mouse models of SCA8 and myotonic dystrophy, and 
in myoblasts from myotonic dystrophy patients. Furthermore, polyglutamine aggregates in 
the myotonic dystrophy mouse model were associated with markers of apoptosis, 
suggesting that these proteins are relevant to disease progression  (Zu et al., 2011).   
Subsequently, RAN translation was also observed to occur in CGG repeats present in the 5’ 
UTR of FMR1 in fragile X-associated tremor ataxia syndrome (FXTAS), producing  
polyglycine and polyalanine containing proteins (Todd et al., 2013). A product of RAN 
translation from FMR1 containing both polyglycine and a C terminal sequence translated 
from the DNA adjacent to the repeats was additionally found to be toxic in a Drosophila 
model, demonstrating the relevance of these RAN translation products to repeat 
pathogenesis (Todd et al., 2013).  
The mechanism for RAN translation has not been characterised, however several potential 
processes have been proposed. Translation initiation may be assisted by the propensity of 
repetitive DNA to form hairpin loops, which are thought to promote translation initiation in 
some situations by slowing the 40S subunit of the ribosome, allowing tRNA anticodons to 
bind (Kozak, 1990, 1989). In support of this hypothesis, hairpin-forming CAG repeats were 
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found to be capable of initiating RAN translation, while non-hairpin-forming CAA repeats 
could not (Zu et al., 2011). A second potential mechanism for the initiation of RAN 
translation is the presence of near ATG codons, differing from ATG by only one base, which 
have been observed to initiate translation under certain conditions (Peabody, 1989), and 
were found to be required for RAN translation of repeats to occur within an in vitro system 
(Zu et al., 2011) 
 
Figure 1.6 Dipeptide repeat protein RAN translation products from GGGGCC repeats 
 
The dipeptide repeat protein products translated from the GGGGCC repeat expansion are shown for each 
reading frame in the sense and antisense orientations. gly: glycine, arg: arginine, pro: proline, ala: alanine. 
 
In 2013, several groups demonstrated that RAN translation also occurs in C9orf72 ALS/FTD. 
The GGGGCC repeat expansion is translated in all reading frames from both the sense (Ash 
et al., 2013; Mori et al., 2013c) and antisense transcripts (Gendron et al., 2013; Mori et al., 
2013a; Zu et al., 2013). This yields 5 different dipeptide repeat (DPR) proteins: glycine-
alanine (GA) and glycine-arginine (GR) in the sense orientation, alanine-proline (AP) and 
proline-arginine (PR) in the antisense orientation, and glycine-proline (GP) from one sense 
frame and one antisense frame (Figure 1.6). These proteins were found to be a component 
of p62 positive, TDP-43 negative inclusions that had previously been observed to be a 
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defining pathological hallmark of C9orf72 FTD/ALS (Al-Sarraj et al., 2011; Mackenzie et al., 
2013; Mann et al., 2013). DPR proteins form characteristic “star-like” cytoplasmic inclusions 
and small round intranuclear inclusions (Figure 1.7) in neurons from many different brain 
regions in C9orf72 FTD/ALS patients, and are additionally observed in dystrophic neurites 
(Ash et al., 2013; Mackenzie et al., 2013; Schludi et al., 2015). DPR pathology is present 
most abundantly throughout the neocortex, hippocampus, cerebellum, and thalamus 
(Schludi et al., 2015). Less frequently, DPR proteins are also observed in other subcortical 
nuclei, some areas of the brain stem and in the spinal cord (Schludi et al., 2015). While DPR 
aggregates were originally purported to be present only in neurons (Mackenzie et al., 
2013), recent studies have shown that this pathology can also be observed in the glial 
ependymal and subependymal cells that line the spinal cord central canal (Schludi et al., 
2015). Aggregates of DPR products from translation of the sense strand are observed to be 
significantly more common than those from the antisense strand, with poly(GA) the most 
abundant protein, followed by less frequent inclusions of poly(GP) and poly(GR), while 
poly(AP) inclusions and poly(PR) inclusions are significantly less common (Mackenzie et al., 
2015). The abundance of poly(GA) aggregates across all brain regions was observed to 
negatively correlate with age of disease onset in C9orf72 FTD/ALS patients, (Davidson et al., 
2014; Mackenzie et al., 2015), and the accumulation of DPR protein aggregates has been 
observed to predate TDP-43 pathology (Baborie et al., 2014; Gijselinck et al., 2012; 
Proudfoot et al., 2014), consistent with a role for DPR proteins in disease pathogenesis. 
However, there is no clear relationship between the frequency of DPR protein aggregates 
within any given brain region and the severity of neurodegeneration or TDP-43 pathology 
in that region (Davidson et al., 2014; Mackenzie et al., 2015, 2013; Mann et al., 2013), 
arguing against a direct relationship between DPR aggregate formation and cell toxicity. 
While several immunohistochemical studies have observed no difference in DPR aggregate 
distribution between C9orf72 FTD, ALS or FTD/ALS patients (Davidson et al., 2014; 
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Mackenzie et al., 2015; Schludi et al., 2015), one study using immunoassays found 
significantly less poly(GP) in the cerebellum of C9orf72 ALS patients compared to C9orf72 
patients with FTD or FTD/ALS (Gendron et al., 2015), and a second study also found a 
higher abundance of poly(GA) inclusions in the cerebellum granule cell layer of C9orf72 FTD 
cases than in C9orf72 ALS or FTD/ALS cases (Schludi et al., 2015), suggesting that 
differential DPR protein accumulation could potentially influence disease subtype. 
The toxicity of several of the DPR proteins has also been demonstrated in a number of 
different cell and animal models. In several immortalised cell line models, toxicity mediated 
by the arginine-containing DPR proteins poly(GR) and poly(PR) has been observed (Kwon et 
al., 2014; Tao et al., 2015; Yamakawa et al., 2014). A reduction in cell line viability was also 
reported as a result of poly(GA) expression (Zhang et al., 2014). However, other studies did 
not observe toxicity as a result of any of these species (May et al., 2014). DPR protein 
toxicity has also been observed in rat primary neuronal cultures, with a reduction in cell 
viability caused by poly(GA) expression found by some groups (May et al., 2014; Zhang et 
 
Figure 1.7 Dipeptide repeat protein inclusions in C9orf72 FTD patient frontal cortex 
 
Poly(glycine-alanine) aggregates in immunostained post-mortem C9orf72 FTD/ALS patient frontal brain. Blue 
stain represents hematoxylin nuclear stain, brown stain represents 3,3’ –diaminobenzidine stain against an anti-
poly(glycine-alanine) primary antibody. A) Inclusions in frontal cortex. Black scale bar = 20 µm in part A. B) Star-
like cytoplasmic inclusion in spinal cord  Grey scale bar = 20 µm in part B. C) Cytoplasmic inclusion in the frontal 
cortex D) Dot-like nuclear inclusion in the frontal cortex E) Diffuse cytoplasmic staining usually defined as a 
“pre-inclusion” in the frontal cortex F) Dystrophic neurite in the frontal cortex. White scale bar = 20 µm in parts 
C-F. Adapted from (Mackenzie et al., 2015) 
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al., 2014) and toxicity mediated by arginine-containing DPR protein expression reported by 
others (Wen et al., 2014). Additionally, poly(GR) and poly(PR) were both found to cause 
toxicity in neurons differentiated from human iPSCs (Wen et al., 2014). 
When expressed in Drosophila, poly(GR) and poly(PR) proteins were sufficient to cause 
severe toxicity (Mizielinska et al., 2014; Wen et al., 2014; Yang et al., 2015). Poly(GR) 
expression was additionally found to suppress Notch signalling in flies (Yang et al., 2015), 
suggesting that these peptides could disrupt key cell signalling pathways in disease. A 
modest reduction in viability was also observed in poly(GA) expressing Drosophila 
(Mizielinska et al., 2014), however this was found to be considerably less severe than the 
toxicity caused by poly(GR) and poly(PR). 
1.6.4 Proposed cellular functions affected in C9orf72 FTD/ALS  
A number of cellular functions are reported to be compromised as a result of gain-of-
function mechanisms initiated by the C9orf72 repeat expansion. Firstly, several groups 
have highlighted the effect of arginine-containing DPR proteins on nucleoli in cell model 
systems, following initial observations that poly(GR) and poly(PR) peptides localise to the 
nucleolus (Kwon et al., 2014; May et al., 2014; Schludi et al., 2015; Tao et al., 2015; Wen et 
al., 2014; Yamakawa et al., 2014; Zu et al., 2013). The presence of poly(GR) and poly(GR) in 
cell culture models was also found to induce nucleolar enlargement, translocation of 
nucleolar markers and disrupted processing of ribosomal subunits (Kwon et al., 2014; Tao 
et al., 2015; Wen et al., 2014). Other groups have additionally implicated RNA gain-of-
function mechanisms in nucleolar dysfunction (Haeusler et al., 2014). However thus far 
studies have failed to observe the same changes in nucleolar morphology in C9orf72 
FTD/ALS post mortem brain (Schludi et al., 2015). The role of the nucleolus in C9orf72 
repeat pathology will be discussed in greater detail in chapter 5. 
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Secondly, a number of reports have highlighted transcriptome changes in C9orf72 ALS 
patients and patient derived cells (Cooper-Knock et al., 2015a; Donnelly et al., 2013; Lagier-
Tourenne et al., 2010; Prudencio et al., 2015; Sareen et al., 2013).  Alterations in alternative 
splicing and alternative polyadenylation have been observed in C9orf72 ALS patient tissue 
and cells, but the exact transcripts found to be dysregulated has been inconsistent 
between studies (Cooper-Knock et al., 2015a; Donnelly et al., 2013; Lagier-Tourenne et al., 
2010; Prudencio et al., 2015; Sareen et al., 2013), which may in part be due to a reduction 
of splicing consistency in these samples (Cooper-Knock et al., 2015a). Additionally, 
transcripts in C9orf72 ALS patient tissue and cells were observed to significantly deviate not 
only from that of control patients, but also from non-C9orf72 ALS patients, (Cooper-Knock 
et al., 2015a; Donnelly et al., 2013; Prudencio et al., 2015), indicating that the disruption of 
RNA metabolism seen in C9orf72 ALS patients may differ from other ALS patients in many 
respects. However, it has not yet been determined whether the observed dysregulation of 
RNA metabolism is caused by RNA or DPR protein gain-of-function mechanisms.  
Finally, three recent papers observed defects in nucleocytoplasmic transport in transgenic 
GGGGCC repeat expressing Drosophila models, in a PR50 expressing yeast line, and in 
C9orf72 FTD patient derived iPSCs, with both RNA gain-of-function and DPR protein gain-of-
function mechanisms implicated by different groups (Freibaum et al., 2015; Jovičić et al., 
2015; Zhang et al., 2015). The potential contribution of a defect in nucleocytoplasmic 
transport to C9orf72 FTD/ALS and the relevance of these new developments to this thesis 
will be examined in depth in section 6.3 of the final discussion chapter. 
Further studies are therefore needed to confirm the involvement of all of the above 
processes in C9orf72 FTD/ALS, and how they may be impacted by RNA or DPR protein gain-
of-function mechanisms.  
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1.7  Thesis aims 
The C9orf72 repeat expansion results in highly diverse clinical outcomes, with an array of 
different types of neuropathology observed in patients. It is presently unclear which 
pathological features play an important role in disease progression, which determine 
clinical subtype, and which may be epiphenomena playing a neutral or even protective 
role. A better understanding of which molecular species mediate toxicity in C9orf72 
FTD/ALS and by what mechanisms would assist in targeting future treatments for this 
disease. 
This project therefore sought to dissect the different C9orf72 FTD/ALS disease mechanisms 
at work, to study their effects in isolation. As the current evidence outlined above supports 
a gain-of-function mechanism as the primary driver of C9orf72 FTD/ALS pathology, I will 
principally be focussing on dissecting the two major gain-of function processes: repeat RNA 
gain-of-function and DPR protein gain-of function.  
My principal aims are: 
 To generate a genetic toolkit that can be used to dissect RNA and DPR protein gain-
of-function mechanisms. 
 To use this toolkit to study gain-of-function disease mechanisms in cell model 
system. 
 To study the relevance of these gain-of-function mechanisms in C9orf72 FTD 
patient tissue. 
In order to achieve these aims, I carried out the following studies: 
 Generation of a tool kit of DNA repeat constructs of differing lengths that isolate 
RNA gain-of-function from DPR-protein gain-of-function (Chapters 3 and 4). 
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 Quantification of the formation of sense and antisense RNA foci from different 
length repeat constructs in a cell model system (Chapter 3). 
 Investigation into the different effects of RNA gain-of-function and DPR-protein 
gain-of-function mechanisms in a transgenic Drosophila model generated using my 
repeat constructs (Chapters 3 and 4). 
 Examination of  the subcellular location of DPR proteins generated from my repeat 
constructs in a cell model system (Chapter 4) 
 Development and testing of an automated image analysis protocol for the 
quantification of DPR protein inclusions in C9orf72 FTD post mortem brain (Chapter 
4). 
 Investigation into a potential pathological mechanism at work in C9orf72 FTD 
patients by examining the effect of poly(GR) inclusion burden on nucleolar volume 
in C9orf72 FTD post mortem brain (Chapter 5).  
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 Materials and Methods Chapter 2: 
2.1  Cloning Protocols 
2.1.1 Annealing and ligation of oligonucleotides 
Poly-acrylamide gel electrophoresis (PAGE) purified oligonucleotides were ordered from 
Sigma Aldrich (Table 2.1). Forward and reverse oligonucleotides were diluted to 100 µM in 
annealing buffer (1 mL annealing buffer stock solution: 100 µL 1M Tris pH8 (Sigma), 500 µL 
1M NaCl (VWR), 20 µL 0.5 M EDTA (Sigma), 280 µL ddH2O, stored at -20 °C). The reaction 
was then heated to 95 °C for 15 minutes, after which the temperature was decreased by 
0.1 °C per minute until the temperature reached 4 °C. To ligate the annealed 
oligonucleotides into a vector, 7.5 μL of oligonucleotides diluted to 7.5 nM and 0.5 μL of 20 
ng/μL linearised vector with compatible overhangs were incubated with 1 μL 10X T4 ligase 
buffer and 1 μL T4 DNA ligase (40 U, New England Biolabs) at 16 °C for 2 hours. 
2.1.2 Preparation of bacterial culture solutions 
2.1.2.1 Luria-Broth (LB; Miller’s Modification) 
To make 500 mL of Luria-Broth, 12.5g LB powder (Sigma) was added to 500 mL ddH2O,  
and was autoclaved at 121 °C for 15 minutes to sterilise. The solution was then left to cool 
to room temperature before addition of either  1) 100 μg/mL ampicillin (for pBlueScript II 
SK+, pcDNA3.1+ and pUASTattB vectors) or 2) 50 μg/mL kanamyacin (for pAcGFP1 vector).  
The solution was stored sealed at room temperature until use. 
2.1.2.2 LB agar 
To make 500 mL of LB agar, 15.25 g LB Agar powder (Sigma) was added to 500 mL ddH2O 
and was autoclaved at 121 °C for 15 minutes to sterilise. The solution was then left to cool 
until approximately 40 °C before addition of either  1) 100 μg/mL ampicillin (for pBlueScript 
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Insert 
Destination 
vector 
Sequence (5’ to 3’) 
(GGGGCC)3 
forward 
pcDNA3.1+   GATCCGGTACCGCTCTTCAGGCCGGGGCCGGGGCCGGGGCCTGC 
(GGGGCC)3 
reverse 
pcDNA3.1+   GCCATGGCGAGAAGTCCGGCCCCGGCCCCGGCCCCGGACGCCGG 
(GGGGCC)4 
+ int A 
forward 
pBlueScript II SK+ [Phos]GGCCAAATTAGGGGCCGGGGCCGGGGCCGG 
(GGGGCC)4 
+ int A  
reverse 
pBlueScript II SK+ [Phos]GCCCCGGCCCCGGCCCCGGCCCCTAATTTG 
(GGGGCC)4 
+ int B 
forward 
pBlueScript II SK+ [Phos]GGCCGTTAAAGGGGCCGGGGCCGGGGCCGG 
(GGGGCC)4 
+ int B 
reverse 
pBlueScript II SK+ [Phos]GCCCCGGCCCCGGCCCCGGCCCCTTTAACG 
(GGGGCC)4 
+ int C 
forward 
pBlueScript II SK+ [Phos]GGCCAATTAAGGGGCCGGGGCCGGGGCCGG 
(GGGGCC)4 
+ int C 
reverse 
pBlueScript II SK+ [Phos]GCCCCGGCCCCGGCCCCGGCCCCTTAATTG 
(Gly-Ala)6 
forward 
pAcGFP1-C1 AATTCTGGTGCAGGAGCTGGTGCAGGAGCTGGTGCAGGAGCTG 
(Gly-Ala)6 
reverse 
pAcGFP1-C1 GGATCCAGCTCCTGCACCAGCTCCTGCACCAGCTCCTGCACCAG 
(Gly-Pro)6 
forward  
pAcGFP1-C1 AATTCTGGTCCAGGACCTGGTCCAGGACCTGGTCCAGGACCTG 
(Gly-Pro)6 
reverse 
pAcGFP1-C1 GGATCCAGGTCCTGGACCAGGTCCTGGACCAGGTCCTGGACCAG 
(Gly-Arg)6 
forward  
pAcGFP1-C1 AATTCTGGTAGAGGAAGAGGTAGAGGAAGAGGTAGAGGAAGAG 
(Gly-Arg)6 
reverse 
pAcGFP1-C1 GGATCCTCTTCCTCTACCTCTTCCTCTACCTCTTCCTCTACCAG 
(Pro-Arg)6 
forward 
pAcGFP1-C1 AATTCTCCTAGACCAAGACCTAGACCAAGACCTAGACCAAGAG 
(Pro-Arg)6 
reverse 
pAcGFP1-C1 GGATCCTCTTGGTCTAGGTCTTGGTCTAGGTCTTGGTCTAGGAG 
(Ala-Pro)6 
forward  
pAcGFP1-C1 AATTCTGCTCCAGCACCTGCTCCAGCACCTGCTCCAGCACCTG 
(Ala-Pro)6 
reverse 
pAcGFP1-C1 GGATCCAGGTGCTGGAGCAGGTGCTGGAGCAGGTGCTGGAGCAG 
Table 2.1 Oligonucleotides used for cloning GGGGCC and DPR protein repeats. 
 int = interruption, gly = glycine, pro = proline, arg = arginine, ala = alanine. 
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II SK+, pcDNA3.1+ and pUASTattB vectors) or  2) 50 μg/mL kanamyacin (for pAcGFP1 
vector). LB agar solution was then poured into 10 cm petri dishes close to a flame, with 20 
mL of solution added per dish. The agar was allowed to set before covering and storing at 4 
°C. 
2.1.3 Transformation of chemically competent E. coli 
3 μL of ligation reaction was added to One Shot® Stbl3™ Chemically Competent E. coli (Life 
Technologies), a recA recombinase-deficient strain that promotes stability when cloning 
repetitive DNA. The cells were incubated on ice for 30 minutes before heat shock at 42 °C 
for 45 seconds, followed by incubation on ice for a further 2 minutes. 250 μL of pre-
warmed SOC media was added to cells, which were then incubated at 30 °C shaking for 2 
hours. Cells were incubated at 30 °C as opposed to the 37 °C incubation temperature 
recommended by manufacturers as the lower temperature was found to reduce the 
frequency of deletions in the repeat constructs by the bacteria.  Cultures were then spread 
onto LB agar plates containing the appropriate antibiotic. Agar plates were incubated at 30 
°C overnight.  
2.1.4 Colony PCR for detection of GGGGCC repeats 
Colonies of transformed E. coli on LB agar plates were each picked into 40 µL ddH2O in a 
96-well plate. 10 µL of these solutions was then added to 200 µL each LB broth with the 
appropriate antibiotic in a 96-well round bottom culture plate, which was then incubated 
shaking at 30 °C until completion of the PCR. The remaining colony solutions in ddH2O were 
heated at 95 °C for 10 minutes. A repeat-primed PCR (Beck et al., 2013; Renton et al., 
2011a) reaction master mix was made by multiplying the volumes listed in Table 2.2 by the 
number of colonies to be tested. 1 µL of solution from each well of the colony solutions in 
ddH2O was then added to 10 µL of master mix per well. The forward and reverse primers 
used are detailed in Table 2.3, and the reaction was incubated as detailed in Table 2.4. 
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Reagent Supplier Volume per well (µL) 
2x FastStart PCR Master  Mix Roche 5  
DMSO Sigma 0.5  
5x Q solution Qiagen 2  
5 mM deazaGTP New England Biolabs 0.4  
25 mM MgCl2 Qiagen 0.4  
100 µM forward primer Sigma 0.05  
100 µM reverse primer Sigma 0.05  
H2O - 0.6  
DNA - 1  
Table 2.2 Reagents for colony PCR reaction 
 
 Primer Sequence (5’ to 3’) 
pBlueScript II SK+ forward (FAM labelled) [6FAM]CCTCGAGGTCGACGGTA 
pBlueScript II SK+ reverse CGCGCAATTAACCCTCACTA 
Table 2.3 Colony PCR primers 
 
Step Temperature Time 
1 95 °C  5 minutes 
2 95 °C  30 seconds 
3 50 °C  30 seconds 
4 72 °C  1 minute 
Repeat steps 2-4, 35 times 
5 72 °C  7 minutes 
6 4 °C  Forever 
Table 2.4 Cycling conditions for colony PCR reaction 
 
65 
 
1 µL of each PCR reaction to be analysed was mixed with 10 µL Hi-Di™ formamide (Life 
Technologies) and 0.5 µL GeneScan™ 500 LIZ® Size Standard (Life Technologies) in a 96-well 
plate, and fragment analysis was carried out using the 3730xl DNA Analyser (AME 
Bioscience), and Peak Scanner™ Software (Applied Biosystems). 
The 200 µL LB starter cultures from samples that contained the correct length inserts (as 
indicated by fragment analysis) were added to 5 mL each LB broth with appropriate 
antibiotics. Cultures were incubated overnight shaking at 30 °C for plasmid DNA 
preparation by miniprep the following day.  
2.1.5 Preparation of plasmid DNA  
To seed bacterial cultures for plasmid minipreps, transformed Stbl3 colonies on LB agar 
plates were picked into 5 ml LB broth with the appropriate antibiotic, followed by 
incubation shaking at 30 °C overnight. Due to the high repeat deletion rate in these 
constructs, 24 or 48 colonies were typically screened.  DNA was extracted using the 
QIAprep Spin Miniprep kit (QIAGEN) as per the manufacturer’s instructions. To elute, 50 µL 
of Buffer EB was added to the column membrane and left to stand for one minute before 
the final centrifugation step.  
To prepare higher concentration and higher purity plasmid stocks for applications such as 
cell transfection, plasmid maxipreps were carried out. First, minipreps were carried out as 
detailed above, however 0.5 ml of each LB culture was retained prior to DNA extraction, 
and was added to 4 ml LB broth containing the appropriate antibiotic, and incubated 
shaking at 30 °C for a further 6 hours in order to seed maxiprep starter cultures. DNA 
minipreps were digested (Section 2.1.7) to release the repeat insert and screen for correct 
size by agarose gel electrophoresis (Section 2.1.8). 500 μL of starter culture corresponding 
to a successful prep was then added to 500 ml of LB broth with the appropriate antibiotic, 
and was incubated shaking overnight at 30 °C. The culture was processed using the 
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EndoFree Maxi Prep Kit (QIAGEN) as per the manufacturer’s instructions. The final DNA 
pellet was left in 500 μL Buffer TE (QIAGEN) overnight to solubilise.  
2.1.6 DNA UV spectroscopy 
Concentration of DNA samples was determined by loading 1 μL of solution onto a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific) and measuring absorbance at 
260 nm. 1 μL of the elution solution used (either ddH2O, Buffer EB or Buffer TE depending 
on the experiment), was used as a blank reference sample to calibrate the 
spectrophotometer. Purity of the DNA sample was checked using the 260 nm to 280 nm 
ratio. 
 
Purpose Digest 
Units of enzyme 
used per 50 μL 
reaction 
Buffer Temperature 
Excise repeat 
insert for RDL 
BspQI/EcoO10I 
double digest 
BspQI: 10 U 
EcoO10I: 20 U 
CutSmart 
Buffer 
37 °C for 1 hour 
50 °C for 1 hour 
Linearise repeat- 
containing vector 
for RDL 
BspQI single digest 
+ Calf Intestinal 
Phosphotase (CIP) 
treatment 
BspQI: 10 U 
CIP: 10 U 
CutSmart 
Buffer 
50 °C for 1 hour, 
CIP added, 37 °C 
for 1 hour 
Excise repeats for 
subcloning into 
pcDNA3.1 vector 
BamHI-HF/NotI-HF 
Double Digest 
BamHI-HF: 20 U 
NotI-HF: 20 U 
CutSmart 
Buffer 
37 °C for 2 hours 
Excise repeats for 
subcloning into 
pUAST attb 
vector 
EcoRI-HF/NotI-HF 
NotI-HF: 20 U 
EcoRI-HF: 20 U 
CutSmart 
Buffer 
37 °C for 2 hours 
Linearise 
pAcGFP1-C1 
vector for 
ligation with 
(DPR)6 oligos 
EcoRI-HF/BamHI-
HF 
EcoRI-HF: 20 U 
BamHI-HF: 20 U 
CutSmart 
Buffer 
37 °C for 2 hours 
Table 2.5 Restriction enzyme digests. 
RDL = Recursive directional ligation.  
67 
 
2.1.7 Restriction enzyme digestion 
Reactions were set up as in Table 2.5 and were incubated in a DNA Engine Tetrad®2 
Thermal Cycler (BioRad) at the required temperature and duration. Single restriction 
enzyme digestion reaction products were treated with Calf Intestinal Phosphotase (CIP) to 
dephosphorylate the free DNA ends and prevent relegation. All restriction enzymes, 
phosphotases and digestion buffers were purchased from New England Biolabs. 
2.1.8 Agarose gel electrophoresis 
Between 0.8 % and 4 % UltraPure™ Agarose powder (Life technologies) was added to 200 
mL 1 x TBE, depending on the predicted size of the digest product of interest. Very small 
digestion products smaller than 200 bp were resolved on a 4 % gel, digestion products 
between approximately 200 bp and 1 kb were resolved on a 2 % gel, and larger digestion 
products above 1 kb in length were resolved on a 1 % or 0.8 % gel. The gel mixture was 
heated in a microwave for 2 minutes and left to cool to approximately 50 °C before the 
addition of 20 µL Ethidium Bromide solution (500 µg/ml in H2O; Sigma) per 200 mL gel, 
inside a chemical fume hood. The gel solution was then poured into a holder with a lane 
comb and left to set. Samples were mixed with 5x DNA loading buffer Blue (Bioline), before 
loading into the gel. A molecular weight marker was also loaded to allow approximation of 
digestion band size, with Hyperladder I (Bioline) loaded for bands of interest up to 1 kb in 
length, and Hyperladder IV (Bioline) loaded for bands of interest larger than 1 kb. 
Electrophoresis was carried out in 1 x TBE buffer at 120 V for 30-90 minutes. The gel was 
imaged using a Gel Doc XR system with Quantity One software (BioRad). 
2.1.9 DNA gel extraction  
The bands of interest were visualised on a UV transilluminator (Peqlab biotechnology 
GmbH) and were excised from the agarose gel with a scalpel, with care taken to limit the 
exposure of the samples to the UV radiation. DNA was extracted using the QIAquick Gel 
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extraction kit (QIAGEN) as per manufacturer’s instructions. To elute, 30 µL of ddH2O was 
added to the column membrane and left to stand for one minute before the final 
centrifugation step. 
2.1.10 DNA Ligation 
A volume of insert and vector DNA to be ligated totalling 8 μL was incubated with 1 μL 10X 
T4 ligase buffer and 1 μL T4 DNA ligase (40 U, New England Biolabs) at 16 °C overnight. As 
the ligation of multiple inserts during recursive directional ligation cloning (see section 
3.2.1) was advantageous, a high insert to vector ratio was used, between 10:1 and 100:1 
molar ratio depending on the concentration of DNA available. For subcloning, lower ratios 
between 3:1 and 10:1 were more typically used.  
2.1.11 Sequencing 
Constructs to be sequenced were either processed by Source Bioscience using dGTP 
chemistry to aid read-through of GC-rich repeats, or were sequenced as follows: The 
reagents listed in Table 2.6 were added for each sequencing reaction in a 96-well plate. 1 
μL of a 5 pmol/μL stock of the required primer was added. For sequencing pBlueScript II 
SK+ constructs either T7 forward primer or M13 reverse primer was added. For pcDNA3.1+, 
pUASTattB or pAcGFP1-C1 primers, see Table 2.7. A PCR amplification reaction was then 
carried out as detailed in Table 2.8. 
Reagent Supplier Volume per well (µL) 
Big dye Life Technologies 1 
Better buffer Life Technologies 5 
Betaine Sigma 1 
Primer Sigma 1 
ddH2O  6.5 
DNA  1.5 
 
Table 2.6 Reagents for sequencing reaction 
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Primer Sequence (5’ to 3’) 
pcDNA3.1+  forward ATCAACGGGACTTTCCAAAATGTCG 
pcDNA3.1+ reverse TGACACCTACTCAGACAATGCGATG 
pUASTattB forward GCGAAAGCTAAGCAAATAAACAAGC 
pUASTattB reverse CCCATTCATCAGTTCCATAGGTTGG 
pAcGFP1-C1 forward ACTACCTGTCCACCCAGAGC 
pAcGFP1-C1 reverse TGAGTTTGGACAAACCACAAC 
T7 forward TAATACGACTCACTATAGGG 
M13 reverse CAGGAAACAGCTATGAC 
Table 2.7 Sequencing primers 
 
Step 
 
Temperature  
 
Time 
1 96 °C 30 seconds 
2 50 °C 15 seconds 
3 60 °C 3 minutes 
Repeat steps 1-3, 30 times 
4 15 °C 5 mins 
Table 2.8 Cycling conditions for sequencing PCR reaction 
 
DNA was precipitated by incubation at room temperature with 1.5 μL 125 mM EDTA 
(Sigma), 1.5 μL 3M sodium acetate (Sigma) and 37.5 μL 100 % ethanol per well, followed by 
centrifugation at 2500 rcf for 30 minutes. Supernatant was removed, and 70 μL of 70 % 
ethanol was added per well. Samples were centrifuged for 15 minutes at 2000 rcf, 
supernatant was removed, and samples were left to dry for 10 minutes. 10 μL of Hi-Di 
formamide (Life Technologies) was added to each well, and the sample was sequenced 
using the 3730xl DNA Analyser (AME Bioscience, Life Technologies).  
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2.1.12 Plasmids 
 
Figure 2.1 pBlueScript II SK+ cloning vector (Agilent #212205) 
 
 
Figure 2.2 PCDNA3.1+ mammalian expression vector (Life Technologies V795-20) 
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Figure 2.3 pAcGFP1-C1 mammalian expression vector (Clontech 632470) 
 
 
 
 
Figure 2.4 pUASTattB Drosophila expression vector 
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2.2  Cell culture 
2.2.1 Culture and passage 
SH-SY5Y cells and HEK 293T cells were grown in complete DMEM (DMEM cat #11960-085 
with 10 % FCS, 5 mM L-Glutamine, 1 mM Pyruvate; Life Technologies), in 10 cm dishes 
incubated at 37 °C/5 % CO2. To passage, cells were washed with 10 mL PBS then incubated 
in 1 mL trypsin with EDTA (Life Technologies) for 2 minutes at 37 °C to detach cells from the 
dish. The reaction was stopped with the addition of 9 mL complete DMEM. Cells were 
dislodged from the dish, transferred into a 15 mL falcon, and were pelleted at 1000 rpm for 
5 minutes. The supernatant was discarded and cells were resuspended in 10 mL complete 
DMEM. Different volumes of this cell solution were then added to several new 10 cm 
dishes and made up to a final volume of 10 mL with complete DMEM to seed several new 
cell cultures at varying concentrations for continued growth. 
2.2.2 Cryopreservation of cells 
For long-term storage, early passage cells from a near confluent dish were typsinised, 
resuspended in complete DMEM, and spun down as detailed in the previous section. After 
removal of the supernatant, the cell pellet was resuspended in 1 mL freezing media, which 
comprised of 90 % complete DMEM culture media with 10 % dimethyl sulphoxide (DMSO; 
Sigma), and transferred into a cryovial. Cryovials were then placed into a Mr. Frosty™ 
Freezing Container (Thermo) filled with isopropanol for gradual cooling, and were 
transferred into a -70 °C freezer overnight. Once thoroughly frozen, the cryovials were 
moved into a liquid nitrogen tank for long term storage. 
2.2.3 Revival of cryopreserved cell stocks 
To defrost cells from a liquid nitrogen stock, individual cryovials were rapidly thawed in a 
37 °C waterbath. 1 mL of prewarmed complete DMEM was added in a dropwise manner to 
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the cryovial while constantly agitating, before transferring into a 15 mL falcon. A further 8 
mL of complete DMEM was added to the falcon tube while constantly agitating, before 
pelleting cells at 1000 rpm for 5 minutes. The cell pellet was then resuspended in 10 mL 
complete DMEM, transferred into a 10 cm dish and incubated at 37 °C/5 % CO2. Defrosted 
cells were grown and passaged as detailed above for at least one week before use in any 
experiments. 
2.2.4 Transient transfection 
SH-SY5Y or HEK 293T cells were plated on 13 mm diameter round glass coverslips in a 24 
well dish at a density of 1.5 x 10-4 cells per well, in 500 μL complete DMEM and were 
incubated at 37 °C/5 % CO2 overnight. For each well, 0.4 ng of DNA to be transfected was 
mixed with 0.04 ng of co-transfection marker (ZsGreen or DsRed; Clontech), and 30 μL of 
OptiMEM (Life Technologies). 1 μL Lipofectamine 2000 (Life Technologies) diluted in 30 μL 
OptiMEM was then added, and the solution was incubated at room temperature for 20 
minutes. In this time, media on the cells was replaced with fresh complete DMEM. The 
transfection solutions were then added dropwise to the wells, and were left to incubate at 
37 °C, 5 % CO2 for 3 hours. The cell culture media then was replaced with fresh complete 
DMEM, and cells were incubated for a further 24 hours at 37 °C, 5 % CO2. 
2.2.5  Fluorescence in situ hybridisation 
Transfected cells were washed in PBS, fixed in 4 % paraformaldehyde (PFA, Polysciences) in 
PBS for 10 mins, washed briefly in 2 x SCC (Sigma), and then incubated in pre-hybridisation 
solution (40 % formamide; Amresco/2 x SSC) for 30 minutes at room temperature. Cells 
were then incubated for 2 hours at 37 °C in hybridisation solution with either a Cy3-labelled 
(GGCCCC)4 probe (Integrated DNA Technologies) for sense RNA foci detection or an Alexa 
488-labelled (GGGGCC)4 probe (Integrated DNA Technologies) for antisense RNA foci 
detection. Hybridisation solution consisted of: 0.2 % BSA (Sigma), 2 x SSC, 1 mg/mL salmon 
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sperm DNA (Sigma), 1 mg/mL tRNA (Sigma), 40 % formamide, 10 % dextran sulphate 
(Sigma), 2 mM vanadyl ribonucleoside (New England Biolabs), with either 20 ng/μL Cy3-
labelled (GGCCCC)4 probe or 25 ng/μL Alexa 488-labelled (GGGGCC)4 probe. Samples were 
then shaken at 37 °C for 3 x 20 minutes in wash solution (40 % formamide/ 2 x SCC), 
followed by 3 x 10 minute washes in 2x SCC at room temperature. Cells were mounted 
using ProLong Gold antifade reagent with DAPI to visualise cell nuclei (Life Technologies). 
2.2.6 Immunofluorescence 
Transfected cells were washed in PBS before fixation in 4 % PFA for 10 minutes at room 
temperature. At this point the cells could be stored in PBS for up to a month if desired. 
Cells were permeabilised with 0.1 % Triton X-100 in PBS for 10 minutes, before incubation 
in 1 % BSA in PBS for 30 minutes to block non-specific interactions. Coverslips were then 
inverted onto a drop of the relevant primary antibodies diluted in PBS (see Table 2.9 below 
for details), and were left to incubate at room temperature for 1 hour. Cells were then 
transferred back to the 24-well dish and washed for 3 x 5 minutes in PBS, before the 
coverslips were inverted onto a drop of the relevant secondary antibodies diluted in PBS 
(see Table 2.10 below for details), and incubated for 1 hour. Finally the cells were washed 
as before for a further 3 x 5 minutes in PBS before mounting on a glass microscope slide 
using ProLong Gold Antifade Mountant with DAPI. 
2.3  Antibodies 
2.3.1 Generation of antibodies to dipeptide repeat proteins 
Custom antibodies to each dipeptide repeat protein were generated by BioGenes GmbH. 
Rabbits were immunised with fusion proteins containing 7 dipeptide repeats (GR, GP, GA, 
AP or PR) conjugated to limulus polyphemus hemocyanin (LPH).   
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Target Host Type Source Product code Application Dilution 
Nucleophosmin Mouse IgG1 Abcam ab10530 Human IF 1:1000 
Nucleolin Mouse IgG1 Santa Cruz sc-8031 Human IF 1:50 
NeuN Rabbit IgG 
Merck 
Millipore 
ABN78 Human IF 1:1000 
GR 
Rat 
 
Hybridoma 
supernatant 
Kind gift 
from 
Friedrich 
Grässer 
5H9 
Human IF 1:25 
Human IHC 1:50 
GR Rabbit IgG Proteintech 23978-1-AP Cell IF 1:200 
GA Rabbit IgG Proteintech 24492-1-AP Cell IF 1:200 
GA Rabbit Antiserum Biogenes* N/A Human IHC 1:200 
GP Rabbit Antiserum Biogenes* N/A 
Cell IF 1:200 
Human IHC 1:4000 
PR Rabbit IgG 
Kind gift 
from Stuart 
Pickering-
Brown 
N/A Cell IF 1:50 
PR Rabbit IgG Biogenes* N/A Human IHC 1:200 
AP Rabbit Antiserum Biogenes* N/A 
Cell IF 1:200 
Human IHC 1:50 
Table 2.9 Primary antibodies used 
* See section 2.3.1 for manufacture details of antibodies generated by Biogenes. IF = Immunofluorescence IHC 
= Immunohistochemistry 
Target Host Conjugate Manufacturer Product code Application Dilution 
Mouse 
Goat 
Alexa 488 
Life 
Technologies 
A11029 
Cell IF / 
Human IF 
1:500 
Rat Alexa 546 A11081 
Rabbit Alexa 546 A11035 
Rabbit Alexa 633 A21071 
Chicken Alexa 633 A21103 
Rabbit Swine Biotin Dako E035301-2 Human IHC 1:200 
Table 2.10 Secondary antibodies used 
IF = Immunofluorescence IHC = Immunohistochemistry 
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2.4  Human histology  
2.4.1 Cases   
Table 2.11 Control patient post mortem case details 
PM = post mortem, AAO = age at onset, AAD = age at death Path = Pathological 
 
Case number PM delay (hrs:mins) AAD Gender Clinical Diagnosis Cause of Death Path Diagnosis 
1 171:00 69 M Neurologically normal Myocardial infarction Normal/ path ageing 
2 24:00 73 F Neurologically normal Pulmonary embolism Path ageing 
3 16:15 88 M Neurologically normal Cardiac arrest Path ageing/ TDP-43 
4 99:00 83 F Neurologically normal 
Bronchopneumonia/ renal 
failure 
Normal/ path ageing/ incidental lewy 
bodies 
5 49:10 80 F Neurologically normal Pancreatic carcinoma Normal/ path ageing 
6 120:00 86 F Neurologically normal N/a Normal/ path ageing 
7 29:40 93 F Neurologically normal N/a Normal/ path ageing/ TDP-43  
8 43:07 91 F Neurologically normal Cerebrovascular disease 
Normal/ path ageing/ incidental lewy 
bodies 
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Case number PM delay (hrs:mins) AAO AAD Duration Gender Clinical Diagnosis Path Diagnosis Mutations 
9 85:35 56 67 11 F HD (EARLY ONSET) FTLD-TDP, Type A C9orf72 
10 99:00 62 68 6 M FTD FTLD-TDP type A C9orf72  
11 51:52 66 71 5 M FTD/MND FTLD-TDPA C9orf72 
12 30:00 59 65 6 M FTD FTLD-TDPA C9orf72 
13 115:00 58 66.8 8.8 F MND FTLD-TDP type A GRN/ C9orf72 
14 94:05 64 66 2 F FTD FTLD-TDP, type B C9orf72 
15 63:05 57 62 5 F FTD FTLD-TDP C9orf72 
16 32:20 54 60 6 M FTD FTLD-TDP, type A C9orf72 
17 77:20 53 63 10 M FTD FTLD-TDP, type A C9orf72  
18 85:50 66 74 8 F FTD FTLD-TDP type A C9orf72 
19 25:53 43 45 2 M FTD FTLD-TDP, Type A C9orf72 homozygous 
Table 2.12 C9orf72 patient post mortem case details. 
PM = post mortem, AAO = age at onset, AAD = age at death Path = Pathological 
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Paraffin embedding (Section 2.4.2), sectioning (Section 2.4.2) and immunohistochemical 
staining for light microscopy (Section 2.4.3), of human brain tissue was kindly carried out by 
Dr. Tammaryn Lashley and colleagues at the Queen Square Brain Bank. Presence of the 
C9orf72 repeat expansion in FTD cases was confirmed by Southern blot or repeat primed 
PCR. 
2.4.2 Tissue Processing 
Formalin fixed brain tissue was embedded in paraffin wax by dehydration in a series of 
ethanol baths, clearing with chloroform, and infiltration with paraffin wax as detailed in 
Table 2.13. Embedded tissue was then stored until required. 7 µm or 20 µm sections were 
cut using a Leica sledge microtome, transferred into 30 % ethanol solution, floated onto 
warm water and then picked up on either Vectabond coated slides (Vector) or superfrost 
slides (BDH). Sections were dried at 37 °C for several hours followed by a 60 °C incubation 
overnight. 
Step Number of 
washes 
Reagent Duration 
(hours) 
1 1 70 % ethanol 6 
2 2 90 %  ethanol 6 
3 4 100 % ethanol 6 
4 2 Chloroform 6 
5 3 Paraffin wax 6 
Table 2.13 Paraffin embedding of post mortem brain specimens 
2.4.3 Immunohistochemistry 
7 µm thick paraffin embedded frontal cortex, cerebellum and hippocampus sections were 
dewaxed for 3 x 5 minute washes in xylene, followed by rehydration in 100 %, 95 % and 70 
% ethanol (Fisher). Slides were incubated in 0.3 % H2O2 (Sigma) in methanol (BDH) for 10 
minutes to block endogenous peroxidase activity, followed a ddH2O wash for a minimum of 
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5 minutes. Sections then underwent antigen retrieval by boiling in citrate buffer in a 
pressure cooker for 10 minutes at maximum pressure.  
Non-specific binding was blocked by incubating slides in 10 % non-fat milk (Marvel) in PBS 
for 30 minutes at room temperature. Slides were then incubated in the relevant primary 
antibody (see Table 2.9 above) either at room temperature for 1 hour, or overnight at 4 °C. 
After two PBS washes, sections were incubated at room temperature for 30 minutes with 
secondary antibody, followed by two more washes in PBS. The slides were then incubated 
for 30 minutes with avidin-biotin complex (Dako), washed in ddH2O, and were then washed 
twice in PBS. Antibody binding was visualised by the reaction of di-aminobenzenase (DAB, 
Sigma) chromagen with the peroxidase complex, which results in a dark brown stain.  Slides 
were incubated in 500 µg DAB / 100 mL PBS, activated with 32 µL 30 % H2O2 solution for 4 
minutes, after which the colour intensity was checked using a light microscope. If a darker 
stain was required, sections could be replaced into DAB solution for further incubation. 
Slides were placed into Mayers haemotoxylin (BDH) for 10 seconds to counterstain for cell 
nuclei, before washing in ddH2O. Sections were then dehydrated by washing in 70 %, 95 % 
and 100 % ethanol, cleared in two washes of xylene and were mounted with Depex 
mounting media (BDH). Slides were then scanned at a 40 x magnification using a Leica 
SCN400. 
2.4.4 Immunofluorescence 
In order to facilitate the visualisation of full cell nuclei and nucleoli in human brain, 20 µm 
thick paraffin embedded frontal cortex sections were used. Sections were first trimmed to 
approximately 15 mm2 in size by scraping away excess tissue using a scalpel. Sections were 
dewaxed and rehydrated as follows: 3 x 5 minute washes in xylene (VWR), 2 x 5 minute 
washes in 100 % ethanol, 1 x 5 minute wash in 90 % ethanol, 1 x 5 minute wash in 70 % 
ethanol, 3 x 5 minute washes in ddH2O.  
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Following rehydration, both a proteinase antigen retrieval, and a heat-induced antigen 
retrieval step were carried out, which was found to be necessary to ensure clear 
visualisation of nucleoli in these sections.  The slides were incubated for 2 minutes in 500 µl 
of pre-prepared proteinase K solution (Dako; diluted in 50 mM Tris-HCl, 15 mM sodium 
azide, pH 7.5), before washing for 5 minutes in ddH2O. Samples were lowered into a 
pressure cooker (Tower 4200H) containing 2 L 10 mM Citrate buffer solution (378 mg/L 
citric acid; VWR, 2.41 g/L sodium citrate; VWR, in ddH2O, pH6), which was made by diluting 
36 mL citric acid solution (21 g/L citric acid; VWR in ddH2O), and 164 mL sodium citrate 
solution (29.41 g/L sodium citrate; VWR in ddH2O) in 1.8 L ddH2O. Samples were heated on 
full power until the pressure indicator was triggered, following which the power was turned 
down to ⅓ of full power for 4 minutes. The cooker was then taken off the heat for 4 
minutes, and then placed under running cold water for 5 minutes. The samples were 
washed 3 x 5 minutes in ddH2O, followed by 2 x 5 minute washes in 1 x PBS. Non-specific 
binding was blocked by incubating slides in 500 µL 10 % FBS in PBS for 30 minutes. Blocking 
solution was then removed, and slides were incubated in 200 µL of the required primary 
antibodies diluted in PBS at 4 °C overnight. Samples were then washed 3 x 5 minutes in PBS 
while rocking, followed by incubation in 200 µL of the required secondary antibodies 
diluted in PBS, for 1 hour at room temperature. After this incubation the slides were 
washed for 5 minutes in PBS while rocking, and were then incubated with 500 µL Sudan 
Black B solution (Sigma; 0.2 % in 70 % Ethanol/ 30 % PBS) for 10 minutes at room 
temperature to reduce autofluorescence in the tissue. Finally, the slides were washed a 
further 3 x 5 minutes in PBS while agitating, and the samples were mounted using 
ProLong® Gold Antifade Mountant with DAPI (Life Technologies) and 24 mm x 50 mm glass 
coverslips. 
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2.5  Analysis of immunofluorescence 
2.5.1 Confocal Microscopy 
Images of immunofluorescent staining were acquired using an LSM710 confocal 
microscope (Zeiss) using a plan-apochromat 40x/1.4 NA oil immersion objective with 
Immersol™ Immersion Oil (Zeiss). See Table 2.14 for details of lasers used. 
Table 2.14 LSM710 laser details 
 
2.5.1.1 Image capture of RNA foci in SH-SY5Y cells 
RNA foci were identified by fluorescence in-situ hybridisation in transfected SH-SY5Y cells 
(Section 2.2.5). For image capture, fifteen z-stack images were acquired by confocal 
microscopy consisting of four 2084 x 2084 pixel z-planes each over a 5 µm depth, to give at 
least 100 transfected cells to analyse. 405 nm, 488 nm and 561 nm lasers all at 2.0 % power 
were used to excite the samples, with a consistent gain and 90 µm pinhole (2 µm sections, 
2.26 AU) used across all images. Z-stacks were converted to a 2D image using a maximum 
intensity projection preceding image analysis. 
2.5.1.2 Image capture of immunofluorescence on human post mortem brain tissue 
For each slide of stained human post mortem brain tissue (Section 2.4.4), twenty z-stack 
images were captured consisting of twelve 2084 x 2084 pixel z-planes each over a 20 µm 
depth, to give between 200 and 1000 non-inclusion bearing neurons and between 20 and 
Laser type Wavelength Maximum power (mW) 
Diode 405-30 405 30 
Argon 458, 488, 514 25 
DPSS 561-10 561 20 
HeNe633 633 5.0 
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150 inclusion bearing neurons to analyse in C9orf72 FTLD patients. 405nm, 488 nm, 561 nm 
and 633 nm lasers all at 2.0 % power were used to excite the samples, with a 90 µm pinhole 
(2 µm sections, 2.26 AU) used across all images. Due to the variability of fluorescence 
intensity between different patient samples, gain was adjusted to peak intensity for each 
patient.  
2.5.2 Image analysis 
Analysis of confocal images was performed using Volocity image analysis software (Perkin 
Elmer).  
2.5.2.1 Analysis of RNA foci in SH-SY5Y cells 
Analysis protocols were designed to quantify the number of sense RNA foci (see Table 2.15 
for a detailed protocol) or antisense RNA foci (see Table 2.16 for a detailed protocol) within 
the nuclei of cells identified using a co-transfection marker. Data was outputted as the 
number of foci detected for each cell expressing the co-transfection marker, and exported 
into Microsoft Excel. 
2.5.2.2 Analysis of immunofluorescence on human post mortem brain tissue 
Analysis protocols were designed to quantify the 3D volume of the nucleolar markers 
nucleophosmin (see Table 2.17 for a detailed protocol) or nucleolin (see Table 2.18 for a 
detailed protocol) within the nuclei of neurons counterstained with NeuN. Both protocols 
also identified the presence or absence of a poly(GR) inclusion within each neuron. Data 
was outputted as the volume of nucleolar staining, the volume of DAPI staining and the 
volume of GR staining for each NeuN positive neuron and for each patient. After exporting 
the data into Microsoft Excel, neurons for which the program had detected no nucleolar 
staining or no DAPI staining were excluded from the analysis. 
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Task Steps in Volocity protocol 
Identify ZsGreen positive cells 
to give population “ZsGreen”. 
Find objects using intensity in 488 channel: threshold 6 
Fill holes in objects 
Exclude objects smaller than 10 µm2 
Separate touching objects: size guide 800 µm2 
Exclude objects smaller than 10 µm2 
Identify DAPI stained nuclei to 
give population “DAPI”. 
Find objects using intensity in 405 channel: threshold 20 
Fill holes in objects 
Exclude objects smaller than 10 µm2 
Identify sense foci stained with 
red FISH probe to give 
population “RNA foci” 
Find objects using intensity in 546 channel: threshold 12 
Exclude objects smaller than 6 µm2 
Separate touching objects: size guide 0.01 µm2 
Exclude objects smaller than 0.05 µm2 
Exclude background staining 
outside of the nucleus to give 
new population: “RNA foci in 
DAPI” 
Exclude “RNA foci” objects not touching “DAPI” objects 
Compartmentalise RNA foci 
into ZsGreen positive cells 
Compartmentalise: Divide “RNA foci in DAPI” between 
“ZsGreen” objects 
Table 2.15 Volocity protocol for quantification of sense RNA foci 
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Task Steps in Volocity protocol 
Identify DsRed positive cells to 
give population “DsRed”. 
Find objects using intensity in 546 channel: threshold 5 
Fill holes in objects 
Exclude objects smaller than 10 µm2 
Separate touching objects: size guide 800 µm2 
Exclude objects smaller than 10 µm2 
Identify DAPI stained nuclei to 
give population “DAPI”. 
Find objects using intensity in 405 channel: threshold 20 
Fill holes in objects 
Exclude objects smaller than 10 µm2 
Identify antisense foci stained 
with green FISH probe to give 
population “RNA foci” 
Find objects using intensity in 488 channel: threshold 9 
Exclude objects smaller than 6 µm2 
Separate touching objects: size guide 0.01 µm2 
Exclude objects smaller than 0.05 µm2 
Exclude background staining 
outside of the nucleus to give 
new population: “RNA foci in 
DAPI” 
Exclude “RNA foci” objects not touching DAPI objects 
Compartmentalise foci into 
DsRed positive cells. 
Compartmentalise: Divide “RNA foci inside DAPI” 
between “DsRed” objects 
Table 2.16 Volocity protocol for quantification of antisense RNA foci  
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Task Steps in Volocity protocol 
Identify DAPI stained nuclei to 
give population “DAPI” 
Find objects using standard deviation intensity in 405 
channel: threshold 0.8 standard deviations 
Exclude objects smaller than 20 µm3  
Close: 5 iterations 
Fill holes in objects 
Separate touching objects: size guide 450 µm3 
Exclude objects smaller than 10 µm3 
Identify nucleophosmin stained 
nucleoli to give population 
“nucleoli” 
Find objects using standard deviation intensity in 488 
channel: threshold 9 standard deviations  
Exclude objects smaller than 0.5 µm3 
Fill holes in objects 
Identify poly(GR) inclusions to 
give population “GR” 
Find objects using intensity in 546 channel: threshold 10 
Exclude objects smaller than 2 µm3 
Close: 5 iterations 
Generate areas 2 pixels dilated 
from nucleoli to give new 
population: “Expanded 
nucleoli” to be used in removal 
of GR background 
Generate a new population by dilating “nucleoli” objects 
by 2 iterations 
Exclude background staining in 
nucleoli from GR population to 
give new population: “GR 
without background” 
Subtract “expanded nucleoli” from “GR” 
Exclude objects smaller than 1 µm3 
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Identify NeuN positive objects 
to give population “NeuN” 
Find objects using standard deviation intensity in 633 
channel: threshold 1.04 standard deviations 
Exclude objects smaller than 1 µm3 
Close: 5 iterations 
Dilate: 3 iterations 
Fill holes in objects 
Separate touching objects: size guide 500 µm3 
Exclude objects smaller than 150 µm3 
Define new population 
“neurons” from DAPI nuclei 
positive for NeuN staining 
Exclude “DAPI” objects not touching “NeuN” objects 
Dilate: 10 iterations 
Separate touching objects: size guide 600 µm3 
Exclude objects smaller than 300 µm3 
Exclude DAPI not inside 
Neurons to give new 
population: “DAPI inside NeuN” 
Intersect “DAPI” objects with “neurons” objects 
Exclude objects smaller than 50 µm3 
Compartmentalise nucleoli, 
DAPI inside NeuN and GR 
without background into 
neurons. 
Compartmentalise: Divide “nucleoli”, “DAPI inside 
NeuN” and “GR without background” between neurons. 
Table 2.17 Volocity protocol for quantification of nucleophosmin volume in poly(GR) inclusion bearing and 
non-inclusion bearing neurons 
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Task Steps in Volocity protocol 
Identify DAPI stained nuclei to 
give population “DAPI” 
Find objects using standard deviation intensity in 405 
channel: threshold 0.8 standard deviations 
Exclude objects smaller than 20 µm3  
Close: 5 iterations 
Fill holes in objects 
Separate touching objects: size guide 450 µm3 
Exclude objects smaller than 10 µm3 
Identify nucleolin stained 
nucleoli to give population 
“nucleoli” 
Find objects using standard deviation intensity in 488 
channel: threshold 9 standard deviations 
Exclude objects smaller than 0.5 µm3 
Fill holes in objects 
Identify diffuse nucleolin 
staining to give population 
“diffuse nucleolin” 
Find objects using standard deviation intensity in 488 
channel: threshold 5 standard deviations 
Exclude objects smaller than 0.5 µm3 
Separate touching objects: size guide 80 µm3 
Identify poly(GR) inclusions to 
give population “GR”. 
Find objects using intensity in 546 channel: threshold 10 
Exclude objects smaller than 2 µm3 
Close: 5 iterations 
Generate areas 2 pixels dilated 
from nucleoli to give new 
population: “Expanded 
nucleoli” to be used in removal 
of GR background 
Generate a new population by dilating “nucleoli” objects 
by 2 iterations 
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Exclude background staining in 
nucleoli from GR inclusion 
objects to give new population: 
“GR without background” 
Subtract “expanded nucleoli” from “GR” 
Exclude objects smaller than 1 µm3 
Identify NeuN positive objects 
to give population “NeuN” 
Find objects using standard deviation intensity in 633 
channel: threshold 1.04 standard deviations 
Exclude objects smaller than 1 µm3 
Close: 5 iterations 
Dilate: 3 iterations 
Fill holes in objects 
Separate touching objects: size guide 500 µm3 
Exclude objects smaller than 150 µm3 
Define new population 
“neurons” from DAPI nuclei 
positive for NeuN staining 
Exclude “DAPI” objects not touching “NeuN” objects 
Dilate: 10 iterations 
Separate touching objects: size guide 600 µm3 
Exclude objects smaller than 300 µm3 
Exclude DAPI not inside 
neurons to give new 
population: “DAPI inside NeuN” 
Intersect “DAPI” objects with “neurons” objects 
Exclude objects smaller than 50 µm3 
Compartmentalise nucleoli, 
DAPI inside NeuN and GR 
without background into 
neurons. 
Compartmentalise: Divide “nucleoli”, “diffuse nucleolin”, 
“DAPI inside NeuN” and “GR without background” 
between “neurons”. 
Table 2.18 Volocity protocol for quantification of nucleolin volume in poly(GR) inclusion bearing and non-
inclusion bearing neurons 
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2.5.3 Analysis of immunohistochemistry 
Analysis of DAB stained post-mortem brain images was carried out using the Definiens 
Developer XD life portal (Definiens) in collaboration with Matthew Ellis. A ruleset was 
developed to quantify the proportion of DPR protein inclusion positive cells within the 
cerebellar granule cell layer and molecular layer of C9orf72 post-mortem patients (Table 
2.19). Four ruleset versions were generated with minor alterations that enabled the 
analysis of varying DAB staining and hematoxylin signal strengths (Table 2.20, 2.21). 
Regions to be analysed were determined impartially by selecting a branch residing a pre-
specified distance from the edge of the slide. Outlining of the areas for analysis was 
performed at a low magnification in the absence of the examination of individual cells.       
Task Steps in Definiens protocol 
1. Identify 
region of 
interest: 
program 
differentiates 
between tissue 
to be analysed 
and background 
around it. 
1a. Generate low resolution map at 25 % scale (allows image to be 
processed more quickly when analysing a large image area) 
1b. Find the darkest value in red, blue and green channels for each 
pixel. Classify the lightest 5th percentile of pixels as background and the 
darkest 95th percentile as region of interest (ROI). 
1c. Remove isolated objects that comprise less than 5% of total tissue 
area (removes any extraneous damaged tissue pieces) 
2. Manually 
outline region 
to be analysed. 
2a. User manually draws a polygon around the regions of tissue to be 
analysed in the low resolution map on each slide, and classifies as 
either “granule cell layer” or “molecular layer”. 
3. Removal of 
very dark debris 
 
3a. On the low resolution map, program identifies areas of 500 μm2 or 
higher in which the lightest red, green or blue value is under 100 units 
and removes these from the ROI. 
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4. Analysis map 
set up 
4a. Using the user drawn areas and the region of interest identified, 
program sets up a separate “Final stain analysis” map for the image 
analysis to be performed on. 
5. Brown DAB 
stain 
identification 
5a. Version 1 (Normal DAB staining in granule cell 
layer). Program identifies the thresholds for the 95th 
percentile of brown staining and defines this as 
“Th_brown”, then identifies the top 93rd percentile 
of brown staining and defines this as 
“Th_brown_temp” . If Th_brown is below 0.4 units 
(i.e. the image contains very little brown staining), 
then this threshold is set to 0.4, and 
Th_brown_temp is set to 0.35 to avoid identification 
of false positives. 
Different 
versions of step 
5a were used 
depending on 
the brain 
region, 
darkness of 
background 
DAB signal and 
darkness of 
hematoxylin 
stain. Please 
see tables 2.20 
and 2.21 for 
which versions 
were used on 
which  
specimens.    
 
5a. Version 2 (Normal DAB staining in molecular 
layer). Program checks the brown value at the 99.9th 
percentile of brown staining and sequentially checks 
0.5 percentile lower until the difference in brown 
value between two successive percentiles is more 
than 0.2 units and defines this as the threshold 
“Th_brown”. A second threshold “Th_brown_temp” 
is set at 1 percentile lower. 
If Th_brown is lower than 0.4 units (i.e. the image 
contains very little brown staining), then the 
program checks the lowest percentile that was 
reached.  If the percentile reached was less than 
50.4 (i.e. no inclusions detected in the area), 
Th_brown is set to 0.6 and Th_brown_temp is set to 
0.55. If the lowest percentile reached was above 
50.4, Th_brown is set to 0.4 and Th_brown_temp is 
set to 0.35. 
5a. Version 3 (Dark DAB staining in granule cell and 
molecular layers). Program identifies the threshold 
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for the 98th percentile of brown staining and defines 
this as “Th_brown”, then identifies the top 95th 
percentile of brown staining and defines this as 
“Th_brown_temp” . If Th_brown is below 0.7 units 
(i.e. the image contains very few dark aggregates), 
then this threshold is set to 0.7, and 
Th_brown_temp is set to 0.65 to avoid identification 
of false positives. 
 
5a. Version 4 (Very dark DAB identification in 
granule cell and molecular layers). Program 
identifies the threshold for the 98th percentile of 
brown staining and defines this as “Th_brown”, then 
identifies the top 95th percentile of brown staining 
and defines this as “Th_brown_temp” . If Th_brown 
is below 0.9 units (i.e. the image contains very few 
dark aggregates), then this threshold is set to 0.9, 
and Th_brown_temp is set to 0.85 to avoid 
identification of false positives. 
 
5a. Version 5 (DAB staining against dark 
hematoxylin in granule cell layer). Program 
identifies the threshold for the 95th percentile of 
brown staining and defines this as “Th_brown”, then 
identifies the top 93th percentile of brown staining 
and defines this as “Th_brown_temp” . If Th_brown 
is below 0.5 units (i.e. the image contains very few 
dark aggregates), then this threshold is set to 0.5, 
and Th_brown_temp is set to 0.45 to avoid 
identification of false positives. 
 
5b. Pixels with brown staining higher than the Th_brown threshold are 
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identified by the program. If the identified pixels are bordering with 
pixels above the Th_brown_temp threshold, the identified area grows 
out to include them. This process is repeated for 3 iterations. 
5c. The difference between levels of brown and blue colour is 
measured, and objects with less than 0.1 units more brown value than 
blue value are removed. This avoids identification of dark 
haemotoxylin stain.  
 
5d. Brown objects are grown by 1 pixel and shrunk by 1 pixel for 3 
iterations. This smooths the object and fills holes.  
5e. Any single pixel brown objects not touching another brown object 
are removed.  
6. Blue 
haemotoxylin 
stain 
identification 
6a. If the mean brown staining value for the image is less than 0.5, i.e. 
there is low brown background staining, then program checks the blue 
value at the 99th percentile of blue staining and sequentially checks 1 
percentile lower until the difference in blue value between two 
successive percentiles is more than 0.0025 units and defines this as the 
threshold “Th_blue”. A second threshold “Th_blue_temp” is set at 4 
percentile lower.   
If the mean brown staining value is more than 0.5, i.e there is a high 
brown background staining, then Th_blue is set to the value of the 40th 
percentile, and Th_blue_temp is set to the 35th percentile. 
6b. Pixels with blue staining higher than the Th_blue threshold are 
identified by the program. If the identified pixels are bordering with 
pixels above the Th_blue_temp threshold, the identified area grows 
out to include them. This process is repeated for 3 iterations. 
6c. Blue objects are grown and shrunk by one pixel for 2 iterations. This 
smooths the objects and fills holes. 
6d. Blood vessels are identified by finding This step was only used in 
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blue objects with a length/width ratio of 
over 3, or a size of over 2000 pixels.  
These objects are then removed from the 
nuclei population.  
the molecular layer and is 
absent in the granule cell 
layer protocol 
6e. Blue objects smaller than 50 pixels are removed.   
7. Separating 
touching nuclei 
(summary) 
7a. Opening: Non-circular objects (with an elliptic fit of < 0.8 where 1 is 
a perfect circle) are opened using a series of rolling balls of increasing 
size which erode away the extremities of the cells and accentuate the 
indentations between cells to facilitate separation.  
7b. Initial separation: Points within the objects which exhibit a concave 
angle of > 15 ° are marked as “corners”.  
A distance map is set up that calculates the distance between all edges 
in the object. Pairs of corners that define the shortest internal distance 
in the object are connected to split the cells.     
7c. Rounding: Merge objects that share 0.5 border distance or more 
(i.e. one object partially encloses another object) 
Merge small objects of 50 pixels or less with a larger bordering object 
when that merge will result in a more circular object.    
7d. Use of dark stained areas: The 85th percentile is used to define 
areas of very dark hematoxylin stain within nuclei. These regions 
undergo 5 iterations of growing by 1 pixel and shrinking by 1 pixel to 
round the objects and remove holes. These objects are then expanded 
into the existing nuclei objects, and the border at which these objects 
meet is used to define a split between the cells.  
7e. Separating remaining objects over 250 pixels: A distance map is set 
up for the remaining objects that are larger than 250 pixels. The pixel 
with the largest distance from the object edge is determined (i.e. the 
centre point of a nucleus). The distance of pixels from the object edge 
is then measured in concentric circles expanding out from this centre 
point. When pixels are found to be further away from the object edge 
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than the previous tier of pixels, this is likely to be a bottleneck between 
nuclei, and the objects are split at this point.  The program undergoes 
multiple loops of this process until no further objects of over 250 pixels 
can be divided. 
7f. The areas of brown objects found within blue objects are merged 
with blue objects to fill holes in nuclei detected due to presence of 
inclusions.   
7g. Rounding: Objects undergo several iterations of growing by 1 pixel 
and shrinking by 1 pixel to round the objects and remove holes. 
7h. Remaining small objects are merged into neighbouring nuclei.  
8. 
Compartmentali
sing brown DAB 
stained objects 
into blue nuclei 
 
 
8a. If a nucleus contains more than one brown object, the areas of the 
inclusions are expanded out into the containing blue object. The blue 
object is then split along where these domains meet. This results in 
one cell only containing one inclusion.   
8b. Classify blue objects containing brown objects as positive nuclei. 
Remaining nuclei are classified as negative nuclei. 
8c. Brown objects not contained within a nucleus are classed as “lone 
brown”. 
9. Export 
9a. Numbers of “Positive nuclei”, “negative nuclei” and “lone brown” 
are exported into a Microsoft Excel spreadsheet for analysis. 
 
Table 2.19 Definiens protocol for quantification of the DPR inclusion frequency. 
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ID Protocol Granule Cell Layer Molecular Layer 
A Normal protocol 
Step 5a. Version 1 (Light 
DAB staining GCL) 
Step 5a. Version 2 (Light 
DAB staining ML) 
Step 6e. (Blood vessel 
identification)  
B Dark DAB protocol  
Step 5a. Version 3 (Dark 
DAB staining) 
Step 5a. Version 3 (Dark 
DAB staining) 
Step 6e. (Blood vessel 
identification) 
C Very dark DAB protocol  
Step 5a. Version 4 (Very 
dark DAB staining) 
Step 5a. Version 4 (Very 
dark DAB staining) 
Step 6e. (Blood vessel 
identification) 
D 
Dark hematoxylin 
protocol 
 
Step 5a. Version 5 (DAB 
detection against dark 
hematoxylin in GCL) 
Step 5a. Version 1 (Light 
DAB staining ML) 
Step 6e. (Blood vessel 
identification) 
 
Table 2.20: Differences between the four rule sets used in Definiens analysis  
 Immunostain 
Case no. p62 GA GP GR AP PR 
9 A B A D A A 
10 A C A D A A 
13 A B A D A A 
14 A C A D A A 
15 A C A D A A 
16 A B A D A A 
17 A C A D A A 
18 A B A D A A 
19 A B A D A A 
20 A B A D A A 
 
Table 2.21 Definiens rule sets used for each patient brain specimen  
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2.6  Statistical analysis 
Statistical analysis was carried out using Prism statistical analysis software (GraphPad 
Software Inc.), with the exception of the nucleolar and nuclear volume comparisons 
(Chapter 5), which were carried out with the kind help of Dr. Vincent Plagnol using R 
programming language.  
2.7  Software list 
Adobe Photoshop 
Definiens Developer XD 
Microsoft Excel 
ND-1000 Nanodrop software (Thermo Scientific) 
Peak scanner (Applied Biosystems) 
Prism (Graphpad Software Inc.) 
Quantity One (BioRad). 
Sequence scanner (Applied Biosystems) 
Volocity Image analysis software (Perkin Elmer) 
Zen black 2011 (Zeiss) 
Zen blue 2011 (Zeiss) 
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Chapter 3:  Investigating RNA gain-of-function 
mechanisms in C9orf72 FTD/ALS 
3.1  Introduction  
As detailed in the main introduction (Chapter 1), there are a number of different molecular 
mechanisms at work that may contribute to the pathology observed in C9orf72 FTD/ALS 
patients: loss of C9orf72 protein function, gain of RNA function or gain of DPR protein 
function. Therefore, an important research question is: what is the impact of each of these 
different pathways on disease progression? Furthermore, which component in this cascade 
would be the best target for future treatments? We opted to first investigate the 
contribution of an RNA gain-of-function mechanism to C9orf72 FTD/ALS pathology, which 
has been observed to play an important role in a number of other non-coding repeat 
pathologies. 
It is difficult to determine how different pathological mechanisms might individually lead to 
neurodegeneration solely by examining patient tissue, due to the vast number of variables 
interacting in human disease. Instead, we can use model systems to manipulate individual 
variables in a controlled environment to determine their importance. Cell culture models 
provide a practical means of rapidly testing a range of different conditions. In order to 
study the gain-of-function mechanisms of a particular DNA sequence, it can be expressed in 
a cell line outside of its normal genetic context. This also permits the manipulation of the 
DNA responsible for disease to determine how it exerts its pathological effect. 
We therefore sought to express GGGGCC repeats in isolation from their genomic context in 
a cell culture system. However, cloning these repeats presents a number of unique 
difficulties. A common strategy to isolate a DNA sequence from patient tissue would be to 
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use polymerase chain reaction (PCR) to replicate the sequence. However, this is impeded in 
C9orf72 FTD/ALS by the repetitive and 100 percent GC nature of these repeats which 
results in a high melting temperature and strong secondary structure formation. Successful 
PCR amplification of the thousands of hexanucleotide repeats observed in patients is 
therefore unfeasible. In addition, the repeats are highly unstable and frequently undergo 
deletions when transformed into bacteria for cloning, necessitating the use of specialised 
cloning protocols.  
This chapter details how we overcome these difficulties to generate a range of repeat 
constructs of different lengths, which allow the study of either RNA gain-of-function in 
isolation, or RNA and DPR gain-of-functions together. These constructs were then 
transfected into a SH-SY5Y neuroblastoma cell line, and the formation of both sense and 
antisense RNA foci were examined in the context of repeat length. These genetic tools 
were also subcloned into a Drosophila melanogaster expression vector and the effect of 
the different constructs were examined in a fly model of neurodegeneration in  
collaboration with Professor Linda Partridge and colleagues at the UCL Institute for Healthy 
Ageing and the Max Planck Institute for Biology of Aging.  
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3.2  Results 
3.2.1 Generation of pure GGGGCC repeat constructs 
To generate long tracts of GGGGCC repeat DNA in a plasmid vector, a strategy of recursive 
directional ligation (RDL) was used to overcome the difficulties imposed by the repetitive, 
GC-rich nature of this sequence (Figure 3.1). This method builds repetitive sequences of 
increasing length by seamlessly ligating smaller building blocks of DNA together in a 
stepwise manner, and has previously been used to synthesise elastin-like polypeptides 
(Meyer and Chilkoti, 2002). Initial oligonucleotides were designed containing 3 GGGGCC  
 
Figure 3.1 Schematic of recursive directional ligation cloning strategy 
Recursive directional ligation (RDL) was used to build a range of repeat sizes. (1) A double digest with EcoOI09I  
and BspQI is carried out on a repeat containing vector to release the repeat insert. (2) The repeat containing 
vector additionally undergoes a single BspQI digest to open the vector backbone. (3) One or more released 
repeat inserts are ligated into the vector backbone, generating a product with 2 or more units of the original 
repeat sequence. (4) Additional rounds of RDL can be carried out to further increase the repeat length 
exponentially. (5) The ligation is designed so that the restriction site between repeat units is removed with no 
break in the GGGGCC repeat sequence, allowing the progressive build-up of larger repeats. 
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Forward:  
Reverse:  
repeats flanked by EcoO109I and BspQI restriction sites (Figure 3.2). Forward and reverse 
oligonucleotides were annealed and ligated into a pBlueScript II SK+ cloning vector digested 
with BamHI and NotI, and the ligation product was transformed into chemically competent 
E. coli. For these initial constructs and for other repeat constructs with inserts of 36 repeats 
or less, colony PCR was carried out to screen for colonies with an insert of the correct size. 
The repeat containing plasmid DNA was then purified, and two restriction enzyme 
digestion reactions were set up: 1) a double digest with BspQI and EcoO109I to release the 
repeat insert, and 2) a single digest with BspQI to open the vector at a site adjacent to the 
repeats. The digests were resolved on an agarose gel on which the length of the digestion 
products was checked, after which the repeat insert DNA from the double digest and the 
linearised vector from the single digest were excised, extracted and ligated together. The 
overhangs produced by EcoO109I and BspQI enzymes are compatible, and adhesion 
between the two results in the removal of both restriction sites with no break left in the 
GGGGCC repeat sequence. The ligation product therefore contains double the number of 
repeats or more, and restriction sites remain present only at the ends of the total repeat 
sequence. More than one repeat insert may also ligate into the linearised backbone 
yielding triple the original number of repeats or more. Indeed, during the first round of RDL 
with the 3 repeat construct, as many as seven inserts ligated into the vector yielding a 
construct with 21 total repeats (Table 3.1). Products from the previous ligation can then 
become the new starting point for the next round of RDL, and can be digested as detailed 
above to perform additional rounds of RDL. This results in an exponential increase in repeat  
 
Figure 3.2  Design of pure repeat oligonucleotides 
 
Sequences of the initial forward and reverse oligonucleotides used for generation of pure repeat constructs. 
Pure repeat oligonucleotides containing 3 repeats were designed with flanking BspQI and EcoOI09I sites to be 
used in RDL. The oligonucleotide was cloned into empty pBluescript II SK+ using BamHI and NotI restriction 
sites.  
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size with each cycle. Constructs of different sizes can also be ligated to generate numerous 
different lengths. A number of precautions were taken in conjunction with our recursive 
directional ligation cloning strategy in an attempt to minimise repeat instability during the 
cloning process. The Stbl3 E. coli strain, which has a mutation in the recA recombinase, was 
used in order to promote repeat stability. It has also previously been shown that passing 
through stationary growth phase can promote increased deletions in bacteria 
Number of 
repeats 
Size 
(bp) 
Generated 
from 
Subcloned into 
pcDNA3.1+ 
Subcloned 
into 
pUASTattb 
3 18 3r oligo   
6 36 3 + 3   
9 54 3 + 3 + 3   
12 72 4 x 3   
15 90 5 x 3   
21 126 7 x 3   
36 216 21 + 15   
42 252 21 + 21   
63 378 21 +21 + 21 *60  
80* 480 
63 + 63 
deletion 
product 
*74  
103* 618 
63 + 63 
deletion 
product 
  
 
Table 3.1 Pure repeat constructs 
Pure repeat sizes generated by RDL, and the repeat lengths subcloned into expression vectors. Asterisks 
denote deletion products.  
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Figure 3.3 Agarose gel displaying pure repeat insert sizes 
 
Pure repeat constructs in pBluescript II SK+ were digested with BspQI and EcoO190I to 
release repeat fragment for sizing. r = repeats. 
 
(Parniewski et al., 2000), and care was therefore taken to prohibit over-growth of cultures 
by limiting incubation times and maintaining cultures at 30 °C. Use of these cloning 
methods allowed the generation of a range of different repeat sizes up to a maximum of 
103 pure repeats (103r; Table 3.1; Figure 3.3).  
3.2.2 Design of interrupted ‘RNA-only’ repeat constructs 
Pure GGGGCC repeats above 103 repeats in length could not be generated as constructs 
above this length were highly unstable and underwent frequent deletions when 
transformed into E.coli. To surmount this limit and generate longer repeats such as those 
seen in human C9orf72 expansion patients, repeat constructs were designed that 
contained interruptions: short, non-repetitive segments of DNA interspersed at regular 
intervals throughout the repeats that act to stabilise the sequence. This strategy has 
previously been used for several in vivo models for myotonic dystrophy without 
compromising the pathogenicity of the repeats (de Haro et al., 2006; Orengo et al., 2008). A 
study examining GAA repeats responsible for Friedreich’s ataxia found that interruptions 
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that made up more than 4 % of the total sequence stabilised the repeats, however an 
interruption content of more than 11 % of the sequence affected DNA secondary structure 
formation (Sakamoto et al., 2001). We therefore designed the interruption content of our 
constructs to fall within this range.   
An AT-rich six base-pair interruption every 16 GGGGCC repeats (in which the interruption 
comprised 5.8 % of total sequence) was insufficient in stabilising the repeats in order to 
achieve more than 160 interrupted repeats, while a six base-pair interruption every 12 
repeats (in which the interruption comprised 7.7 % of total sequence) was able to stabilise 
over 1000 repeats (Figure 3.4). This format of 12 repeats with a 6 nucleotide interruption 
was therefore chosen to be optimal for our constructs. 
After determining that a six base-pair interruption every 12 repeats was optimal for the 
stabilisation of these repeats, the first reports were published describing RAN translation of 
the C9orf72 repeat expansion (Ash et al., 2013; Mori et al., 2013c). We therefore 
redesigned our interruptions to contain stop codons in all six reading frames in order to 
generate ‘RNA-only’ constructs for the purpose of dissecting RNA and DPR protein gain-of-
function disease mechanisms.  
   
 
 
Figure 3.4 Properties of pure and interrupted repeat constructs. 
 
Schematic diagram of the proportion of sequence comprised of interruptions. Purple bars represent GGGGCC 
repeat DNA. White bars represent 6 base pair AT rich interruptions 
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Three different AT-rich interruption sequences of 6 nucleotides in length were designed, 
which we termed interruptions A, B and C. Each interruption contained stop codons in two 
of the 6 reading frames (one sense frame and one antisense frame) to prohibit peptide 
production in all frames when expressed together (Figure 3.5). Interruptions were designed 
to occur every 12 repeats, alternating between the three different sequences, with a stop 
codon therefore occurring in each individual reading frame every 36 repeats. Three 
alternating interruption sequences were required as it was not possible to introduce more 
than two stop codons into a 6 base-pair AT rich sequence without either a) introducing an 
ATG start codon or b) introducing an EcoO109I restriction site.  
In order to insert the interruptions into the repeat sequence, t hree pairs of 
oligonucleotides were designed flanked by BspQI and EcoO109I overhangs, each containing 
one of the 3 interruptions plus 4 hexanucleotide repeats (Figure 3.6). Each pair of 
oligonucleotides were annealed and ligated into a BspQI and EcoO109I digested 
pBlueScript II SK+ vector containing 8 pure repeats. This resulted in three constructs that 
contained 12 repeats plus either interruption A (12ri A), B (12ri B) or C (12ri C). 12ri A was 
then singly digested with BspQI to open the plasmid adjacent to the repeat insert, while 
  
 
Figure 3.5 Design of stop codon containing interruptions 
 
In the RNA-only constructs, three AT rich interruptions occur every 12 GGGGCC repeats, each containing a stop 
codon in one sense and one antisense frame. This schematic shows the frames of RAN translation that are 
stopped in each interruption, resulting in one stop codon occurring in each frame every 36 repeats. 
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Forward:  
Reverse: 
 
Figure 3.7 Generation of alternating interruption constructs 
 
Flow chart detailing the initial cloning steps taken to generate the initial RNA-only constructs with three distinct 
alternating interruptions. Purple bar represents GGGGCC repeat sequence. Green, blue and orange bars 
represent interruptions A, B and C. Arrows illustrate the ligation order.  
 
 
Figure 3.6  Design of Interrupted repeat oligonucleotides 
 
Sequences of the initial forward and reverse oligonucleotides used for generation of pure repeat constructs. 
Three different forward and three different reverse interrupted oligonucleotides were designed, each 
containing a different interruption with stop codons in 2 frames and 4 GGGGCC repeats, which were cloned into 
pure 8 repeat constructs in pBluescript II SK+ to give a total of 12 repeats and an interruption.  
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12ri B underwent double digestion to release the insert, and these two products were 
ligated to yield 24 repeats containing interruptions A and B (24ri AB; Figure 3.7). Finally, 
24ri AB was singly digested with BspQI to open the plasmid adjacent to the repeat insert, 
while 12ri C underwent double digestion to release the insert, and these two products 
were ligated to yield 36 repeats containing interruption A, B, and C (36ri ABC; Figure 3.7). 
This 36ri ABC construct was then used as the initial building block for the process of RDL,  
Number 
of 
repeats 
Units of 
36 
No. of 
interruptions 
Size of 
insert 
(bp) 
Generated 
from 
Subcloned 
into 
pcDNA3.1+ 
Subcloned 
into 
pUASTattB 
12 0 1 78  
8 + 4r with 
interruption 
oligo 
  
24 0 2 156  12 + 12   
36 1 3 234  24 + 12   
72 2 6 468  36 + 36   
108 3 9 702  72 + 36 *107  
144 4 12 936  72 + 72   
288 8 24 1,872  144 + 144   
576 16 48 3,744  288 + 288   
864 24 72 5,616  
288 + 288 
+288   
1152 32 96 7,488  864 + 288   
 
Table 3.2 RNA-only interrupted repeat constructs 
Interrupted repeat sizes generated by RDL, and the repeat lengths subcloned into expression vectors. 
Asterisks denote deletion products  
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Figure 3.8 Agarose gel displaying interrupted repeat insert and cloning vector sizes 
 
Larger interrupted constructs in pBluescript II SK+ (vector band at 3 kb) were digested 
with BamHI and NotI to release repeat fragment for sizing. ri = interrupted repeats. 
 
 
 
 
 
 
Figure 3.9 G-quadruplex formation by pure and interrupted repeats 
 
Circular dichroism (CD) spectra for pure and interrupted repeats. Both 24 pure 
repeats (24r) and 24 repeat constructs interrupted every 12 repeats (24ri) exhibit 
CD spectra characteristic of G-quadruplex formation, indicating the retention of 
secondary structure formation by interrupted repeats. 
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which proceeded as described in section 3.2.1. A range of RNA-only construct sizes were 
built up to a largest stable size of 1152 interrupted repeats (1152ri) requiring 5 RDL cycles 
from the 36 interrupted repeat block (Table 3.2; Figure 3.8). Circular dichroism carried out 
by Dr. Andrew Nicoll on RNA from pure repeats and 24 repeat constructs interrupted every 
12 repeats showed that both structures formed spectra characteristic of G-quadruplexes 
(Figure 3.9), indicating that these repeats retain their ability to form disease relevant 
secondary structure.  
3.2.3 Subcloning of repeat constructs into mammalian and fly expression vectors 
A range of different sized pure repeats (r) and interrupted repeats (ri) were subcloned into 
a pcDNA3.1+ vector for expression in mammalian cells, and also into pUASTattB for 
expression in Drosophila melanogaster (Figure 3.10). For subcloning into pcDNA3.1+ the 
vector and each repeat construct to be subcloned was digested with BamHI and NotI, while 
for subcloning into pUASTattB, the vector and repeat constructs to be cloned were 
digested with EcoRI and NotI. The digests were resolved on an agarose gel to check the size  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.10 Agarose gel displaying subcloned repeat insert sizes 
 
Pure and interrupted repeat constructs cloned into pUASTattb were digested with EcoRI 
and NotI to release repeat fragment for sizing. r = pure repeats, ri = interrupted repeats. 
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of the digestion products against the expected size using the molecular weight markers. 
Insert bands of the correct size that did not show deletion products or smearing were 
extracted and ligated into the desired vector, and high concentration DNA at transfection 
grade purity was prepared by maxiprep.  
3.2.4 Sequencing of repeat constructs 
To check for deletions and mutations and to determine the exact repeat length, sequencing 
was attempted for all constructs generated. Due to the repetitive, GC-rich nature of the 
constructs, the maximum lengths for which sequencing was possible in full were 103r and 
108ri.  Both ends of the 288ri, 576ri and 1152ri repeats were sequenced as far as possible 
to screen for mutations, but exact size could not be determined by sequencing. The 
majority of constructs were found to be free from mutations, and those constructs found 
to contain point mutations were discarded. 
3.2.5 Optimisation of SH-SY5Y transfection 
To characterise the different constructs generated, transient transfection was carried out in 
the neuroblastoma cell line SH-SY5Y. A neuronal-like cell line was chosen as neurons are 
the cells principally affected by degeneration in C9orf72 FTD/ALS. In order to distinguish 
which cells had been transfected with the repeat constructs, cultures were co-transfected 
with either the green fluorescent marker ZsGreen or the red fluorescent marker DsRed, 
with a 10:1 ratio of repeat construct to co-transfection marker. To optimise the 
Lipofectamine2000 transfection protocol, a range of different cell densities, DNA 
quantities, transfection reagent quantities and transfection reagent incubation times were 
tested. Cells were examined by fluorescence microscopy, with transfection conditions 
chosen which: 1) maximised the percentage of transfected cells, which was determined by 
the percentage of ZsGreen-expressing cells and 2) minimised the loss of cell viability caused 
by the transfection process, which was approximated by the frequency of condensed or 
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blebbing DAPI stained nuclei. The chosen transfection protocol resulted in ZsGreen 
expression in approximately 25% of cells. To test for the co-occurrence of a transfected 
plasmid with a co-transfected marker, DsRed and ZsGreen were transfected into cells at a 
10:1 ratio of DsRed to ZsGreen. This resulted in a 95 % co-occurrence between the two 
markers, indicating that the co-transfection marker can signify transfected cells with 
reasonable reliability (Figure 3.11).  
 
 
Figure 3.11 Co-occurrence of DsRed and ZsGreen in optimised SH-SY5Y transfection protocol 
 
SH-SY5Y cells co-transfected with ZsGreen (green) and DsRed (red). DAPI nuclear stain shown in blue.  
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Figure 3.12 Sense RNA foci formation in transfected SHSY-5Y cells 
Presence or absence of sense RNA foci formation detected by 
fluorescence in situ hybridisation (FISH) in SH-SY5Y cells transfected 
with an array of different length pure and interrupted repeat 
constructs. Sense RNA foci are visualised in red by FISH with a 
(GGCCCC)4 Cy3- tagged probe. Nuclei are visualised by DAPI nuclear 
stain in blue. Red boxes show magnified areas of the image in the red 
channel to better display faint sense RNA foci. r = pure repeats, ri = 
interrupted repeats. Scale bar = 10 μm.  
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3.2.6 Characterisation of sense RNA foci formation 
In order to study sense RNA foci formation by repeat constructs in cells, a range of pure 
and interrupted ‘RNA-only’ repeat constructs of different lengths were transfected into SH-
SY5Y cells, and RNA fluorescence in situ hybridisation (FISH) was carried out with a Cy3-
labelled (GGCCCC)4 RNA probe, complementary to the sense GGGGCC RNA. Subsets of cells 
transfected with pure or interrupted repeat constructs containing 21 repeats or more were 
observed to exhibit distinct sense RNA foci formation when examined by confocal 
fluorescence microscopy, which was not observed in empty vector, 3r or 9r transfected 
cells (Figure 3.12). To quantify the number of sense foci present in each ZsGreen-positive 
cell, images of transfected cells were acquired by confocal microscopy, and an automated 
image analysis protocol was developed using Volocity image analysis software. DAPI 
stained nuclei were identified in the blue 405 nm channel, cells expressing the ZsGreen co-
tranfection marker were identified in the green 488 nm channel, and RNA foci identified by 
the FISH probe were identified in the red 546 nm channel. RNA foci identified outside of 
DAPI stained areas were excluded by the software due to high background fluorescence in 
the cytoplasm that lead to a higher false positive rate than was acceptable. Therefore, only 
nuclear RNA foci were counted.  
The number of RNA foci present within each ZsGreen-positive cell was quantified for each 
coverslip of transfected cells. These values were used to determine the percentage of 
ZsGreen-positive cells that contained one or more RNA foci and the mean number of RNA 
foci present in positive cells. In SH-SY5Y cells transfected with pure repeat constructs, a 
significant positive correlation was observed between repeat length and the percentage of 
ZsGreen-positive cells exhibiting sense RNA foci when a linear regression was performed 
(p<0.0001, r2 = 0.6194; Figure 3.13a). Repeat length in interrupted constructs was also 
positively correlated with the percentage of ZsGreen-positive cells exhibiting sense RNA 
foci, with some saturation in the percentage of foci positive cells observed in the largest  
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Figure 3.13 
Correlation of sense 
RNA foci formation 
with repeat length in 
SH-SY5Y cells 
 
A)The percentage of 
transfected cells 
with sense RNA foci 
was plotted against 
repeat length for 
pure repeats and a 
linear regression was 
performed  
B) The percentage of 
transfected cells 
with sense RNA foci 
was plotted against 
repeat length for 
interrupted repeats. 
C) As the percentage 
of transfected cells 
with sense RNA foci 
appeared to reach 
saturation in larger 
interrupted repeats, 
log of number of 
repeats was plotted 
against log of per-
centage of trans-
fected cells with 
sense RNA foci. A 
linear regression was 
performed on this 
transformed inter-
rupted repeat data. 
R
2
 values are shown 
as a measure of 
goodness of fit. P 
values shown denote 
the significance of a 
linear trend with a 
non-zero slope. Error 
bars represent 
standard error of 
mean (SEM). Red 
lines indicate line of 
best fit. Dashed 
black lines represent 
95% confidence 
band for the line of 
best fit. A minimum 
of 3 experimental 
replicates were 
carried out for each 
repeat length. 
 
 
r2 = 0.6194 
P < 0.0001 
 
r2 = 0.6502 
P < 0.0001 
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Figure 3.14 Quantification of sense RNA foci formation in SH-SY5Y cells 
 
A) The percentage of transfected cells containing sense RNA foci in SH-SY5Y cells transfected with an array of 
different length pure (light bars) and interrupted (dark bars) repeat constructs. B) Mean number of sense RNA 
foci per cell exhibited by RNA-foci-positive SH-SY5Y cells transfected with an array of different length pure and 
interrupted repeat constructs. Error bars represent standard error of mean (SEM). A minimum of 3 
experimental replicates were carried out for each repeat length. r = pure repeats, ri = interrupted repeats.  
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repeat lengths (Figure 3.13b). A log transformation was carried out on both x and y values 
for these data to linearise the observed trend, and a linear regression showed a significant 
positive correlation between the percentage of sense RNA foci positive cells and 
interrupted repeat length (p<0.0001, r2= 0.6502; Figure 3.13c). Bar graphs were plotted for 
cells transfected with each construct to compare sense RNA foci formation by cells 
transfected with pure and interrupted constructs (Figure 3.14). The presence of 
interruptions in RNA-only constructs had no apparent effect on RNA foci formation: the 
same proportion of cells exhibited foci in 103r (8.9 ± 2.6 %) and 107ri (7.9 ± 2.0 %), or 36r 
(3.1 ± 0.64 %) and 36ri (3.4 ± 1.5 %) transfected cells, with no significant difference found 
between the two pairs by one-way analysis of variance (ANOVA) with Bonferroni post-hoc 
test on the selected columns. Sense RNA foci were exhibited most frequently in cells 
transfected with our largest repeat construct 1152ri, with foci observed in 27 ± 2.9 % of 
transfected cells (SEM; Figure 3.14a). There was a small background level of RNA foci-
positive cells picked up in empty pcDNA3.1+ vector, 3r and 9r transfected cells, which may 
be due to the automated RNA foci counting process and the occasional presence of 
autofluorescent debris among cells. While RNA foci are formed in only a low percentage of 
cells in the 36r and 36ri constructs, this does not prohibit the occasional formation of larger 
numbers of foci in a single cell: several 36r and 36ri transfected cells exhibited over 20 foci, 
with a highest foci burden in a single cell of 43 foci. Quantification of RNA foci number per 
cell in foci-positive cells reveals no clear correlation between average number of foci in 
foci-positive cells and repeat length (Figure 3.14b). To further examine whether any 
differences in the distribution of RNA foci number per cell could be seen between 
constructs, histograms were plotted for the percentage of sense RNA foci positive cells that 
formed a given number of foci (Figure 3.15). The number of sense RNA foci exhibited by 
transfected cells was binned into groups of 5, and the percentage of the sense RNA foci 
positive cells exhibiting a number of foci within each bin was plotted. The proportion of the  
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Figure 3.15  Frequency distribution of number of sense RNA foci per cell 
 
Histogram displaying the proportion of cells exhibiting sense RNA foci in SH-SY5Y cells transfected with different 
repeat constructs. A) The number of sense RNA foci expressed in all sense RNA foci positive cells was binned 
into groups of 5, with each bar representing the percentage of cells transfected with a given repeat construct 
that express a quantity of sense RNA foci within that bin range. B) The percentage of sense RNA foci positive 
cells exhibiting between 1 and 10 sense RNA foci was examined in more detail. 
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population exhibiting a given number of sense RNA foci was observed to diminish with 
increasing foci number (Figure 3.15a). As approximately 80 % of foci positive cells exhibited 
between 1 and 10 foci, a second histogram was plotted for this range in which cells 
exhibiting individual numbers of foci was analysed, and around half of all sense RNA foci 
positive cells were observed to exhibit one RNA focus (Figure 3.15b). No clear difference in 
the distribution of RNA foci number between different repeat lengths was apparent. 
3.2.7 Characterisation of antisense RNA foci formation 
A smaller subset of the constructs generated were co-transfected into SH-SY5Y cells with a 
DsRed transfection marker for examination of antisense RNA foci formation. RNA FISH was 
carried out using an Alexa 488-labelled (GGGGCC)4 RNA probe complementary to the 
GGCCCC antisense repeat transcript. A subset of cells transfected with pure or interrupted 
repeat constructs containing 103 repeats or more were observed to exhibit antisense RNA 
foci formation when examined by confocal fluorescence microscopy (Figure 3.16), 
demonstrating that these can be formed in cultured cells despite a lack of a promoter in 
the antisense direction. A second protocol on Volocity image analysis software was 
developed as described above to detect antisense foci formation, in which RNA foci were 
located in the green 488 nm channel, and the DsRed co-transfected cells in the red 546 nm 
channel. The percentage of transfected cells expressing antisense RNA foci correlated 
positively with repeat length as seen for sense RNA foci formation, with 1152ri again 
forming RNA foci in the greatest percentage of cells at 22 ± 2.5 % (Figure 3.17a). No clear 
antisense RNA foci formation was observed in 36r and 36ri transfected cells, while 
approximately 1 % of 103r and 107ri transfected cells formed antisense foci, compared to 
the 8-9 % of 103r and 107ri transfected cells which were positive for sense foci (Figure 
3.18a). In addition, no more than 2 antisense RNA foci per cell were detected in all 103r 
and 107ri transfected cells (Figure 3.17b). Antisense foci were formed in around 20 % fewer  
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cells in 576ri and 1152ri transfected samples compared to sense foci, with the average 
number of foci formed per cell in foci-positive cells also reduced by over half (Figure 3.18). 
Histograms were plotted for the number of antisense foci present in each foci-positive cell, 
with the number of foci binned into groups of 5 (Figure 3.19). The percentage of antisense 
RNA foci positive cells that formed a given number of antisense RNA foci was plotted. As 
was seen for sense foci, the proportion of the population exhibiting a given number of 
antisense RNA foci was observed to diminish with increasing foci number (Figure 3.19a). As 
approximately 90 % of antisense RNA foci positive cells exhibited between 1 and 10 foci, a 
second histogram was again plotted for this range in which cells exhibiting individual  
Figure 3.16 Antisense RNA foci formation in transfected SHSY-5Y cells 
Presence or absence of antisense RNA foci formation detected by FISH 
in SH-SY5Y cells transfected with an array of different length pure and 
interrupted repeat constructs. Antisense RNA foci are visualised in green 
by FISH with a (GGGGCC)4 Alexa488-labelled probe. Nuclei are visualised 
by DAPI nuclear stain in blue. Red boxes show magnified areas of the 
image in the green channel to better display faint antisense RNA foci. 
Scale bar = 10 μm. r = pure repeats, ri = interrupted repeats.   
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Figure 3.17 Quantification of antisense RNA foci formation in SH-SY5Y cells 
 
A) The percentage of transfected cells that contain antisense RNA foci in SH-SY5Y cells transfected with a subset 
of different length pure (light bars) and interrupted (dark bars) repeat constructs B) Mean number of antisense 
RNA foci per cell exhibited by transfected cells that contain antisense RNA foci in SH-SY5Y cells transfected with 
a subset of different length pure and interrupted repeat constructs. Error bars represent standard error of 
mean (SEM). A minimum of 3 experimental replicates were carried out for each repeat size. r = pure repeats, ri 
= interrupted repeats. 
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Figure 3.18 Comparison of sense and antisense RNA foci formation in SH-SY5Y cells 
 
A) The percentage of transfected cells that contain sense (red bars) or antisense (green bars) RNA foci in SH-
SY5Y cells transfected with a subset of different length pure (light bars) and interrupted (dark bars) repeat 
constructs B) Mean number of sense or antisense RNA foci per cell exhibited by transfected cells that contain 
RNA foci in SH-SY5Y cells transfected with a subset of different length pure and interrupted repeat constructs. 
Error bars represent standard error of mean (SEM). A minimum of 3 experimental replicates were carried out 
for each repeat size. r = pure repeats, ri = interrupted repeats. 
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Figure 3.19 Frequency distribution of number of antisense RNA foci  
 
Histogram displaying the proportion of cells exhibiting antisense RNA foci in SH-SY5Y cells transfected with 
different repeat constructs. . A) The number of antisense RNA foci expressed in all sense RNA foci positive cells 
was binned into groups of 5, with each bar representing the percentage of cells transfected with a given repeat 
construct that express a quantity of sense RNA foci within that bin range. B) The percentage of sense RNA foci 
positive cells exhibiting between 1 and 10 antisense RNA foci was examined in more detail. 
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numbers of foci were analysed, with around half of antisense RNA foci positive cells 
exhibiting one focus (Figure 3.19b). No difference in the distribution of antisense RNA foci 
number between different repeat lengths was apparent. 
3.2.8 Expression of pure and RNA only repeats in a Drosophila melanogaster 
model 
 In collaboration with Prof Linda Partridge and researchers at the UCL Institute for Heathy 
Aging and the Max Planck Institute for Biology of Aging, a number of repeat expressing fly 
lines were generated. Generation of Drosophila lines was carried out by Dr. Sebastian 
Grönke and colleagues, while characterisation of the transgenic flies was carried out by Dr. 
Teresa Niccoli and colleagues. Pure and interrupted “RNA-only” constructs that had been 
subcloned into the pUASTattB vector were inserted into an identical genetic locus under 
the UAS promotor. Using the GMR–Gal4 driver, expression of the repeats was driven in the 
 
 
Figure 3.20 Expression of pure and RNA-only repeat constructs in Drosophila 
 
A) Representative images of eyes from Drosophila incubated at 27 °C expressing pure 3r, 36r, 103r, and 
interrupted RNA-only (RO) 36ri, 108ri and 288ri repeats under the GMR-GAL4 driver. Scale bar represents 200 
µm. B) Survival curves of flies expressing repeat constructs in adult neurons under the Elav-GeneSwitch driver. 
 
A B 
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fly eye. Examination of eye phenotype provides an easily assessable readout of 
degeneration. The expression of 36, 108 and 288 RNA-only repeats did not alter the 
configuration of the fly eye compared to a control line expressing 3 pure repeats (Figurre 
3.20a). Conversely, both 36 and 103 pure repeats caused visible eye degeneration, with 
103 pure repeats exhibiting a more severe degenerative phenotype than 36 pure repeats. 
These repeat constructs were also expressed in adult fly neurons using an inducible Elav-
GeneSwitch driver. Flies expressing 36 or 103 pure repeats died within 30 days of 
induction, however no difference was seen between flies expressing 3 repeats and those 
expressing 36, 108 or 288 RNA-only repeats (Figure 3.20b). Once more, 103 pure repeats 
caused a more severe decrease in survival compared to 36 pure repeats. These data 
suggest that the primary species responsible for toxicity in these flies is DPR protein gain-
of-function as opposed to RNA gain-of-function, and that the severity of toxicity rises with 
increased repeat length. 
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3.3  Discussion 
3.3.1 Summary of results 
In this chapter, we developed and characterised a new set of genetic tools that can be used 
to isolate RNA gain-of-function from DPR protein gain-of-function mechanisms of 
pathology caused by C9orf72 hexanucleotide repeats.  
A range of unique GGGGCC repeat constructs have been generated in this study.  Pure 
GGGGCC repeats, which model both RNA and DPR protein gain-of-function mechanisms, 
were generated in sizes ranging from 3 to 103 repeats, while RNA-only interrupted 
GGGGCC repeats, which model only RNA gain-of-function mechanisms and preclude the 
production of DPR proteins, were generated in sizes ranging from 36 to 1152 repeats. Our 
largest RNA-only 1152 repeat construct falls within the range of repeat lengths observed in 
patients with the C9orf72 repeat expansion. The array of different repeat sizes produced 
allows any phenomena observed in cells to be correlated with repeat length, facilitating the 
study of pathological phenotypes in a dose-dependent manner. A positive correlation was 
observed between repeat length and the percentage of transfected neuroblastoma cells 
containing both sense and antisense RNA foci, with no discernible difference in foci 
formation observed between pure and RNA-only constructs. However, no correlation was 
observed between repeat length and the number of RNA foci per cell exhibited by foci 
positive cells. Sense RNA foci were formed in a higher percentage of transfected cells than 
antisense RNA foci, with a higher number of sense foci formed in cells on average. 
Additionally, a higher repeat length threshold was observed for antisense RNA foci 
formation compared to sense RNA foci formation.  
When these repeat constructs were expressed in a Drosophila model, pure repeats of 36 
repeats and longer caused degeneration when expressed in the fly eye and adult neurons, 
while RNA-only repeats did not cause a discernible degenerative phenotype. More severe 
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degeneration was also observed in 103 pure repeats compared to 36 pure repeats, 
suggesting a correlation between repeat length and toxicity. The lack of toxicity observed in 
flies that produce GGGGCC repeat RNA but not DPR proteins suggests that RNA gain-of-
function is not the primary toxic mechanism in this Drosophila model. 
3.3.2 Cloning strategy for GGGGCC repeats 
Generating these DNA repeat constructs necessitated overcoming a number of the 
inherent properties exhibited by long GGGGCC repeats that hamper the use of standard 
cloning protocols. First, repetitive constructs frequently undergo deletions when 
transformed into E. coli during the cloning process. This is in contrast to repeat instability in 
in human repeat disorders, in which a trend towards expansion is usually observed 
(McMurray, 2010). This difference may be due in part to the fact that in patients large 
repeat expansions are more often observed in non-dividing cells, in which the repair of 
single strand breaks is thought to lead to expansion, whereas in rapidly dividing cells such 
as E. coli, deletions more often occur due to errors such as template slippage and 
recombination during DNA replication (McMurray, 2010). Indeed, while deletions were 
frequently observed during the cloning of our repeat constructs, particularly in our pure 
repeat constructs and at higher repeat lengths, repeat expansions were very rarely 
observed during the cloning process.   
To minimise the instability of our repeat constructs, we used a recA recombinase deficient 
Stbl3 E.coli strain. Transformed bacteria were also incubated at 30°C to maintain bacterial 
growth within log phase, as stationary growth phase has been observed to increase the 
frequency of repeat deletion (Parniewski et al., 2000). While these precautions allowed the 
construction of a maximum of 103 pure repeats, beyond this point constructs underwent 
large deletions, which we overcame with the use of interruptions to stabilise the repeat 
sequences. Interruptions have been shown to stabilise long repetitive sequences in a 
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number of myotonic dystrophy models without mitigating their pathological function. 480 
CTG repeats with a 5 bp interruption every 20 repeats were observed to form RNA foci that 
sequestered MBLN1 homolog muscleblind protein in a Drosophila model, resulting in 
muscle wasting and degeneration in the fly eye (de Haro et al., 2006). In addition, 960 CTG 
repeats with a 5 bp interruption every 20 repeats was expressed in a mouse model, and 
recapitulated many aspects of myotonic dystrophy including myotonia, dysregulated 
alternative splicing, severe muscle wasting resulting in a functional impairment in treadmill 
tests, and co-localisation of MBLN1 to CUG RNA foci in skeletal muscle (Orengo et al., 
2008). One study into the effect of interruptions on GAA repeats, present in Friedreich’s 
ataxia, found that the inclusion of interruptions that comprised of more than 4 % of the 
repeat sequence substantially increased its stability: in this study a pure repeat sequence 
was reduced on average to 8 % of its original length after one re-cultivation in E. coli, while 
a sequence of a similar length with 4 % interruption content was only reduced to 85 % of its 
original size on average (Sakamoto et al., 2001). While increasing the interruption content 
was observed to further increase repeat stability over numerous re-cultivations, an 
interruption content of over 11 % disrupted the formation of secondary structure 
(Sakamoto et al., 2001). Our interrupted GGGGCC constructs were therefore designed with 
interruptions comprising 7.7 % of the total sequence, which was found to facilitate the 
construction of over 1000 repeats without disrupting RNA foci or G-quadruplex formation.  
3.3.3 Investigating RNA foci formation in a SH-SY5Y cell culture model 
There were a number of advantages to using a transiently transfected over-expression 
model in this study. Primarily, it provided a method for rapidly screening a wealth of 
different repeat constructs which facilitated a detailed examination of the effect of repeat 
dose on sense and antisense RNA foci formation. Furthermore, this cell model was a useful 
initial test to identify which constructs warranted further study in other models, such as in 
Drosophila. This model also served as an important proof of concept, demonstrating that 
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pure and interrupted constructs exhibit both sense and antisense foci formation to the 
same extent. This supports the notion that the interruptions do not disrupt the initiation of 
RNA gain-of-function mechanisms by these repeats, however further studies are needed to 
determine whether both pure and interrupted repeat constructs exhibit the same 
sequestration of RNA binding proteins.  
Evidently, however, there are a number of ways in which the cells in this culture system 
differ from the cells in patients with C9orf72 FTD/ALS, which should be taken into 
consideration when interpreting the results in this chapter. As C9orf72 FTD/ALS principally 
affects the CNS, a neuronal-like cell line SH-SY5Y was chosen, which was originally derived 
from a human metastatic bone tumour biopsy (Biedler et al., 1973). This line expresses a 
number of immature neuronal markers and exhibits a neuroblastoma-like morphology, 
including the formation of short neurites (Kovalevich and Langford, 2013). In contrast to 
primary neuronal cultures, unlimited numbers of these immortalised cells can be grown in 
the lab with relative ease, with low culture to culture variability (Kovalevich and Langford, 
2013). However, the post-mitotic nature of neurons is posited to be one of the reasons why 
the CNS is particularly susceptible to degeneration caused by genetic mutations which are 
ubiquitously expressed across cell types. In addition, the expression of repetitive DNA 
differs in a number of ways between patient neurons and our SH-SY5Y cell model. Firstly, 
repeat DNA is over-expressed under a strong CMV promotor in this cell model, with 
multiple vector copies potentially taken up in each transfected cell, which is likely to 
increase the burden of repetitive DNA in this cell culture model compared to patients. In 
addition, the time course for which the repeats are expressed in cells also differs greatly in 
this cell model from in vivo. While the C9orf72 repeat expansion occurs in patients over an 
entire lifetime, in our cell system the repeats were expressed over a much shorter time 
period of 24 hours, meaning that we cannot study the long term effects that the repeats 
cause in patient tissues. Furthermore, in vitro culture is a stressful environment for cells, 
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which will differ greatly from a cell’s in vivo niche, and will therefore alter the response of a 
cell to the repeats. All of these factors will affect the expression and behaviour of the 
repeat constructs to an extent, and it is therefore important to use cell culture models in 
conjunction with other studies, such as the in vivo Drosophila model we developed using 
the same constructs, as well as comparing observations made in cell models to those made 
in patient tissue where possible. 
3.3.4 A comparison of RNA foci formation in cell culture, patient brain and iPSCs 
Sense RNA foci formation was first described in one of the initial studies reporting the 
existence of a GGGGCC repeat in C9orf72, with 25 % of neurons in the frontal and motor 
cortices observed to exhibit foci (DeJesus-Hernandez et al., 2011). However, an ensuing 
study was unable to replicate this finding, bringing the existence of RNA foci in C9orf72 
patients into question (Simón-Sánchez et al., 2012). Subsequently however, our group as 
well as others have developed optimised higher sensitivity FISH protocols, which clearly 
indicate the presence of both sense and antisense RNA foci formation in C9orf72 patient 
brain (Donnelly et al., 2013; Gendron et al., 2013; Lagier-Tourenne et al., 2013; Mizielinska 
et al., 2013; Zu et al., 2013). A sizeable degree of variation can be seen between the exact 
frequencies of sense and antisense RNA foci observed in different studies, which may be in 
part due to a high patient to patient variability as well as variations between the 
sensitivities of the FISH protocols used by different groups. 
Despite the disparities between C9orf72 patient neurons and the cell system explored in 
this chapter, there are some striking similarities in RNA foci formation observed in these 
two contexts.  Studies examining C9orf72 patient brain have found that sense and 
antisense RNA foci are not exhibited in every neuron, but in a subset of the population 
(Cooper-Knock et al., 2015b, 2014; Gendron et al., 2013; Lagier-Tourenne et al., 2013; Lee 
et al., 2013; Mizielinska et al., 2013; Zu et al., 2013), which is also observed in our cell 
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culture model. It is unclear at present which factors are responsible for promoting RNA foci 
in one cell, but not a neighbouring cell. In the frontal cortex, cerebellar granule cell layer, 
and hippocampus, a higher proportion of cells were observed to exhibit sense RNA foci in 
comparison to antisense foci (Gendron et al., 2013; Mizielinska et al., 2013; Zu et al., 2013), 
as was also observed in my SH-SY5Y cell model. As we would anticipate transcription of the 
C9orf72 locus to be promoted predominantly in the sense direction, a higher frequency of 
sense RNA foci is perhaps to be expected. Conversely, however, one study in C9orf72 ALS 
patients found that in the motor cortex and purkinje cell layer of the cerebellum, antisense 
RNA foci were more prevalent than sense foci (Cooper-Knock et al., 2015b). Additionally, 
antisense foci burden was observed to correlate with TDP-43 cytoplasmic localisation in 
C9orf72 ALS motor neurons (Cooper-Knock et al., 2015b), while no correlation was 
observed between the presence of TDP-43 aggregates and the formation of sense or 
antisense RNA foci in the frontal cortex, cerebellum or hippocampus of C9orf72 FTD 
patients (Mizielinska et al., 2013). These data suggest that different areas of the brain may 
be differentially affected by sense or antisense foci, which could potentially be a 
contributing factor to whether a patient presents with ALS or FTD pathology.   
A number of different groups have examined sense and antisense RNA foci formation in the 
frontal cortex which is summarised in Table 3.3, with between 10-37 % of neurons forming 
sense RNA foci, and 8-26 %  of neurons forming antisense RNA foci (DeJesus-Hernandez et 
al., 2011; Gendron et al., 2013; Mizielinska et al., 2013; Zu et al., 2013). A study from our 
group also noted a positive correlation between sense RNA foci burden in the frontal cortex 
and age of onset, consistent with a role for sense RNA foci in C9orf72 FTD pathology 
(Mizielinska et al., 2013). The percentage of cells exhibiting RNA foci in our largest 1152ri 
construct, which most closely resembles the repeat length observed in patients with the 
expansion, falls towards the upper bound of the percentages of neurons observed to 
produce RNA foci by different studies in C9orf72 FTD frontal cortex, with 27 ± 2.9 % of  
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transfected cells exhibiting sense RNA foci, and 22 ± 2.5 % of cells exhibiting antisense RNA 
foci.   
Induced pluripotent stem cells (iPSCs) and neurons differentiated from these cells (iPSNs) 
have also been observed to form sense RNA foci (Almeida et al., 2013; Donnelly et al., 
2013; Sareen et al., 2013).  As seen in both C9orf72 FTD/ALS patient brain tissue and in our 
SH-SY5Y cell model, a large proportion of cells did not exhibit RNA foci in these studies. The 
percentages of cells observed to express sense RNA foci varied greatly both between 
studies, and also between iPSC lines within each study. One study reported sense RNA foci 
formation in between 20 % and 60 % of iPSCs depending on the line, including in lines 
derived from the same carrier, suggesting that numerous different environmental as well 
as genetic factors may interact to affect RNA foci formation (Almeida et al., 2013). Work in 
C9orf72 ALS iPSC lines has additionally implicated that the interaction between GGGGCC 
repeat RNA and RNA binding proteins may be important in the formation of RNA foci, as 
knockdown of GGGGCC RNA binding protein ADARB2 in C9orf72 ALS iPSCs resulted in a 
significant reduction in the number of sense foci positive cells (Donnelly et al., 2013). 
When RNA foci number per cell was quantified in our SH-SY5Y cell model, the majority of 
RNA foci positive cells were observed to exhibit just one focus, with a smaller proportion 
exhibiting a few foci, and a minority of cells exhibiting a large number of foci. This 
Reference Cohort Sense foci Antisense foci 
Dejesus-Hernandez et al. (2012) FTD 25 % N/A  
Gendron et al. (2014) FTD/ALS 10 % 8 % 
Mizielinska et al. (2014) FTD 37 % 26 % 
Zu et al. (2014) ALS 15 % 10 % 
Table 3.3 Percentage of C9orf72 patient frontal cortex neurons detected to be positive for sense or 
antisense foci in different studies. 
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distribution profile has also been observed in C9orf72 FTD patient frontal cortex 
(Mizielinska et al., 2013), as well as in C9orf72 ALS patient fibroblasts and iPSC-derived 
motor neurons (Lagier-Tourenne et al., 2013; Sareen et al., 2013). However, while a higher 
average number of sense RNA foci were formed per foci-positive cell compared to 
antisense RNA foci in our SH-SY5Y cell model, the converse was observed in C9orf72 FTD 
patient brain (Mizielinska et al., 2013), as well as in patient fibroblasts (Lagier-Tourenne et 
al., 2013). Individual neurons in C9orf72 FTD patient brain tissue were observed to express 
up to 60 antisense RNA foci, with a maximum of 10 sense foci seen in any one cell 
(Mizielinska et al., 2013). Additionally, significantly more antisense foci than sense foci 
were  detected on average per foci positive neuron (Mizielinska et al., 2013). Likewise, a 
maximum of 40 sense RNA foci were observed in C9orf72 ALS patient fibroblasts, while up 
to 90 antisense foci in a single cell were observed (Lagier-Tourenne et al., 2013). In 
contrast, a maximum of 58 sense foci were detected in SY-SY5Y cells compared to a 
maximum 39 antisense foci, and 1152ri transfected cells exhibited an average of 6.2 sense 
foci per positive cell compared to 2.7 antisense foci. This may be due to the overexpression 
used in this model, in which transcription is driven much more strongly in the sense 
direction using a CMV promotor, in contrast to the repeats in patient cells which exist in a 
broader genomic context, thus potentially causing differences in transcription. It is also 
possible that degradation of antisense RNA foci is less efficient than sense RNA foci, which 
would lead to an accumulation of antisense RNA foci over time within patient cells. 
3.3.5 GGGGCC repeat length and RNA foci formation 
An array of different length repeat constructs were generated as a consequence of the RDL 
cloning strategy used to build long repeats.  This enabled the correlation of repeat length 
against RNA foci formation in our SH-SY5Y cell model, and produced some interesting 
results. One finding was that while the percentage of transfected cells exhibiting sense or 
antisense foci was significantly correlated with repeat length, the average number of foci 
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exhibited by a positive cell remained the same.  A similar percentage of the RNA-foci-
positive cell population was observed to exhibit any given number of foci independent of 
the length of the repeat construct. This is exemplified by the observation that several cells 
transfected with 36 pure or interrupted repeats that exhibited over 30 foci. One 
interpretation of this result could be that increased repeat length promotes the initial 
nucleation of RNA foci, but that once RNA aggregation has been initiated, other factors 
determine the extent of foci formation. 
The relationship between repeat length and foci formation has been examined in several 
studies in patient-derived cells. One study examining RNA foci formation in patient-derived 
fibroblast cultures found that while the percentage of cells exhibiting sense RNA foci in 
different lines varied between 15 and 45 %, there was no clear relationship evident 
between repeat length, patient age, or clinical diagnosis versus the percentage of cells that 
exhibited sense RNA foci (Lagier-Tourenne et al., 2013). Additionally, a study examining 
patient derived iPSCs and neurons differentiated from these cells did not observe a 
correlation between cell repeat length and either the percentage of sense RNA foci positive 
cells or the number of sense foci per cell (Almeida et al., 2013). This suggests that factors 
other than repeat length are likely to affect the extent of RNA foci formation in cells, 
however precise measurement of long GGGGCC repeats presents a technical challenge, and 
inaccuracies in repeat sizing could potentially mask a correlation between repeat length 
and cell phenotype. In a case homozygous for the repeat expansion (Fratta et al., 2013), 
both sense and antisense RNA foci were found to be more frequent in the frontal cortex 
than heterozygous cases, with more sense and antisense RNA foci also detected per cell on 
average (Mizielinska et al., 2013), arguing in favour of some dose dependent effect of the 
repeats on RNA foci formation in cells.     
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3.3.6 GGGGCC repeat length and patient disease course 
The relationship between C9orf72 repeat length and disease progression in patients is 
currently unclear. In a number of other repeat disorders, a very clear correlation is 
observed between repeat length and age of onset. The length of the CAG repeat expansion 
in Huntington’s disease, for example, can be used to predict a statistical probability of 
disease onset at a given age (Langbehn et al., 2004). In myotonic dystrophy patients, 
inherited CTG repeat length was found to be predictive of disease onset, however, the high 
somatic instability of CTG repeats necessitates that inherited repeat length is estimated 
from the spread of repeat sizes present in patient cells (Morales et al., 2012). Additionally, 
the degree of somatic instability in myotonic dystrophy patients was also found to correlate 
inversely with disease onset, with more rapid expansion of the repeat leading to an earlier 
disease onset (Morales et al., 2012). 
C9orf72 hexanucleotide repeats have been observed to be highly unstable. In one report, a 
patient with around 90 GGGGCC repeats in the blood was found to have an expansion of 
thousands of repeats when tested in the CNS, indicating a high potential for differences in 
repeat sizes between different tissues (Fratta et al., 2015). A study into the correlation 
between C9orf72 repeat length and disease phenotype by van Blitterswijk et al. (2013) also 
found a high degree of somatic instability in patient tissue, with differences in repeat size 
observed in different brain areas as well as in the blood. Counterintuitively, this report 
found that repeat length correlates positively with age of onset in the frontal cortex of FTD 
patients, with shorter repeat lengths associated with an earlier disease onset (van 
Blitterswijk et al., 2013). This correlation was not observed in other brain regions or in 
other disease subtypes, and the implications underlying this trend are presently unclear. 
This difference in repeat length could be hypothesised to be caused by the somatic 
instability of the repeat sequence and the propensity for repeats to expand over time, with 
longer repeats therefore observed in older patients, however another study found no 
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significant correlation between C9orf72 expansion size in the cerebellum and age at 
autopsy (Suh et al., 2015). Additionally, repeat length was observed to be significantly 
lower in cerebellum compared to those in the frontal cortex and blood, and patients with 
cerebellar repeat lengths in the top 25th percentile were observed to have significantly 
reduced disease duration compared to the total cohort  (van Blitterswijk et al., 2013). While 
the cerebellum is not a major site of pathology in FTD or ALS, it is possible that the smaller 
average repeat length reflects a lower degree of somatic instability in this area and 
therefore approximates inherited repeat length which was seen to be predictive of disease 
onset in myotonic dystrophy (Morales et al., 2012). Several studies have also looked into 
the relationship between C9orf72 repeat length and disease subtype. While one report 
observed no significant difference between repeat length in the frontal cortex, cerebellum 
or blood between patients with MND, FTD or FTD/MND (van Blitterswijk et al., 2013), work 
by another group found that C9orf72 repeat length in the blood was shorter in FTD patients 
than ALS patients (Suh et al., 2015), suggesting that repeat length could potentially a 
determining factor for clinical disease presentation in patients. Furthermore, C9orf72 
expansion size was observed to be significantly associated with diminished disease duration 
for patients with FTD but not ALS (Suh et al., 2015), raising the question of whether repeat 
length differentially affects different disease subtypes. However, the relationship between 
GGGGCC repeat length and disease progression remains unclear and further studies are 
needed to fully comprehend these conflicting reports. 
There must exist some form of relationship between repeat length and disease onset, as 
we know that healthy individuals most often exhibit 2 GGGGCC repeats, with individuals 
exhibiting no signs of pathology reported up to at least 32 repeats (Beck et al., 2013; Ratti 
et al., 2012). Some studies have reported the presence of psychiatric symptoms and 
cognitive deterioration in individuals with intermediate repeat lengths between 20 and 30 
units (Byrne et al., 2014; Gómez-Tortosa et al., 2013), however others have reported that 
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while these intermediate repeat lengths were observed to affect transcription at the 
C9orf72 locus, no association was observed between these lengths and disease (van der 
Zee et al., 2013). These different observations could be explained by differing repeat 
lengths between different tissues due to somatic repeat instability. One case report also 
described a patient with approximately 70 repeats in blood, who did not exhibit signs of 
degeneration or RNA foci in fibroblasts at age 89, while offspring from this patient were 
observed to carry an expansion of approximately 1750 repeats and exhibited RNA foci (Xi et 
al., 2015a). The relationship of repeat length and disease onset is further complicated by 
the incomplete penetrance of the disease, with individuals carrying large expansions 
occasionally living neurologically healthy lives into old age, and disease onset observed in 
some patients in their 80s (Majounie et al., 2012b).  
A number of factors may underlie the ambiguous correlation with of disease phenotype 
with C9orf72 repeat length. Firstly, there is an absence of patients with repeat lengths in 
the low hundreds, meaning that any differences in disease phenotype caused by a 
difference in repeat length within this range cannot be observed. It is also likely that a 
number of other genetic and environmental factors interact to affect disease progression, 
which could mask the contribution of repeat length and render it an inadequate predictor 
of disease prognosis. Another possibility is that repeat length exists as a binary switch, with 
the existence of a discrete repeat length threshold beyond which the full pathology occurs. 
This is an interesting possibility as it might also suggest the existence of a binary switch 
within the molecular disease mechanism, in which a tipping point is reached in the cell 
leading to full pathogenesis. However, methods for more accurately determining repeat 
length in patient brain may yet reveal clearer correlations between repeat length and 
patient disease severity in patients of different disease subtypes that cannot be detected at 
present. 
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3.3.7 Investigating RNA gain-of-function toxicity in a Drosophila model 
The constructs generated in this work provide a useful tool that can be applied to a range 
of different models. In a collaboration between Linda Partridge’s group and our own, a 
range of pure and RNA-only were expressed in Drosophila melanogaster, in the eye and in 
adult neurons (Mizielinska et al., 2014). Sense repeat RNA transcripts were detected in flies 
expressing pure and RNA-only constructs. Additionally, sense RNA foci were observed in 
the nuclei of the Drosophila salivary glands, which were examined due to their large nuclei 
which facilitated foci visualisation. However, no expression of antisense transcripts was 
detected in flies, meaning that the contribution of antisense RNA gain-of-function was not 
examined in this model. There is the potential for the effect of antisense RNA to be 
determined in future studies using promotor driven GGCCCC antisense repeat constructs.  
RAN translation was observed to be successfully attenuated by the RNA-only constructs 
when expressed in the Drosophila model. Poly(GR) expression was assessed using dot-blot 
analysis, with 36 and 103 pure repeats found to undergo translation to produce poly(GR) 
protein, but not 36, 108 or 288 repeat RNA-only constructs. Additionally, western blot 
analysis revealed the presence of poly(GP) in 36 and 103 pure repeats, but not in 36, 108 or 
288 repeat RNA-only constructs. This suggests that our construct designs are effective in 
inhibiting RAN translation in the RNA-only repeat constructs used in this model, while 
allowing the induction of RAN translation in the pure repeats.  Due to the design 
constraints of the interrupted RNA-only constructs, which limited the percentage of the 
sequence that could comprise of interruptions, one stop codon occurs every 36 repeats in 
any one frame in these constructs. RAN translation has been found to be length 
dependent; it is not yet certain what the minimum number of repeats that can cause RAN 
translation is, but a low level of RAN translation has been observed in constructs from 38 
repeats in length when expressed in HEK293 cells (Mori et al., 2013c). However, the 
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absence of DPR proteins detected from Drosophila expressing RNA-only constructs 
suggests that our design is effective in inhibiting RAN translation in this model. 
36 and 103 pure repeats were observed to cause degeneration when expressed in the 
Drosophila eye as well as a reduction in survival when expressed in adult neurons. 
However, no such toxicity was observed in flies expressing 36, 108 or 288 RNA-only 
repeats. This suggests that, at least in this Drosophila model, sense RNA gain-of-function is 
not the predominant mechanism of toxicity as constructs that produce both repetitive RNA 
and DPR proteins result in degeneration, but constructs that produce only repetitive RNA 
and no DPR proteins do not. This additionally implicates DPR proteins in the observed 
degeneration, however, it does not preclude a role for RNA toxicity. Thus far, the greater 
instability of the larger 576 and 1152 RNA-only constructs has precluded the production of 
flies with longer repeat lengths. However, it would be interesting to investigate whether 
any RNA gain-of-function toxicity becomes apparent at longer repeat lengths.  
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Chapter 4:  Investigating dipeptide repeat protein 
gain-of-function mechanisms in C9orf72 FTD/ALS 
4.1  Introduction 
In the previous results chapter, the RNA gain-of-function mechanisms of pathology caused 
by the C9orf72 repeat expansion were assessed in cell culture and Drosophila melanogaster 
model systems. While our pure GGGGCC repeat constructs, which produce both RNA and 
DPR proteins, caused acute toxicity when expressed in Drosophila, the expression of RNA-
only constructs did not cause observable degeneration in this model system, thus 
implicating a role for DPR proteins in mediating GGGGCC repeat expansion toxicity. We 
therefore sought to characterise the role DPR proteins play in C9orf72 FTD/ALS. 
In this chapter, we detail the design and construction of new ‘protein-only’ DNA constructs 
that code individually for each of the five DPR proteins in a number of different repeat 
lengths in order to determine their pathological role. These protein-only constructs 
together with our pure and RNA-only DNA constructs form a powerful molecular toolkit, 
enabling the comprehensive dissection of the different gain-of-function mechanisms at 
work in C9orf72 FTD/ALS in a repeat length dependent manner.  
Protein-only constructs were transfected into a HEK293T cell line, and the subcellular 
localisation of GFP tagged and untagged DPR proteins of different lengths was 
characterised with immunofluorescent staining. A number of these protein-only constructs 
were then subcloned into a Drosophila vector and expressed in a fly model as part of our 
collaboration with Prof. Linda Partridge at the UCL Institute for Healthy Ageing and Max 
Planck Institute for Biology of Aging, in order to study the effect of individual DPR proteins 
in this system. 
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The role of DPR proteins in human brain has recently been subject to a great deal of 
debate. While a correlation has been reported between DPR protein inclusion burden and 
age of disease onset in C9orf72 FTD/ALS patients, a lack of correlation has also been 
observed between the degree of degeneration in different brain regions and the level of 
DPR protein burden in each area (Davidson et al., 2014; Gomez-Deza et al., 2015; 
Mackenzie et al., 2013; Schludi et al., 2015). Some studies have reported a distinct DPR 
protein burden profile in patients with different disease subtypes (Gendron et al., 2015; 
Schludi et al., 2015), but other studies have failed to replicate this (Mackenzie et al., 2015). 
To help clarify the relevance of DPR protein gain-of-function pathology to human C9orf72 
patients in greater detail, we designed a fully quantitative, high throughput and unbiased 
method for determining DPR protein aggregate frequency as detected by 
immunohistochemistry in human brain sections, in the form of an image analysis protocol. 
We then tested this protocol by calculating the percentage of DPR protein inclusion 
positive cells in C9orf72 FTD post-mortem cerebellum. 
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4.2  Results 
4.2.1 Cloning protein only constructs 
To further dissect different gain-of-function mechanisms in C9orf72 FTD/ALS, we generated 
‘protein-only’ DNA constructs that yield each individual DPR protein in isolation, and do not 
produce GGGGCC RNA. DNA sequences were designed that use alternative codons to those 
found in GGGGCC repeats to code for each DPR protein separately. The protein-only DNA 
sequences were non-repetitive and had a lower GC content than pure GGGGCC repeats, 
allowing for the synthesis of different length repeat constructs without the use of the RDL 
cloning strategy. GFP tagged (DPR)6 constructs were made by ligating oligonucleotides 
coding for six repeats of each of the DPR proteins (Table 4.1) into a pAcGFP1-C1 
mammalian expression vector in frame with GFP. Sequences encoding 36 and 100 
dipeptide repeats were synthesised by GeneArt in a pMK-RQ vector, and were subcloned 
into pcDNA3.1+ mammalian expression vector and pUASTaattB Drosophila expression 
vector to yield untagged (DPR)36 and (DPR)100 constructs. (DPR)6-GFP and (DPR)36 constructs 
were generated for all five DPR proteins, and (DPR)100 constructs were generated for GA, 
GR, PR and AP, however a stable (GP)100 construct could not be generated with the  
  
Dipeptide Sequence 
  Amino 
acid 
GC-only 
codons 
Alternative 
Codons 
(Gly-Ala)6 GGTGCAGGAGCTGGTGCAGGAGCTGGTGCAGGAGCT Glycine 
GGC 
GGG 
GGT  
GGA 
(Gly-Pro)6 GGTCCAGGACCTGGTCCAGGACCTGGTCCAGGACCT Alanine 
GCC 
GCG 
GCT 
GCA 
(Gly-Arg)6 GGTAGAGGAAGAGGTAGAGGAAGAGGTAGAGGAAGA Proline 
CCC 
CCG 
CCT 
CCA 
(Pro-Arg)6 CCTAGACCAAGACCTAGACCAAGACCTAGACCAAGA 
Arginine 
CGC 
CGG 
CGT 
CGA 
AGA 
AGG (Ala-Pro)6 GCTCCAGCACCTGCTCCAGCACCTGCTCCAGCACCT 
Table 4.1 Sequence of (DPR)6  repeats and available amino acid codons 
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alternative codons available. The resulting vectors were sequenced to check for mutations. 
No sequence changes were detected in the generated constructs with the exception of 
(AP)6.GFP, which underwent a modest expansion to (AP)7-GFP. 
4.2.2 Characterisation of DPR protein production in cell model 
We next sought to characterise the production and subcellular localisation of protein 
produced by our different length DPR protein-only constructs.  (DPR)6/7-GFP, (DPR)36 and 
(DPR)100 constructs and empty pcDNA3.1+ vector were transiently transfected into the 
immortalised human embryonic kidney cell line HEK293T, which have been widely used in 
the literature to study DPR proteins and RAN translation in C9orf72 FTD/ALS (May et al., 
2014; Mori et al., 2013c; Tao et al., 2015; Yamakawa et al., 2014; Zu et al., 2013). (DPR)36 , 
(DPR)100 and empty vector transfected cells were co-transfected with a ZsGreen co-
transfection marker to identify transfected cells, while GFP tagged (DPR)6/7-GFP constructs 
were transfected alone. Transfected cells underwent immunofluorescent staining with 
antibodies against the relevant DPR protein. An array of different antibodies reactive 
against each DPR protein were tested in a range of concentrations on cells transfected with 
each of the protein-only constructs as well as empty vector control. Antibodies and 
concentrations that yielded the most robust immunofluorescent signal in protein-only 
transfected cells compared to background staining in empty vector controls were selected 
to examine in more detail.  
The co-localisation of antibody signal with GFP tag signal in (DPR)6/7-GFP transfected cells 
was studied to investigate antibody specificity (Figures 4.1 to 4.5; Table 4.3). Antibodies 
against poly(GP), poly(GR), poly(AP) and poly(PR) identified diffuse cytoplasmic localisation 
of (DPR)6 protein in GFP positive cells, with no discernible signal observed in empty vector 
transfected cells, indicating that these antibodies are specifically reactive to their  
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Figure 4.1 Subcellular localisation of protein produced by transiently expressed glycine-alanine constructs in 
HEK293T cells 
Immunofluorescent images of HEK293T cells transfected with glycine-alanine (GA) protein-only constructs.  
Empty vector, GA36 and GA100 transfected cells were co-transfected with ZsGreen, shown in green. Green 
fluorescence in (GA)6-GFP transfected cells represents GFP tagged construct. GA immunostain shown in red, 
DAPI nuclear stain shown in blue.  Scale bar represents 20 µm. Images are representative of n = 3. 
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Figure 4.2 Subcellular localisation of protein produced by transiently expressed glycine-proline constructs in 
HEK293T cells 
Immunofluorescent images of HEK293T cells transfected with glycine-proline (GP) protein-only constructs.  
Empty vector, GP36 and GP100 transfected cells were co-transfected with ZsGreen, shown in green. Green 
fluorescence in (GP)6-GFP transfected cells represents GFP tagged construct. GP immunostain shown in red, 
DAPI nuclear stain shown in blue.  Scale bar represents 20 µm. Images are representative of n = 3. 
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Figure 4.3 Subcellular localisation of protein produced by transiently expressed glycine-arginine constructs in 
HEK293T cells 
Immunofluorescent images of HEK293T cells transfected with glycine-arginine (GR) protein-only constructs.  
Empty vector, GR36 and GR100 transfected cells were co-transfected with ZsGreen, shown in green. Green 
fluorescence in (GR)6-GFP transfected cells represents GFP tagged construct. GR immunostain shown in red, 
DAPI nuclear stain shown in blue.  Scale bar represents 20 µm. Images are representative of n = 3. 
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Figure 4.4 Subcellular localisation of protein produced by transiently expressed alanine-proline constructs in 
HEK293T cells 
Immunofluorescent images of HEK293T cells transfected with alanine-proline (AP) protein-only constructs.  
Empty vector, AP36 and AP100 transfected cells were co-transfected with ZsGreen, shown in green. Green 
fluorescence in (AP)7-GFP transfected cells represents GFP tagged construct. AP immunostain shown in red, 
DAPI nuclear stain shown in blue.  Scale bar represents 20 µm. Images are representative of n = 3. 
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Figure 4.5 Subcellular localisation of transiently expressed proline-arginine constructs in HEK293T cells 
Immunofluorescent images of HEK293T cells transfected with proline-arginine (PR) protein-only constructs.  
Empty vector, PR36 and PR100 transfected cells were co-transfected with ZsGreen, shown in green. Green 
fluorescence in (PR)6-GFP transfected cells represents GFP tagged construct. PR immunostain shown in red, 
DAPI nuclear stain shown in blue.  Scale bar represents 20 µm. Images are representative of n = 3. 
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Table 4.2 Summary of subcellular DPR protein localisation in HEK293T cells transfected with protein-only constructs 
  
Construct Signal 
GA GR GP PR AP 
Nucleus Cytoplasm Nucleus Cytoplasm Nucleus Cytoplasm Nucleus Cytoplasm Nucleus Cytoplasm 
DPR6GFP  
 
GFP 
+ 
Diffuse 
+ 
Diffuse 
+ 
Aggregates 
+ 
Diffuse 
+ 
Diffuse 
+ 
Diffuse 
+ 
Aggregates 
+ 
Diffuse 
+ 
Diffuse 
+ 
Diffuse 
α-DPR - - - 
+ 
Diffuse 
- 
+ 
Diffuse 
- 
+ 
Diffuse 
- 
+ 
Diffuse 
DPR36 α-DPR - 
+ 
Small 
infrequent 
aggregates 
- 
+ 
Diffuse 
- - 
+ 
Frequent 
aggregates 
+ 
Infrequent 
aggregates 
+ 
Diffuse 
+ 
Diffuse 
DPR100  α-DPR - 
+ 
Large 
frequent 
aggregates 
- 
+ 
Diffuse 
N/A N/A 
+ 
Infrequent 
aggregates 
+ 
Frequent 
aggregates 
+ 
Diffuse 
+ 
Diffuse 
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respective DPR protein targets. However, while GFP was also observed to be present in the 
nucleus of (DPR)6/7-GFP transfected cells, poly(GP), poly(GR), poly(AP) and poly(PR) were 
not detected in the nucleus of these cells by their respective antibodies. 
While GFP signal was observed in (GA)6-GFP transfected cells, no anti-poly(GA) antibody 
signal was visible in these cells (Figure 4.1). However, very frequent, large, star-like 
inclusions of poly(GA) were detected in (GA)100 transfected cells, with smaller and very 
infrequent poly(GA) inclusions detected in (GA)36 transfected cells, suggesting that this 
antibody recognises insoluble aggregates of poly(GA), and that longer poly(GA) repeat 
length promotes more extensive inclusion formation. Despite a lack of intranuclear anti-
poly(GR) or anti-poly(PR) antibody signal, arginine containing (GR)6-GFP and (PR)6-GFP 
transfected cells exhibited GFP positive aggregates within the nucleus, which resembled 
the nucleolar localisation observed by other groups (Figure 4.3 and Figure 4.5) (Schludi et 
al., 2015; Tao et al., 2015; Yamakawa et al., 2014). (PR)36 transfected cells were observed to 
form anti-poly(PR)-positive aggregates that were present primarily within the nucleus, 
however in (PR)100 transfected cells, anti-poly(PR)-positive aggregates were mainly present 
in the cytoplasm, suggesting a differential cellular localisation of poly(PR), dependent on 
protein length. Conversely, only diffuse cytoplasmic anti-poly(GR) antibody staining was 
observed in (GR)36 and (GR)100 transfected cells. Cells transfected with (AP)36 and (AP)100 
exhibited diffuse nuclear and cytoplasmic anti-poly(AP) antibody signal, despite a lack of 
nuclear anti-poly(AP) antibody signal observed in (AP)7-GFP transfected cells (Figure 4.4). 
Finally, no anti-poly(GP) antibody signal was detectable in (GP)36 transfected cells, despite a 
cytoplasmic anti-poly(GP) antibody signal detectable in (GP)6-GFP transfected cells (Figure 
4.2). 
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4.2.3 Effect of protein only constructs in a Drosophila melanogaster model 
To investigate the effect of individual DPR proteins in a living model system, we again 
collaborated with Prof. Linda Partidge and researchers at the UCL Institute for Heathy Aging 
and the Max Planck Institute for Biology of Aging to generate repeat construct expressing 
Drosophila melanogaster lines (see section 3.2.8 for previous Drosophila collaboration 
work). Generation of Drosophila lines was carried out by Dr. Sebastian Grönke and 
colleagues, while characterisation of the transgenic flies was carried out by Dr. Teresa 
Niccoli and colleagues. (DPR)36 and (DPR)100 protein-only constructs that had been
 
 
Figure 4.6 Expression of protein-only repeat 
constructs in Drosophila 
A) Representative images of eyes from Drosophila 
expressing 36 or 100 repeats of proline-alanine 
(PA), glycine-alanine (GA), glycine-arginine (GR), 
and proline-arginine (PR) protein-only constructs 
under the GMR-GAL4 driver. Scale bar represents 
200 µm. B) Survival curves of flies expressing 100 
repeat protein-only constructs in adult neurons 
under the Elav-GeneSwitch driver, or expressing 
the driver alone (elavGS/+). 
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subcloned into pUASTattb were inserted into an identical genetic locus under the UAS 
promotor. Using the GMR–Gal4 driver, expression of the repeats was driven in the fly eye, 
which can be easily assessed for signs of degeneration. While no disruption to the 
morphology of the fly eye was apparent in flies expressing poly(AP) or poly(GA) protein-
only constructs of 36 or 100 repeats in length, marked ocular degeneration was observed in 
flies expressing arginine containing poly(GR) or poly(PR) protein-only repeats, with severe 
deterioration of the ordered compound eye structure (Figure 4.6a).  Expression of 100 GR 
or PR protein-only repeats resulted in a more severe phenotype than 36 protein-only 
repeats indicating that the toxicity of these repeats increases with repeat length. Protein-
only repeats were additionally expressed in fly adult neurons using an inducible Elav-
GeneSwitch driver. Flies expressing 100 PR or GR repeats exhibited an extreme reduction in 
survival, with lethality observed in the majority of flies expressing these constructs within 
10 days of expression induction (Figure 4.6b). A more modest reduction in survival was also 
observed in flies expressing 100 GA protein-only repeats, and no loss of viability was 
observed in flies expressing 100 PA protein-only repeats. These data show that the 
arginine-containing DPR proteins poly(GR) and poly(PR) are sufficient to cause severe, 
repeat length dependent toxicity in this Drosophila model system, in contrast to the lack of 
toxicity observed from GGGGCC RNA alone (section 3.2.8).  
4.2.4 Development of an image analysis protocol for DPR aggregate quantification 
in C9orf72 FTD/ALS patient post-mortem brain 
To determine the relevance of the DPR protein toxicity observed in our Drosophila models 
to C9orf72 pathology in human patients, we investigated the distribution of DPR protein 
aggregates in post-mortem human C9orf72 FTLD patient brain. Previous studies into DPR 
protein inclusion frequency have been carried out either by counting inclusions by eye in a 
small sample size of cells or patients, or in a semi-quantitative manner in which an 
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estimation of inclusion density is made, often using a four-step scale with categories such 
as “absent”, “rare”, “moderate” or “frequent”. We therefore sought to develop an 
unbiased, fully automated, fully quantitative image analysis protocol that can be used to 
analyse large numbers of cells in order to more accurately assess differences in inclusion 
frequencies for different DPR proteins. 
Immunohistochemical staining for DPR protein and p62 aggregates was optimised and 
performed by Dr. Tammaryn Lashley at the Queen Square Brain bank on post-mortem brain 
sections from eight heterozygous C9orf72 FTLD cases, one homozygous C9orf72FTLD case 
and one C9orf72 ALS case. Cerebellum, frontal cortex and hippocampus sections from each 
patient were individually labelled with antibodies against each of the five DPR proteins 
(poly(GA), poly(GP), poly(GR), poly(AP) and poly(PR)) or p62. These inclusions were then 
visualised using a brown 3,3’-diaminobenzidine (DAB) chromagen substrate. Cell nuclei 
were counterstained with the blue nucleic acid stain hematoxylin (Figure 4.7). Due to the 
absence of discrete channels for each individual antibody signal in this 
immunohistochemical staining, a more sophisticated image analysis protocol is required 
than was utilised in the previous chapter to quantify immunofluorescent staining.  To 
achieve this, we collaborated with digital image analyst Matthew Ellis in the Institute of 
Neurology Division of Neuropathology to design an image analysis ruleset using the 
software Definiens Developer XD.  
The different brain regions stained display variances in cell size, cell density and staining 
profile, and consequently each area requires a customised analysis protocol. We therefore 
focussed on the optimisation of an initial DPR analysis protocol in a single brain region, 
which can be adapted in future for use in other areas. The cerebellum was chosen as the 
initial analysis region for a number of reasons: 1) the more limited degree of degeneration  
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Figure 4.7 p62 inclusions in different regions of C9orf72 FTD patient brain 
Representative images of inclusions in different brain regions from patient #14. Sections were immunostained 
with p62 primary antibody and visualised with 3,3’-diaminobenzidine (DAB; brown) . Nuclei were visualised with 
hematoxylin (blue). Scale bar represents 20 µm.   
 
in the cerebellum compared to the frontal cortex facilitates the initial design of a basic 
analysis protocol, which can then be adapted further to accommodate for the more 
prevalent debris and tissue damage artefacts present in the frontal cortex, 2) the granule 
cell layer presents a particular challenge to quantifying inclusions by eye due to the vast 
number of small, densely packed neurons in this region, and development of an automated 
protocol would therefore be highly beneficial in this area,  3) examination of DPR 
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aggregation in the cerebellum may aid understanding of the unique cerebellar pathology 
observed in C9orf72 FTD/ALS patients. 
Figure 4.8 displays representative images for each of the immunostains to be examined in 
the cerebellum granule cell layer and molecular layer. Considerable differences exist 
between the staining profiles of the different antibodies used, with a particularly high 
background DAB stain observed in slides stained with poly(GA) primary antibody compared 
to the other stains. The level of DAB background in poly(GA) stained slides also varies 
 
Figure 4.8 p62 and DPR protein inclusions in the cerebellum granule cell layer and molecular layer of C9orf72 
FTLD patients  
Representative images of immunostains using different antibodies in the cerebellum granule cell layer (GCL) 
and molecular layer (ML) including p62, glycine-alanine (GA), glycine-proline (GP), glycine-arginine (GR), 
alanine-proline (AP), and proline-arginine (PR), all visualised with 3,3’-diaminobenzidine (DAB; brown) . Nuclei 
were visualised with hematoxylin (blue). White arrows highlight examples of inclusions in the granule cell layer. 
White scale bar represents 20 µm in the granule cell layer. Black scale bar represents 20 µm in the molecular 
layer. 
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greatly between different patients (Figure 4.9). Additionally, poly(GR) stained slides 
exhibited very dark hematoxylin staining compared to other slides, which reduced the 
contrast between inclusions and cell nuclei.  These inconsistencies necessitated the 
development of four complimentary analysis rulesets, each customised for a particular 
staining profile (see methods section 2.5.3 for full details of protocols used). We first 
developed a basic protocol to identify blue hematoxylin stained nucleli and brown DAB 
stained inclusions in the majority of stained slides. In this protocol, the threshold for 
identification of DAB staining is determined using the value for the 95th percentile of brown 
staining intensity in each region of interest to account for small differences in DAB signal 
strength between slides. However this relative threshold is prevented from dropping below 
a set absolute value of 0.4 arbitrary units of colour intensity to avoid false identification of 
 
Figure 4.9 Variability of poly(GA) immunostaining in the cerebellum granule cell layer and molecular layer 
Representative images of glycine-alanine (GA) immunostaining in the cerebellum granule cell layer (GCL) and 
molecular layer (ML) in patients #15 and #18, visualised with 3,3’-diaminobenzidine (DAB; brown), highlighting 
the patient to patient variability in staining. Nuclei were visualised with hematoxylin (blue). Patient #18 was 
analysed using the ‘dark’ protocol, patient #15 was analysed using the ‘very dark’ protocol. Scale bar represents 
20 µm. 
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inclusion objects due to low or absent DAB staining in some specimens. A sophisticated cell 
splitting algorithm was also designed to isolate individual nuclei from multiple touching 
cells, which was of particular importance in the densely populated granule cell layer. Within 
the protocol, two separate subroutines with slight modifications were used to analyse 
granule cell or molecular layer areas. Identification of cell nuclei in the molecular layer was 
adapted from that used in the granule cell layer to enable recognition of fainter 
hematoxylin staining present in these cells. Additionally, due to the presence of frequent 
blood vessels in the molecular layer, a vessel removal step was included for this area. This 
step identified areas of blue staining that had a length to width ratio of over 3 or that were 
over 2000 pixels in size, and excluded them (Figure 4.10).  
While this basic algorithm was effective at identifying inclusions in slides stained for p62, 
poly(GP), poly(AP), and poly(PR) stained slides, it did not accurately characterise inclusions 
in poly(GA) or poly(GR) stained slides due to the differences in tissue staining.  The dark 
hematoxylin stain in poly(GR) stained specimens resulted in the false classification of some 
areas of dark purple hematoxylin stained nuclei in the granule cell layer as DAB stained 
poly(GR) inclusions. We therefore designed an alternate version of the DAB stain 
identification procedure with an increased minimum threshold for inclusion identification 
from 0.4 to 0.5 units within the granule cell layer, which counteracted this problem.  
The presence of high DAB background immunoreactivity in poly(GA) stained specimens 
yielded an unacceptable number of objects falsely identified as inclusions. Additionally, the 
degree of background staining was highly variable between different poly(GA) stained 
patient specimens, rendering the development of a single suitable protocol for all poly(GA) 
stained slides problematic (Figure 4.9). We therefore classified these poly(GA) stained 
slides into two categories “dark” or “very dark” according to the magnitude of background 
signal as assessed by eye. A “dark” protocol was designed in which the minimum inclusion  
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Figure 4.10 Blood vessel identification in the cerebellum molecular layer 
 
Identification and disqualification of blood vessel structures (outlined in dark blue) in the cerebellum molecular 
layer by the analysis protocol. Inclusion positive cells outlined in red, inclusion negative cells outlined in cyan. A) 
Lower magnification image of object classification by analysis protocol. White scale bar represents 100 µm. B-D) 
Higher magnification images of object classification by analysis protocol. Black scale bar represents 20 µm. 
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Figure 4.11 Classification of inclusion-positive and inclusion-negative cells by the analysis protocol 
 
Representative images of inclusion-positive (outlined in red) and inclusion negative (outlined in cyan) cells in 
the cerebellum granule cell layer (GCL) and molecular layer (ML). Images show examples of accurate 
identification of rare alanine-proline (AP) inclusions, moderate glycine-proline (GP) inclusions, frequent p62 
inclusions in the homozygous C9orf72 FTLD case, and glycine-alanine (GA) inclusions against a high staining 
background. Primary antibodies were visualised with 3,3’-diaminobenzidine (DAB; brown). Nuclei were 
visualised with hematoxylin (blue) White scale bar represents 20 µm in the GCL, black scale bar represents 20 
µm in the molecular layer. 
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intensity threshold was increased to 0.7 units, and a “very dark” protocol was designed in 
which the minimum inclusion intensity threshold was increased to 0.9 units. The initial 
intensity threshold for inclusion identification was also increased to the 98th percentile for 
both “dark” and “very dark” protocols. These alterations resulted in a more accurate 
representation of inclusion burden across different immunostained samples, with fewer 
regions mistakenly identified as inclusions. Together these adjustments resulted in a toolkit 
of four protocol versions: normal, dark hematoxylin, dark DAB and very dark DAB. These 
can be selected depending on the staining profile of each slide to be analysed to yield the 
most accurate representation of the staining.  
The relevant automated analysis protocols were run on the cerebellum granule cell layer 
and molecular layers for all patients. Figure 4.11 shows examples of the identification of 
inclusion-positive cells (outlined in red) by the analysis program, in a range of different 
stains and patients, including rare poly(AP) inclusions, moderate poly(GP) inclusions, 
frequent p62 inclusions in the homozygous C9orf72 FTLD case, and poly(GA) inclusions 
against a high DAB stain background. The resulting values of inclusion-positive and 
inclusion-negative cells in each area examined were exported for analysis. 
4.2.5 DPR protein inclusion frequency in the cerebellum granule cell layer 
The percentage of cells within the cerebellar granule cell layer that are positive for each of 
the five DPR protein inclusions and p62 was plotted for each patient (Figure 4.12). p62 and 
poly(GA) positive inclusions were found to be most frequent, present in a mean of 11.94 ± 
5.06 % and 13.39 ± 4.73 % of cells respectively. Poly(GP) inclusions were approximately half 
as frequent as p62 or poly(GA) inclusions, with an average of 5.21 ± 3.50 % of cells found to 
be positive. Poly(GR) inclusions were infrequent in this brain area, with 1.36 ± 0.68 % of 
cells exhibiting these inclusions on average. Lastly, the antisense repeat transcript products 
poly(AP) and poly(PR) were present in the lowest percentage of cells, with a mean of 0.11 ±  
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Figure 4.12 
Quantification of 
DPR protein 
inclusion burden in 
the cerebellum 
granule cell layer. 
A-B) The percentage 
of cells positive for 
glycine-alanine (GA), 
glycine-proline (GP), 
glycine-arginine 
(GR), alanine-proline 
(AP), and proline-
arginine (PR) DPR 
protein or p62 
inclusions in the 
granule cell layer 
was plotted for each 
patient analysed. 
Red horizontal line 
represents the mean 
inclusion frequency 
in heterozygous 
(het) FTLD patients. 
Error bars represent 
the standard error 
of the mean (SEM). 
Red points indicate 
homozygous (hom) 
FTLD patient. Blue 
points indicate het 
ALS patient. points 
representing zero 
positive cells were 
omitted from the 
logarithmic scale 
graph. 
C) The percentages 
of inclusion positive 
cells for each 
inclusion type were 
connected for each 
patient to show 
variation of inclusion 
burden within each 
case.  
Legend displays 
patient ID numbers 
next to the relevant 
line colour. Points 
representing zero 
positive cells were 
omitted from the 
logarithmic scale 
graph. 
 
 
 
A 
B 
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0.03 % and 0.15 ± 0.03 % of cells found to be positive for these inclusions. A high degree of 
variation between patients was observed in the percentage of cells exhibiting a given 
inclusion, particularly between the levels of p62, poly(GA) and poly(GR) inclusions with 
standard deviations of 14.3, 13.4 and 9.9 % observed respectively. As a result of this high 
variance, no statistically significant difference was detected between the means of any of 
the inclusion frequencies in heterozygous C9orf72 FTLD patients by one-way ANOVA when 
all pairs of individual group means were compared by Bonferroni’s multiple comparison 
test.  
A number of outliers were observed in this data set. These were examined by eye, and the 
accuracy of the analysis protocol quantification was confirmed in each case. Heterozygous 
C9orf72 FTLD patient #10 was observed to consistently exhibit very few inclusions of any 
DPR protein in the cerebellum granule cell layer, despite robust DPR pathology in other 
brain areas including the adjacent molecular layer, with inclusions observed in a minimum 
of 0.02 % of cells for poly(PR) inclusions, to a maximum of 0.21 % of cells for poly(GA) 
inclusions. Heterozygous C9orf72 FTLD patient #13 was also observed to exhibit an 
unusually low percentage of poly(GP) positive cells (0.02 % of cells), while the number of 
inclusions of other DPR proteins and p62 fell closer to the group means.    
A single homozygous C9orf72 FTLD patient (#20) and a single heterozygous C9orf72 ALS 
patient (#15) were also tested in this data set, but were not included in the statistical 
analyses performed. The homozygous C9orf72 FTLD patient #20 exhibited the highest 
percentage of p62 and poly(GA) inclusion positive cells of all patients tested (44.5 and 41.1 
% of cells respectively), and the second highest percentage of poly(GP) positive cells (13.1 
% of cells), however this patient also exhibited a below average burden of poly(AP) and 
poly(PR) inclusions (0.02 and 0 % of cells within the area analysed respectively). The 
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heterozygous C9orf72 ALS case #15 did not show any clear deviation from the 
heterozygous FTLD mean frequency of any of the inclusion proteins tested.     
4.2.6 DPR protein inclusion frequency in the cerebellum molecular layer 
The percentage of DPR protein or p62 inclusion positive cells within the cerebellar 
molecular layer was plotted for each patient (Figure 4.13). In this region, the analysis 
protocol detected poly(GA) inclusions in a higher proportion of cells than any other marker, 
with a mean of 22.07 ± 3.95 % of cells containing an inclusion. p62, poly(GP) and poly(GR) 
positive inclusions were detected in approximately one third as many cells as poly(GA), 
with an average of 8.97 ± 2.76 %, 7.96 ± 2.32 % and 6.94 ± 1.67 % of cells respectively 
found to contain these inclusions. Finally, poly(AP) and poly(PR) inclusions were once more 
found to be the least frequent in this area, with 0.35 ± 0.09 % and 0.17 ± 0.06 % of cells 
respectively found to be positive on average. A high degree of patient to patient variability 
was again observed in the percentage of cells exhibiting any given inclusion, with a highest 
standard deviation of 11.2 % observed for poly(GA) inclusions. When a one-way ANOVA 
was performed on the data set and all pairs of inclusion group means were compared, a 
significant difference was observed between the frequency of poly(GA) inclusions and all 
other inclusions (corrected p values: p62 p < 0.01, poly(GP) p < 0.01, poly(GR) p < 0.001, 
poly(AP) p <0.0001, poly(PR) p <0.0001), however no significant difference was observed 
between any other pairs tested. 
In contrast to observations in the granular cell layer, the heterozygous C9orf72 FTLD 
patient #10 exhibited robust DPR pathology within the cerebellum molecular layer. 
However, similar to observations in the granule cell layer, a very low number of poly(GP) 
inclusions were detected in the cerebellum molecular layer of heterozygous C9orf72 FTLD 
patient #13, with only 0.15 % of cells exhibiting an inclusion, while levels of other DPR 
proteins and p62 in this patient once again fell closer to the group means.  
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Figure 4.13 
Quantification of 
DPR protein 
inclusion burden in 
the cerebellum 
molecular layer. 
A-B) The percentage 
of cells positive for 
glycine-alanine (GA), 
glycine-proline (GP), 
glycine-arginine 
(GR), alanine-proline 
(AP), and proline-
arginine (PR) DPR 
protein or p62 
inclusions in the 
molecular layer was 
plotted for each 
patient analysed. 
Red horizontal line 
represents the mean 
inclusion frequency 
in heterozygous 
(het) FTLD patients. 
Error bars represent 
the standard error 
of the mean (SEM). 
Red points indicate 
homozygous (hom) 
FTLD patient. Blue 
points indicate het 
ALS patient. points 
representing zero 
positive cells were 
omitted from the 
logarithmic scale 
graph. 
C) The percentages 
of inclusion positive 
cells for each 
inclusion type were 
connected for each 
patient to show 
variation of inclusion 
burden within each 
case.  
Legend displays 
patient ID numbers 
next to the relevant 
line colour. Points 
representing zero 
positive cells were 
omitted from the 
logarithmic scale 
graph. 
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The homozygous C9orf72 FTLD patient #20 exhibited the highest percentage of p62 and 
poly(GA) inclusion positive cells of all patients tested (30.4 and 53.4 % of cells respectively) 
as was observed in the granule cell layer, but fell closer to the heterozygous C9orf72 FTD 
group means with regards to the frequency of poly(GP), poly(GR), poly(AP), and poly(PR) 
inclusions. The heterozygous C9orf72 ALS case #15 did not show any clear deviation from 
the heterozygous FTLD mean frequency of any of the inclusion proteins tested in this 
region, as was also observed in the granule cell layer. 
4.2.7 Comparison of DPR protein expression in the cerebellum granule cell layer 
and molecular layer 
We next looked to compare the DPR protein inclusion burden in the cerebellum molecular 
layer and granule cell layers. Firstly, the frequency of each type of inclusion in the granule 
cell layer was plotted against the corresponding frequency in the molecular layer in each 
patient (Figure 4.14). Linear regressions were carried out for each inclusion type, and a 
significantly non-zero slope was found for p62 (p < 0.001, r2 = 0.76) and poly(GA) (p < 0.001, 
r2 = 0.74) inclusion frequency, indicating that a patient with a high burden of these 
inclusions in one of the regions is likely to have a high burden in the other. A marginally 
significant correlation was also observed for poly(GP) inclusion frequency (p = 0.494, r2 = 
0.50), and a marginally non-significant correlation was observed for poly(GR) inclusion 
frequency (p = 0.0533, r2 = 0.49). However, no significant correlation was observed 
between the regions for poly(AP) or poly(PR) inclusion frequency.  
Next, we examined whether there was a difference in inclusion burden between the two 
areas for any of the inclusion types examined. To do this, the percentage of inclusion-
positive cells in the molecular layer was divided by the percentage of inclusion-positive 
cells in the granule cell layer for each inclusion type in each patient to give the fold change 
between the two areas (Figure 4.15). Plotting these values highlights the regional disparity  
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Figure 4.14 Correlation of inclusion burden in the cerebellum molecular layer and granule cell layers 
 
The percentage of inclusion-positive cells in the cerebellum granule cell layer was plotted against the 
percentage of inclusion-positive cells in the cerebellum molecular layer for p62, glycine-alanine (GA), glycine-
proline (GP), glycine-arginine (GR), alanine-proline (AP), and proline-arginine (PR) inclusions. Red points indicate 
homozygous C9orf72 FTLD patient, blue points represent heterozygous C9orf72 ALS patient. Linear regressions 
were carried out on heterozygous FTLD patients for each comparison. Red lines represent lines of best fit. 
Dashed black lines show 95 % confidence band for line of best fit. P values shown denote the statistical 
probability of a linear trend with a non-zero slope. r
2 
values are shown as a measure of goodness of fit.  
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Figure 4.15 Comparison of inclusion frequency in the cerebellum granule cell and molecular layers 
For each patient, the percentage of inclusion positive cells in the molecular layer was divided by the percentage 
of inclusion positive cells in the granule cell layer for p62, glycine-alanine (GA), glycine-proline (GP), glycine-
arginine (GR), alanine-proline (AP), and proline-arginine (PR) inclusions. Red points indicate homozygous 
C9orf72 FTLD patient, blue points represent heterozygous C9orf72 ALS patient, purple points represent outlier 
patient #10. Points were omitted when either of the molecular layer or granule cell layer had zero positive cells 
for a given inclusion type. Dotted line represents boundary at which there is no change in inclusion frequency 
between the two regions.    
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in inclusion burden exhibited by heterozygous C9orf72 FTLD patient #10, which exhibited 
117, 95, 92 and 377 times more inclusions of p62, poy(GA), poy(GP), and poly(GR) 
respectively in the molecular layer compared to the granule cell layer. This patient was 
subsequently excluded from the means and standard errors plotted of the remaining 
heterozygous C9orf72 FTLD patients to avoid biasing these values to this outlying point. In 
the remaining patients, an 11.3 ± 4.8 fold higher percentage of poly(GR) inclusion positive 
cells was observed on average in the molecular layer compared to the granule cell layer. 
Approximately double the percentage of poly(GA) inclusion-bearing cells (2.2 ± 0.5 fold), 
and triple the poly(AP) inclusion-bearing cells (3.0 ± 0.8 fold) was also observed in the 
molecular layer compared to the granule cell layer, while p62 and poly(PR) burden was 
similar in both regions. 
4.2.8 Examining relationship between C9orf72 disease course and DPR burden in 
the cerebellum 
We next examined whether any relationship could be observed between the inclusion 
burden of any of the DPR proteins or p62 within the cerebellum molecular layer or granule 
cell layer, and the disease course of the patients studied (Figure 4.16). The percentage of 
cells positive for each inclusion type in either the molecular layer or granule cell layer was 
plotted against either patient age of disease onset, or disease duration. However, no 
significant correlation was found for any of the comparisons tested.  
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Figure 4.16 Correlation of inclusion burden with patient disease course 
The percentage of inclusion-positive cells for p62, glycine-alanine (GA), glycine-proline (GP), glycine-arginine 
(GR), alanine-proline (AP), and proline-arginine (PR) inclusions in the cerebellum granule cell layer (GCL) or 
molecular layer (ML) was plotted against patient age of onset or disease duration. Red points indicate 
homozygous C9orf72 FTLD patient, blue points represent heterozygous C9orf72 ALS patient. Linear regressions 
were carried out on heterozygous FTLD patients for each comparison. Red lines represent lines of best fit. 
Dashed black lines show 95 % confidence band for line of best fit.  
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4.3  Discussion 
4.3.1 Summary of results 
In this chapter, we investigated a role for DPR protein gain-of-function disease mechanisms 
in C9orf72 FTD/ALS by examining the consequences of DPR protein production in a cell 
model system, in transgenic Drosophila, and in human post-mortem brain. 
We expanded our toolkit of DNA constructs to enable the dissection RNA gain-of-function 
from DPR protein gain-of-function mechanisms by generating a set of ‘protein-only’ repeat 
constructs that individually code for each of the five DPR proteins, but do not produce 
repetitive RNA. When transiently transfected into a HEK293T cell model system, (GA)100  
formed star-like inclusions similar to those observed in human C9orf72 FTD/ALS patient 
post-mortem brain. (PR)36 and GFP tagged (GR)6-GFP and (PR)6-GFP constructs expressed in 
these cells were observed to aggregate within the nucleus, mirroring the nucleolar 
localisation profile observed by other groups. Conversely, in longer (PR)100 constructs, 
aggregates were observed to form in the cytoplasm, suggesting that repeat length can 
affect DPR protein localisation. 
We then expressed these protein-only constructs in a Drosophila melanogaster model 
system, and found that expression of the arginine-containing DPR proteins poly(GR) and 
poly(PR) was sufficient to cause severe degeneration when expressed in the fly eye or adult 
neurons, implicating a toxic role for these proteins in C9orf72 pathology. A mild reduction 
in viability was caused by the expression of poly(GA) repeats in fly adult neurons, but no 
degeneration was observed as a result of poly(AP) expression.  
Finally, we developed an automated, high throughput and unbiased protocol for 
quantifying DPR protein and p62 aggregation in immunohistochemically stained sections of 
C9orf72 FTD/ALS patient post-mortem brain, to enable examination of the relevance of 
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DPR protein toxicity to disease in human patients. An array of complimentary rulesets were 
developed for use with several differing staining profiles, which were then applied to 
stained patient sections of the cerebellum granule cell and molecular layers. p62 and 
poly(GA) positive inclusions were found to be the most frequent, while fewer poly(GP) and 
poly(GR) inclusions were observed, and poly(AP) and poly(PR) aggregates were detected 
only rarely. A disparity in inclusion frequency was observed between the cerebellum 
molecular layer and granule cell layers, with a trend for higher poly(GR) inclusion burden in 
the molecular layer observed. Furthermore, DPR protein inclusions were found to be 
almost absent in the granule cell layer of one FTLD patient who had robust DPR pathology 
in the molecular layer. Finally, we examined whether inclusion burden in the cerebellum 
molecular layer or granule cell layer correlated with patient disease course, but found no 
correlation.     
4.3.2 Subcellular localisation of DPR proteins in cell models 
To study the subcellular localisation of the different DPR proteins, our protein-only repeat 
constructs were transiently transfected into a HEK293T cell line. While this cell line was 
primarily chosen due to its high transfection efficiency rate and its wide use in the study of 
DPR proteins and RAN translation in C9orf72 FTD/ALS, it has also been found that HEK293 
cells expresses a number of markers that are associated with early differentiating neuronal 
cells (Shaw et al., 2002), suggesting that this cell line does not exclusively represent a 
kidney epithelial lineage.  
The subcellular localisation of DPR proteins observed in HEK293T cells transfected with our 
constructs is largely consistent with studies of constructs and cell models by other groups, 
however some interesting differences in subcellular localisation can be observed between 
different reports, raising the question of which factors might affect the localisation of these 
proteins. Several other groups have reported that cells transfected with poly(GA) 
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constructs form star-like cytoplasmic aggregates similar to those seen in patient brain (May 
et al., 2014; Schludi et al., 2015; Wen et al., 2014; Yamakawa et al., 2014; Yang et al., 2015), 
while others have also observed diffuse, cytoplasmic poly(GA) signal (Tao et al., 2015; 
Yamakawa et al., 2014; Zu et al., 2013). Increasing repeat length was observed to promote 
more extensive poly(GA) aggregate formation in our model, however repeat length alone 
does not predict the presence of diffuse or aggregating poly(GA) as both forms have been 
observed in cells transfected with long constructs with over 100 repeats as well as in 
constructs as short as 30 repeats (May et al., 2014; Schludi et al., 2015; Tao et al., 2015; 
Wen et al., 2014; Yamakawa et al., 2014; Yang et al., 2015; Zu et al., 2013). This difference 
also does not appear to be exclusively driven by cell type, as both diffuse and aggregate 
forming poly(GA) has been observed in HEK293T cells (May et al., 2014; Tao et al., 2015; 
Yamakawa et al., 2014; Zu et al., 2013). In our cell system, insoluble poly(GA) aggregates 
were recognised, however soluble poly(GA) that exhibited a diffuse, cytoplasmic 
localisation in our (GA)6-GFP tagged constructs was not bound by our antibody. This 
suggests that soluble or insoluble poly(GA) repeats may be differentially recognised 
depending on the antibody used, and that both soluble and insoluble forms of poly(GA) are 
most likely present in transfected cells. 
In our model, (GR)6-GFP and (PR)6-GFP constructs were observed to aggregate in the 
nucleus, recapitulating the nucleolar localisation observed in most cell models (Kwon et al., 
2014; May et al., 2014; Schludi et al., 2015; Tao et al., 2015; Wen et al., 2014; Yamakawa et 
al., 2014; Zu et al., 2013). An interesting difference in the subcellular localisation of 
poly(PR) aggregates was observed between our PR36 and PR100 transfected cells. In PR36 
transfected cells, anti-poly(PR) antibody signal primarily detected intranuclear aggregates, 
while in PR100 transfected cells the inclusions were primarily cytoplasmic. This suggests that 
poly(PR) may be differentially processed by cells depending on peptide length. Recent work 
has shown that nucleocytoplasmic transport is disrupted in models of C9orf72 FTD/ALS 
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(Freibaum et al., 2015; Jovičić et al., 2015; Zhang et al., 2015), with (PR)50 treatment 
specifically found to disrupt nuclear protein import in yeast (Jovičić et al., 2015). Longer 
poly(PR) repeat length may therefore disrupt nuclear import and disfavour nucleolar 
binding, promoting the formation of cytoplasmic aggregates. However, cellular models with 
a range of different length poly(PR) repeats have been observed to form both intranuclear 
and cytoplasmic poly(PR) aggregates, indicating that once again multiple different factors 
such as cell type, repeat length and antibody used determine the observed subcellular 
localisation of poly(PR) (May et al., 2014; Schludi et al., 2015; Tao et al., 2015; Wen et al., 
2014; Yamakawa et al., 2014; Zu et al., 2013).   
In our cell model GFP signal could be detected within the nucleus of cells transfected with 
all (DPR)6/7-GFP constructs, however the anti-DPR protein antibodies used detected only 
cytoplasmic protein. This could reflect an inability for the antibody to enter the nucleus due 
to insufficient permeabilisation, however, the detection of intranuclear poly(PR) aggregates 
in PR36 and PR100 transfected cells suggests that this is not the case. It may therefore be 
beneficial to generate untagged (GR)6 and (PR)6 constructs to determine whether the 
presence of the tag is affecting antibody recognition of these DPR protein epitopes. 
Both poly(GP) and poly(AP) have consistently been detected in a diffuse cytoplasmic 
localisation in cell models by numerous studies (May et al., 2014; Schludi et al., 2015; Tao 
et al., 2015; Wen et al., 2014; Yamakawa et al., 2014; Zu et al., 2013). An interesting aspect 
to studying poly(GP) production in cells is that this is the only DPR protein produced from 
both sense and antisense transcripts. One group developed poly(GP) protein-only 
constructs that additionally mimic the unique downstream regions of the respective sense 
and antisense translated poly(GP) frames, however both constructs were observed to 
exhibit similar diffuse cytoplasmic localisation in transfected cells (Zu et al., 2013). While 
our (GP)6-GFP, (AP)7-GFP, AP36 and AP100 constructs all exhibited cytoplasmic DPR signal, no 
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signal could be detected in our GP36 transfected cells. As we were unable to generate a 
GP100 protein-only construct, it is not known whether longer poly(GP) proteins can be 
detected in our system. It may be beneficial to attempt to generate an intermediate length 
poly(GP) construct between 36 and 100 repeats in order to determine whether increased 
repeat length would enable the detection of this DPR protein in our system.  
4.3.3 DPR protein expression in a transgenic Drosophila model 
In the previous chapter, we found that while pure constructs that produce both GGGGCC 
repeat RNA and DPR proteins caused degeneration in a Drosophila model, RNA-only 
constructs which produce repetitive RNA but not DPR proteins did not. This implicated DPR 
proteins as the species responsible for toxicity in this model. Treatment of flies expressing 
36 or 103 pure repeats with a non-lethal dose of cyclohexamide, an inhibitor of protein 
biosynthesis, was found to alleviate the reduction in lifespan caused by these constructs, 
further supporting a protein gain-of-function mechanism of toxicity (Mizielinska et al., 
2014).  To further investigate this possibility, we produced flies expressing protein-only 
constructs coding for poly(GA), poly(GR), poly(PR) and poly(AP) DPR proteins of 36 and 100 
repeats in length, to determine which of the individual DPR proteins are sufficient to cause 
a toxic effect. The arginine containing DPR proteins poly(GR) and poly(PR) were found to 
cause severe degeneration when expressed in the Drosophila eye and an abrupt drop in 
viability when expression was induced in adult neurons, which was more severe in flies 
expressing 100 protein-only repeats compared to 36 repeats. In contrast, no effect was 
seen in poly(AP) expressing flies, and only a modest decrease in survival was caused by 
induction of poly(GA) expression in adult neurons, with no visible degeneration observed 
when poly(GA) was expressed in fly eye. Arginine-containing DPR proteins are therefore 
sufficient to cause toxicity in this Drosophila model, implicating that these proteins could 
play an important role in C9orf72 FTD/ALS pathology. 
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Evidence for toxicity by poly(GR) and poly(PR) arginine-containing DPR proteins has also 
been reported in numerous other models. Several other transgenic Drosophila models have 
been generated subsequent to the publication of our model, which also exhibit strong 
toxicity upon expression of poly(GR) and poly(PR) protein-only repeat constructs, but not 
upon expression of other DPR proteins (Wen et al., 2014; Yang et al., 2015). One study also 
found that expression of 160 pure repeats within the first intron of an artificial C9orf72 
minigene in Drosophila eye or adult neurons did not exhibit an obvious neurodegenerative 
phenotype, which coincided with a lack of nuclear export of repeat RNA from this 
construct, and therefore reduced RAN translation of DPR protein products in the cytoplasm 
(Tran et al., 2015). Transformation of PR50 into a Saccharomyces cerevisiae yeast cell model 
also exhibited toxicity, which was found to be modified by numerous factors involved in 
nucleocytoplasmic transport, indicating that this process could be a mechanism through 
which arginine-containing DPR protein toxicity operates (Jovičić et al., 2015).     
4.3.4 Evidence for arginine containing DPR protein toxicity in cell culture models  
Poly(GR) and poly(PR) induced toxicity has also been observed in a number of cell culture 
models. Exogenously applied synthetic GR20 and PR20 DPR proteins were observed to bind 
to nucleoli and induce toxicity in cultured human astrocytes and U2OS cells. Furthermore, 
cells treated with PR20 exhibited aberrant RNA processing, including missplicing and 
reduced maturation of rRNA (Kwon et al., 2014). Transient transfection of PR50 and GR50 
protein-only constructs also reduced survival in cultured rat primary cortical and motor 
neurons. Furthermore, longitudinal live-cell imaging study of PR50-GFP transfected cortical 
neurons found that PR50-GFP aggregate bearing neurons exhibited a significantly higher risk 
of death compared to transfected neurons with diffuse PR50-GFP signal. Toxicity was also 
observed in cortical neurons transfected with poly(PR) constructs as short as 25 repeats, at 
which length poly(GR) was not observed to be toxic, suggesting that poly(PR) may be the 
more potent toxic species (Wen et al., 2014). Together, these studies support a pathogenic 
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role for poly(PR) and poly(GR), and additionally implicate that disruption of nucleolar 
function as a mechanism toxicity 
Arginine-containing DPR proteins have additionally been observed to cause toxicity in some 
transiently transfected immortalised cell lines (Tao et al., 2015; Yamakawa et al., 2014), but 
not in others (May et al., 2014). Increased cell death was detected by propidium iodide 
staining in NSC-34 and HEK293 cell lines transfected with GFP tagged GR30 and PR30 protein-
only constructs, with no toxicity observed in cells transfected with other DPR protein 
constructs of a similar length compared to GFP only controls (Tao et al., 2015). Additionally, 
transfection of Neuro2a cells with GR100 protein-only constructs increased caspase-3 
immunoreactivity compared to GFP transfected controls, however this toxicity was not 
observed in PR100 transfected cells (Yamakawa et al., 2014). Another study investigated 
toxicity using an LDH assay in HEK293 cells transfected with protein-only constructs 
between 80 and 175 repeats in length, but did not observe toxicity for any of the five DPR 
proteins tested (May et al., 2014). The variable toxicity exerted by poly(GR) and poly(PR) 
constructs in different model systems highlights that numerous environmental factors such 
as repeat length, cell type, incubation time, expression level and cellular stressors may 
modulate the action of these molecules. The context of poly(GR) and poly(PR) expression in 
patient brain may therefore also be important in modulating the extent to which these 
molecules cause toxicity.  
4.3.5 Rationale for use of an automated image analysis protocol in determining 
DPR protein burden in C9orf72 patient post-mortem brain  
A number of studies have been carried out examining the distribution of DPR protein 
inclusions in C9orf72 patient brain, however DPR proteins aggregates have thus far been 
found not to correlate with the degree of degeneration in different brain regions or with 
TDP-43 deposition (Davidson et al., 2014; Gomez-Deza et al., 2015; Mackenzie et al., 2013; 
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Schludi et al., 2015), despite the strong toxicity shown by arginine-containing dipeptides in 
cell and Drosophila models. However, other research has found that DPR protein 
deposition predates TDP-43 inclusion formation (Baborie et al., 2014; Proudfoot et al., 
2014). The global extent of poly(GA) aggregation has also been observed to negatively 
correlate with disease onset (Davidson et al., 2014),  and several conflicting studies have 
been released suggesting that different DPR protein inclusion profiles might be attributed 
to different disease subtypes (Gendron et al., 2015; Schludi et al., 2015). A more in-depth 
quantitative analysis of how DPR inclusion distribution profile differs between brain regions 
and between different patients may therefore help to determine how these entities might 
modulate the disease. 
In this chapter, we designed and tested an automated analysis protocol for determining the 
frequency of different DPR protein and p62 inclusions in C9orf72 post mortem brain. 
Analysis of inclusion frequency is commonly carried out in a semi-quantitative manner in 
which inclusion frequency within a region is scored in categories such as “absent”, “rare”, 
“moderate” or “frequent”. Alternately, inclusions can be counted exactly by eye. However, 
these methods may be subject to bias or inconsistency: a given field of cells may be 
counted or classified differently by different researchers, or indeed by the same researcher 
on a different day depending on the context in which the field is viewed. Furthermore, the 
time consuming nature of counting by eye limits the sample size of cells, patients and brain 
regions that can be accurately assessed. Conversely, automated image analysis allows 
inclusion burden to be determined in a large number of cells and patients in a consistent, 
unbiased manner. Assessment of inclusions in a large sample size increases the statistical 
power of the analysis, enhancing the ability to detect differences between different 
patients and inclusion types.  
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To detect DPR inclusions, we employed an immunohistochemical staining method using 
3,3'-diaminobenzidine (DAB) and hematoxylin, which affords a high sensitivity of epitope 
detection in comparison to immunofluorescent staining due to greater signal amplification. 
However, automated analysis of immunohistochemistry with DAB and hematoxylin 
presents additional difficulties compared to immunofluorescence due to the absence of 
discrete channels for each antibody signal. The exact hue and intensity of each stain as well 
as the intensity of background signal can vary considerably between different antibodies, 
brain regions and quality of patient tissue, necessitating the use of complex computational 
algorithms for stain recognition (van Der Laak et al., 2000).  Additionally, differences can 
arise between samples if the entire cohort to be analysed is not stained at the same time, 
as is often the case when large numbers of sections are to be processed. This inherent 
variation must therefore be accounted for in any automated analysis protocol used. In 
order to detect inclusion frequencies across all specimens with a similar degree of 
accuracy, areas of staining were identified by determining relative intensity compared to 
background staining levels. For specimens that differed substantially from the norm, such 
as the poly(GA) and poly(GR) sections examined, modified protocols were designed that 
were optimised for accurate representation these different staining profiles. Ideally, 
immunostaining should be optimised to maximise consistency between stains and enable 
analysis with a single all-encompassing protocol, however this is not always possible with 
the antibodies available. In this study, we manually selected the most suitable protocol for 
use with each specimen, however the program could be adapted in future to calculate the 
profile of DAB or hemotoxylin stain intensity exhibited in slides to be analysed and 
automatically run the most suitable ruleset in order to completely remove any user bias 
and perform a fully automated and impartial analysis.   
177 
 
4.3.6 Relative frequencies of DPR proteins in C9orf72 FTD/ALS patient brain  
The quantification of DPR protein frequency performed in this chapter suggests that 
different DPR protein inclusions are present in the brain at very different frequencies, with 
poly(GA) inclusions found to be the most frequent,  poly(GP) and poly(GR) inclusions less 
frequent, and antisense transcript RAN translation products poly(AP) and poly(PR) 
inclusions observed only rarely, as has been previously been reported (Mackenzie et al., 
2015; Schludi et al., 2015). This variation in frequency suggests differential expression, 
aggregation or turnover of these peptides. 
The significantly lower frequency of poly(AP) and poly(PR) suggests that RAN translation 
may exhibit a higher efficiency in the sense orientation than in the antisense orientation.  
The mechanisms underlying this are not yet understood, but one possible explanation 
could be a differential secondary structure formation by antisense repeats. A low 
availability of antisense RNA may also limit antisense RAN translation: a lower proportion 
of neurons have been observed to exhibit antisense RNA foci than sense RNA foci (Gendron 
et al., 2013; Mizielinska et al., 2013; Zu et al., 2013), and the larger number of antisense 
foci observed per antisense-foci-positive neuronal nuclei could also reflect a failure to 
export antisense transcripts from the nucleus following transcription, therefore preventing 
their translation. 
Certain DPR proteins may also be degraded more quickly than others. Indeed, a previous 
study found that poly(GA) is the only DPR protein that is not degraded by the proteasome 
(Yamakawa et al., 2014), which would corroborate with the high frequency of poly(GA) 
inclusions observed. Different DPR proteins may additionally have varying propensities for 
aggregation. In an immunoassay study performed on C9orf72 FTD/ALS patient cerebellum, 
significantly more insoluble poly(GA) was detected than soluble, while the inverse was true 
for poly(GP) (Gendron et al., 2015). Another study examining protein-only constructs in a 
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transiently transfected cell model also found that when each DPR protein was individually 
expressed in cells, poly(GA) was the only peptide that formed the characteristic star-like 
inclusions, however co-expression of (GA)80 and (GR)80 resulted in the recruitment of (GR)80 
into the inclusions (Yang et al., 2015). This suggests that the high frequency of poly(GA) 
inclusions may be driven by its high propensity for aggregation, with other DPR proteins 
then recruited into these aggregates to a lesser extent. 
It is also interesting that poly(GA) inclusions were observed to be more frequent on 
average in the cerebellum molecular layer than p62 inclusions. It is possible that this is 
partially driven by the darker poly(GA) staining, which despite the adjustment of the 
protocol to account for the differing staining profile, facilitates the detection of additional 
faint inclusions in comparison to the lighter p62 staining. However, while p62 is thought be 
present in most inclusions (Mann et al., 2013; Mori et al., 2013c), infrequent p62 negative 
DPR protein inclusions have been detected in C9orf72 FTD/ALS patient brain (Schludi et al., 
2015), so further verification using double immunostaining would be beneficial to 
determine whether a substantial subset of poly(GA) inclusions are indeed p62 negative 
within this region.       
The homozygous C9orf72 FTD case (#20) included in our cohort also exhibited some 
interesting trends regarding relative inclusion frequencies that may reflect the impact of 
repeat dosage on DPR protein burden. In both the molecular layer and the granule cell 
layer, patient #20 exhibited considerably more frequent p62 and poly(GA) inclusions than 
any other patient, with these inclusions formed in more than double the percentage of 
cells compared to the mean burden in heterozygous C9orf72 FTLD patients. However, the 
same was not observed for poly(GP), poly(GR), poly(AP), or poly(PR) aggregates, which 
were formed in a more similar proportion of cells in the homozygous case compared to 
heterozygous C9orf72 patients on average. This suggests that increased repeat burden 
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favours poly(GA) inclusion formation, but not necessarily formation of other DPR protein 
aggregates. In order to study this further it would be interesting to correlate DPR protein 
inclusion burden with patient repeat length, to determine whether a similar trend is 
observed.  
4.3.7 Caveats for determining relative DPR protein inclusion frequency using 
immunohistochemistry  
When evaluating the different DPR protein inclusion frequencies observed in this 
immunohistochemical staining, it should also be considered that different antibodies may 
have varying sensitivities and specificities for their target antigen, which could have a large 
impact on the number of aggregates detected in patient brain sections. Different 
antibodies raised against the same protein will also bind different epitopes, which will 
determine which conformations of the protein are recognised by the antibody. Indeed, in 
the cell culture work presented in this chapter an anti-poly(GA) antibody recognised 
insoluble poly(GA) aggregates in the (GA)36 and (GA)100  transfected HEK293T cells, but not 
soluble, fluorescently tagged (GA)6-GFP, suggesting that the epitope recognised by this 
antibody might only be available in the aggregated form of poly(GA). Which conformations 
the different DPR proteins take in patient brain, how prevalent these conformations are, 
and which forms are bound by the antibodies used will consequently effect the frequency 
of DPR inclusions observed in immunostained sections. It is therefore possible that our 
anti-poly(GA) antibody has a higher sensitivity than our antibodies for other DPR proteins, 
or that the epitope it recognises is very commonly found in C9orf72 FTLD patient brain. It 
may be the case that development of better antibodies for the more infrequently detected 
DPR protein inclusions, such as poly(PR) and poly(AP), will reveal that these species are 
more abundant than we currently presume. Other studies have observed similar disparities 
in abundance among the different DPR proteins, with frequent poly(GA) inclusions, fewer 
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poly(GP) and poly(GR) inclusions and rare poly(PR) and poly(AP) inclusions (Mackenzie et 
al., 2015; Schludi et al., 2015). However,  effective poly(GA) antibodies may be inherently 
easier to manufacture than antibodies for poly(PR) or poly(AP), which could lead to the 
similarity in DPR protein inclusion frequencies observed between groups, and might 
present one reason why poly(GA) inclusions have thus far been most frequently studied 
DPR inclusion type within the field. In order to verify the frequencies of DPR proteins 
observed in this thesis and other studies, future research could be carried out using 
techniques that do not rely on antibody based detection of proteins, such as mass 
spectrometry.    
4.3.8 DPR protein burden in C9orf72 FTD/ALS patient cerebellum 
We chose to first examine the cerebellum to facilitate the initial optimisation of the 
analysis protocol, and observed some interesting patterns and differences between the 
two layers examined that require further thought and investigation. A trend for higher 
percentage of poly(GA), poly(GP), poly(GR) and poly(AP) inclusion positive cells was 
observed in the molecular layer compared to the granule cell layer. This was particularly 
apparent for poly(GR) inclusions, which were present at a more than ten-fold higher 
frequency in the molecular layer than in the granule cell layer. One factor to be considered 
regarding this difference is the slight increase in the threshold in DAB staining identification 
which was required in the granule cell layer due to the presence of dark hematoxylin stain 
to avoid the false identification of dark portions of nuclei as inclusions. While this could 
result in a slight reduction of the poly(GR) inclusions identified, an omission of 90 % of all 
inclusions is unlikely and was not observed when the analysis was checked by eye, arguing 
that the difference observed is largely genuine. One heterozygous FTD patient (#10) was 
also observed to exhibit an extremely unequal inclusion burden between the two regions 
for all DPR proteins and p62: a robust DPR protein inclusion pathology was observed in the 
cerebellum molecular layer, while inclusions were almost absent from the adjacent granule 
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cell layer. As these two areas were stained on the same sections at the same time, this 
limits the likelihood of this difference being due to experimental error. It is not yet clear 
how these differences in inclusion burden between two regions of the cerebellum might 
impact a patient’s pathology, or what factors might be important to render one region 
susceptible to DPR protein pathology but an adjacent region invulnerable. As cerebellar 
atrophy is thought to be a distinguishing feature of C9orf72 FTD/ALS in comparison to other 
forms of these diseases(Sha et al., 2012; Whitwell et al., 2012), it would be interesting to 
investigate how frequent patients with highly mismatched cerebellum DPR burden such as 
patient #10 are in the C9orf72 patient population, and to examine whether the presence or 
absence of inclusions within a sub region of the cerebellum has any impact on patient 
disease presentation. 
Another heterozygous C9orf72 FTD patient (#13) exhibited unusually few poly(GP) 
inclusions in either the cerebellum molecular layer or granule cell layer.  As this low 
staining affects both regions on a single stained slide, it would be beneficial to repeat this 
immunostaining to rule out any experimental error. However, one immunoassay study 
detected a lower poly(GP) burden  specifically in C9orf72 ALS patient cerebellum (Gendron 
et al., 2015). While patient #13 was classed pathologically as FTLD, they were previously 
clinically identified as MND. However, although the single ALS patient included in this 
cohort exhibited below average poly(GP) burden in both areas, it was not markedly lower 
than other FTD patients tested. This data set is currently too small to draw any firm 
conclusions from this trend, and application of this optimised protocol to a larger data set 
with more patients of differing disease subtypes would therefore be needed to investigate 
this further. 
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4.3.9 Further development of the automated DPR protein analysis protocol 
Following the examination DPR protein frequency in the cerebellum, this analysis program 
can now be edited and expanded to function in other brain regions of interest such as the 
frontal cortex and hippocampus. Additional functionality will be required in order to 
successfully quantify inclusions within the frontal cortex. Firstly, the greater variability in 
cell size and hematoxylin intensity within this region will require further optimisation of the 
cell nuclei identification process. Secondly, additional steps will be required to filter out the 
more extensive debris and tissue shrinkage artefacts present in this region. Further 
adaptation to allow distinction between cytoplasmic inclusions, nuclear inclusions and 
dystrophic neurites would also be desirable to determine the frequency of these entities, 
especially in the light of a recent study, which found poly(GA) positive dystrophic neurites 
to correlate with degeneration in patient frontal cortex (Mackenzie et al., 2015). 
This protocol could then be applied to a larger cohort of patients across multiple regions in 
order to examine how these aggregates may affect disease course. In the literature, there 
have been some conflicting reports as to which inclusions in which areas might correlate 
with disease subtype. One study found that poly(GA) inclusions were more abundant in the 
cerebellum granule cell layer in C9orf72 FTLD cases than in ALS or mixed FTD/MND cases, 
(Schludi et al., 2015), however this was not replicated by a second study (Mackenzie et al., 
2015). Poly(GP) levels were also observed to be lower in the cerebellum in ALS cases 
compared to FTD or FTD/ALS cases (Gendron et al., 2015), but again this was not found to 
be the case in another study (Mackenzie et al., 2015). The possibility of increased patient 
sample size afforded by automated analysis may therefore provide clarity to the question 
of how DPR protein frequency in different regions may impact disease type.  
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Chapter 5:  The role of the nucleolus in C9orf72 FTD 
5.1  Introduction 
The nucleolus is a sub-compartment within the cell nucleus whose principal function is the 
manufacture, processing and assembly of ribosomal subunits. Nucleoli form around 
tandemly repeated ribosomal genes known as nucleolar organising regions (NORs), and are 
comprised of three main sub regions: fibrillar centres, dense fibrillar components and 
granular components (Boisvert et al., 2007). The fibrillar centres are enriched with a 
specialised ribosomal RNA (rRNA) polymerase, RNA polymerase I, and transcription of the 
rDNA repeats occurs primarily at the border between the fibrillar centres and the dense 
fibrillar components (Boisvert et al., 2007). These transcripts are then modified by small 
nucleolar ribonuclear proteins (snoRNPs) in the dense fibrillar component, and are finally 
assembled within the granular component before being exported to the cytoplasm 
(Boisvert et al., 2007). Due to the involvement of the nucleolus in ribosomal production, it 
has a critical role to play in the cellular stress response, in which the downregulation of the 
highly energy-consuming process of rRNA production can be used to reduce cell energy 
expenditure and limit protein synthesis (Grummt, 2013). However, prolonged inhibition of 
ribosomal production can result in cellular damage, and nucleolar stress is known to be 
involved in the stabilisation of p53 under conditions of stress, promoting cell death (Olson, 
2004).  Consequently, nucleolar dysfunction has been reported in a number of different 
diseases, including several neurodegenerative disorders (Lee et al., 2014; Parlato and Liss, 
2014; Tsoi and Chan, 2014). 
Recently, several studies have reported aberrant nucleolar morphology and function in 
C9orf72 cell culture models and patient derived cell lines. A number of these models have 
exhibited a change in nucleolar volume, which is known to reflect a functional change in 
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rRNA synthesis (Olson, 2011). In particular, the arginine containing DPR proteins poly(GR) 
and poly(PR), which were shown to cause severe toxicity in our Drosophila model (detailed 
in section 4.2.3), have been implicated as the cause of nucleolar dysfunction. Synthetic 
(GR)20 and (PR)20 peptides applied to U2OS cells and cultured astrocytes were found to be 
taken up by cells, bind to nucleoli, and promote an increase in small nucleolar and 
ribosomal proteins, a reduction in mature ribosomal subunits, and increased cell death 
(Kwon et al., 2014). Additionally, (GR)30 and (PR)30 peptides co-localise with the nucleolar 
proteins nucleolin and nucleophosmin when overexpressed in cell lines and cause nucleolar 
swelling and dispersal of nucleophosmin into the nucleoplasm, accompanied by a reduction 
in the maturation of ribosomal subunits (Tao et al., 2015). Mass spectrometry analysis also 
showed that (GR)30 protein interacts with a number of nucleolar proteins including 
ribosomal subunits and nucleophosmin (Tao et al., 2015). Overexpression of (GR)50 and 
(PR)50 constructs in rat cortical neurons resulted in their co-localisation with nucleolin and 
fibrillarin (another nucleolar protein), with increased nucleolar area observed (Wen et al., 
2014). Furthermore, B-lymphoblasts, fibroblasts, and motor neurons differentiated from 
C9orf72 ALS patient derived iPSCs  were also observed to exhibit dispersal and fractionation 
of nucleolin, and a reduction in the maturation of the 45s ribosomal subunit was detected 
in C9orf72 ALS motor cortex (Haeusler et al., 2014).  
However, despite substantial evidence for nucleolar dysfunction in cell model systems and 
in vitro studies, no evidence for aberrant nucleolar morphology has previously been 
reported in C9orf72 patient brain. One study examined nucleolar size in a small sample of 
two control patient and two C9orf72 FTD/ALS patient frontal cortices by using ferret 
diameter in single plane images, but found no difference in diameter between control 
neurons, C9orf72 poly(GR) inclusion-positive neurons or C9orf72 poly(GR) inclusion-
negative neurons (Schludi et al., 2015). However, the methodology in this approach lends 
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itself to a great deal of inaccuracy and may not be sufficient to detect a difference in 
nucleolar volume.   
We therefore carried out a more in depth study to conclusively investigate whether a 
difference in nucleolar morphology exists in C9orf72 FTD patient neurons. We also 
examined whether changes in nucleolar morphology are associated with the presence of 
poly(GR) inclusions to assess the involvement of arginine-containing DPR proteins in this 
dysfunction. To achieve this, we examined a larger cohort of eight control and eight 
heterozygous C9orf72 FTD patients, plus one homozygous C9orf72 FTD patient, and 
captured z-stack images to analyse structures in frontal cortex sections in 3D in order to 
accurately assess changes in nucleolar volume. 
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5.2  Results 
5.2.1 Immunofluorescent staining of human C9orf72 FTD frontal cortex 
To examine the relationship between neuronal nucleolar morphology and poly(GR) 
aggregate formation in C9orf72 FTD, immunofluorescent staining was carried out on 
human post-mortem C9orf72 FTD patient and non-neurodegenerative control patient 
frontal cortical sections. The frontal cortex was examined as this brain region is severely 
affected by degeneration in C9orf72 FTD (Snowden et al., 2012). In order to assess the 
potential involvement of arginine-containing DPR proteins in nucleolar dysfunction, we also 
examined the presence of poly(GR) inclusions, which are considerably more frequent in 
C9orf72 patient tissue than poly(PR) inclusions. To maximise the number of full nucleolar 
and nuclear volumes that could be visualised and measured, 20 µm thick sections of cortex 
were stained.  Sections underwent triple immunofluorescent staining with the following 
antibodies: 1) anti-poly(GR) DPR protein primary antibody raised in rat, with an anti-rat 
Alexa Fluor 546 red fluorescent secondary antibody 2) anti-NeuN neuronal marker primary 
antibody raised in rabbit, with an anti-rabbit Alexa Fluor 633 far-red fluorescent secondary 
antibody and 3) either an anti-nucleolin or anti-nucleophosmin nucleolar protein primary 
antibody raised in mouse, with an anti-mouse Alexa Fluor 488 green fluorescent secondary 
antibody. Additionally, mountant solution containing DAPI nuclear stain was used to detect 
chromatin in the blue 405 nm channel. To obtain clear visualisation of nucleolar 
immunostaining in these thick sections, a robust antigen retrieval step was required to 
recover antigenic sites masked by cross-linking in the tissue fixation process. When sections 
underwent antigen retrieval by the standard procedure used by our group of boiling in 
citrate buffer (pH6) in the microwave, poly(GR) inclusions and NeuN signal could be 
visualised but nucleolar staining was observed to be faint, present in only a minority of  
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Figure 5.1  Representative images of poly(GR) inclusions and nucleoli  in C9orf72 FTD post mortem brain 
 
Maximum intensity projections of z-stack images from C9orf72 FTD frontal cortex stained with either (A-E) anti-
nucleophosmin (NPM; green) or (F-J) anti-nucleolin (NCL; green) nucleolar marker. All sections were also 
stained with DAPI nuclear stain (blue), anti-poly(GR) antibody (red), and anti-NeuN neuronal marker (magenta). 
Scale bars both represent 10 µm in small single channel images or larger merge images. Optimised staining 
protocol shows clear nucleoli within cell nuclei. Star-like cytoplasmic poly(GR) inclusions are also visible in some 
neurons. 
 
cells, and variable between different patients. Several different antigen retrieval protocols 
were therefore tested, and a combined protocol of proteinase K digestion followed by 
boiling in citrate buffer (pH6) at high pressure within a pressure cooker was found that 
yielded clear and consistent staining for all antibodies, without excessive damage to tissue 
architecture. To ensure clear epitope visualisation with each of the primary antibodies 
used, a range of different primary antibody concentrations were tested, and a 
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concentration that yielded strong immunofluorescent staining of the target protein with 
minimal background staining was selected. To develop an image capture protocol for 
confocal microscopy that could clearly detect immunofluorescent signal in all four 
fluorescent channels with minimal bleed-through signal from other wavelengths, patient 
brain sections were singly stained for DAPI and each of the three primary antibodies with 
their respective secondary antibodies. The range of wavelengths collected for each channel 
was adjusted such that clear signal was observed from the singly stained section positive 
for the fluorophore to be detected in that channel, but so that minimal signal was detected 
for the sections stained with other fluorophores. 
5.2.2 Design of automated image analysis protocol 
Following the optimisation of the immunofluorescent staining and detection, frontal 
cortical sections from eight different non-neurodegenerative disease control patients, eight 
different heterozygous C9orf72 FTD patients and one homozygous C9orf72 FTD patient 
were stained to detect nuclephosmin, poly(GR) inclusions, NeuN and DAPI (Figure 5.1a), 
with additional sections from the same patients then stained to detect nucleolin, poly(GR) 
inclusions, NeuN and DAPI (Figure 5.1b). To measure nucleolar volume in neurons with and 
without poly(GR) inclusions, twenty z-stack images were acquired in each stained section 
by confocal fluorescence microscopy using a 40 x objective, and an automated image 
analysis protocol was developed using Volocity image analysis software. DAPI stained 
nuclei were identified as 3D volumes in the blue 405 nm channel, nucleolar volumes 
(represented by either nucleolin or nucleophosmin staining) were identified in the green 
488 nm channel, poly(GR) inclusion volumes were identified in the red 546 nm channel, 
and NeuN-positive neuronal volumes were identified in the far-red 633 nm channel (Figure 
5.2). Due to slight patient-to-patient variation in staining, DAPI, nucleoli and NeuN 
populations were identified by measuring signal a set number of standard deviations above 
the mean voxel intensity for each image. Variation in staining between patients was not 
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observed to correlate with presence or absence of the C9orf72 repeat expansion, but may 
be due to slight differences in tissue preservation and post-mortem delay. As poly(GR) 
signal is present in C9orf72 patient sections but not in controls, an absolute intensity value 
was used to avoid identification of false poly(GR)-positive areas in patients with no 
inclusions. Different thresholds were used to identify nucleophosmin and nucleolin staining 
due to slight differences in signal strength, and a higher abundance of low-intensity diffuse 
nucleolin signal outside of a more defined high-signal-intensity nucleolar compartment. To 
assess dispersal of nucleolin from the nucleolar compartment into the nucleoplasm, this 
diffuse nucleolin signal was measured in the green 488 nm channel using a second lower 
threshold intensity (Figure 5.3). The nucleolar population was then subtracted from the 
diffuse nucleolin population to give the volume of nucleolin within the nucleoplasm.  
Due to a high level of background fluorescence observed inside nucleoli in the red 546 nm 
channel in both control patient and C9orf72 FTD patient sections, the nucleolar population 
was subtracted from the poly(GR) population, such that any poly(GR) signal present solely 
within a nucleolus was not counted. No genuine poly(GR) inclusions contained solely within  
 A                                                               B 
      
Figure 5.2 Volocity volumetric image analysis 
 
A) 3D representation of GR inclusion objects (red) identified within a z-stack image by Volocity image analysis 
software. B) Maximum intensity projection of nucleophosmin stained neurons showing identification of objects 
as nuclei (purple line), nucleoli (yellow line), GR inclusions (red line) and NeuN positive neurons (green line). 
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the nucleolus were evident above background staining levels upon examination of the 
images by eye. 
To identify neuronal nuclei, a new population was made containing DAPI-stained nuclei 
that were also positive for NeuN staining. These areas were then dilated by 10 pixels to 
encompass cytoplasmic inclusions not touching the nucleus, and DAPI, nucleolar and 
poly(GR) volumes touching these areas were compartmentalised as belonging to a specific 
neuron. DAPI, nucleolar or poly(GR) volumes that touched more than one neuron were 
assigned to the neuron to which their centroid was closest. The analysis protocol yielded a 
list of neurons present in each image, with the total volume of nucleolar staining, DAPI 
staining and poly(GR) staining compartmentalised in each neuron. Tables of neurons were 
compiled for each patient: any neurons that did not contain any DAPI signal or nucleolar 
signal were removed from the analysis, and neurons were then divided into two groups  
Figure 5.3 Nucleolar and diffuse nucleolin 
identification 
A) Maximum intensity projections of the green 
488 nm channel in z-stack images from nucleolin 
stained C9orf72 FTD frontal cortex. Figure shows 
identification of nucleolin, in which a high 
intensity threshold is used to identify bright, 
defined nucleolar structures (outlined by the 
program in white in B), and diffuse nucleolin, in 
which a lower intensity threshold is used to 
identify all nucleolin staining above background 
levels (outlined by the program in white in C). 
Scale bar represents 10 µm. 
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Control patients 1 2 3 4 5 6 7 8 
N
u
cl
e
o
p
h
o
sm
in
 
No. GR- cells 520 585 871 456 561 605 576 882 
No. false positives 1 4 4 1 1 2 0 2 
Total no. cells 521 589 875 457 562 607 576 884 
% false positives 0.19% 0.68% 0.46% 0.22% 0.18% 0.33% 0.00% 0.23% 
N
u
cl
e
o
lin
 
No. GR- cells 513 520 669 344 265 261 232 634 
No. false positives 0 0 0 0 0 0 0 0 
Total no. cells 513 520 669 344 265 261 232 634 
% false positives 0% 0% 0% 0% 0% 0% 0% 0% 
Table 5.1 Details of neurons analysed in control patient cortices  
GR- = poly(GR) inclusion-negative 
 
C9 FTD Patients 10 11 12 14 16 17 18 19 20 
N
u
cl
e
o
p
h
o
sm
in
 
No. GR- cells 964 427 784 720 696 836 434 721 634 
No. GR+ cells 26 23 101 18 53 50 39 20 139 
Total no. cells 990 450 885 738 749 886 473 741 773 
% GR+ cells 2.63% 5.11% 11.41% 2.44% 7.08% 5.64% 8.25% 2.70% 17.98% 
N
u
cl
e
o
lin
 
No. GR- cells 616 469 519 584 688 503 198 525 378 
No. GR+ cells 17 24 66 16 61 26 19 21 92 
Total no. cells 633 493 585 600 749 529 217 546 470 
% GR+ cells 2.69% 4.87% 11.28% 2.67% 8.14% 4.91% 8.76% 3.85% 19.57% 
 TOTAL GR+ CELLS 2.65% 4.98% 11.36% 2.54% 7.61% 5.37% 8.41% 3.19% 18.58% 
Table 5.2 Details of neurons analysed in C9orf72 FTD patient cortices 
GR- = poly(GR) inclusion-negative, GR+ = poly(GR) inclusion-positive 
 
that were either positive or negative for poly(GR) signal. C9orf72 patient sections contained 
between 16 and 139 poly(GR)-positive neurons within the images taken (Table 5.2).  
In heterozygous C9orf72 FTD patients poly(GR) inclusions were present in an average of 5.8 
± 1.1 % of neurons (mean ± SEM). A notably high poly(GR) inclusion burden was observed  
in the single homozygous C9orf72 FTD patient (#20), with 18.6 % of neurons exhibiting a 
poly(GR) inclusion in the frontal cortex, which could be ascribed to the additional expanded 
repeat allele present in this patient.  
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The majority of control patients were completely absent for poly(GR) positive neurons, 
however between 1 and 4 positive neurons were detected in 7 out of 8 control patient 
sections stained with nucleophosmin (Table 5.1). Out of a total 5071 nucleophosmin 
stained control neurons analysed, 15 were identified as poly(GR) positive, representing 
0.30 % of the cell population. When these images were examined by eye, it was confirmed 
that these were false positives, which often occurred due to the presence of residual 
autofluorescent debris on the slide despite the use of a sudan black autofluorescence 
quenching step. A similar false positive error rate may also be expected in the poly(GR) 
positive neuron population in C9orf72 patients, but would represent as little as 1 to 5 % of 
the total inclusion burden.  Out of a total 3438 nucleolin stained control neurons analysed, 
none were identified as poly(GR) positive. 
5.2.3 Nucleolar volume 
To examine the distribution of nucleolar sizes within the neuronal populations analysed, 
frequency histograms were plotted for the nucleophosmin and nucleolin volumes present 
in the neuronal populations from each C9orf72 FTD patient brain (Figure 5.4). Additionally, 
data for all control patient neurons, C9orf72 FTD patient poly(GR)-inclusion-positive 
neurons and C9orf72 FTD poly(GR)-inclusion-negative neurons were pooled and plotted 
(Figure 5.5). A non-normal, positively-skewed distribution was observed for nucleolar 
volume. The majority of individual patient histograms show a positive shift in both 
nucleophosmin and nucleolin volume in poly(GR)-inclusion-positive neurons compared to 
poly(GR)-inclusion-negative neurons, suggesting that poly(GR) inclusions are associated 
with an increased nucleolar volume (Figure 5.4). When data for all patients was pooled, 
there was also a slight shift to the right for nucleophosmin and nucleolin volume in neurons 
that contained poly(GR) inclusions compared to poly(GR)-negative neurons in both C9orf72 
FTD patients and control patients (Figure 5.5).  
193 
 
 A  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Frequency distribution of nucleolar volumes in individual post-mortem patient cortex 
 
Frequency histograms of nucleolar volumes from poly(GR)-inclusion-positive (red) and poly(GR)-inclusion-
negative (orange) neurons, in either A) nucleoophosmin stained or B) nucleolin stained sections from each 
individual C9orf72 FTD patient.  
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Figure 5.5 Pooled frequency distribution of nucleolar volumes in post-mortem patient cortex 
 
Histograms displaying nucleolar volumes pooled from all control patients (blue), GR-inclusion-negative neurons 
(C9 GR-) from all C9orf72 FTD patients (orange) and GR-inclusion-positive (C9 GR+) neurons from all C9orf72 
FTD patients (red) for either A) nucleoophosmin stained or B) nucleolin stained sections from each individual 
C9orf72 FTD patient. 
 
We next performed two statistical tests to answer the following questions: 1) Is there a 
significant difference in nucleolar volume between control patient neurons, and poly(GR)-
inclusion-negative neurons from C9orf72 FTD patients? 2) Is there a significant difference in 
nucleolar volume between poly(GR)-inclusion-positive neurons and poly(GR)-inclusion-
negative neurons in C9orf72 FTD patients? Due to the non-normal distribution of the 
nucleolar volumes, median nucleolar volume was plotted as a location parameter for each 
patient (Figure 5.6). 
To test whether there is a significant difference in median nucleolar volume in poly(GR)-
inclusion-negative neurons from C9orf72 FTD patients compared to control neurons, an 
unpaired students t-test was carried out on these two groups. While no significant 
difference was observed between nucleolin volume in control and C9orf72 FTD poly(GR)-
negative cells (p = 0.284), a significant decrease was observed in nucleophosmin volume in 
C9orf72 FTD poly(GR)-inclusion-negative neurons compared to control patient neurons (p < 
0.05). 
Next we looked to see if there was a statistically significant difference in nucleolar volume 
in poly(GR)-inclusion-positive neurons in C9orf72 FTD patients compared to poly(GR)-  
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Figure 5.6 Median neuronal nucleolar volumes in post-mortem frontal cortex 
 
Quantification of neuronal nucleolar volume as determined by (a) nucleophosmin or (b) nucleolin 
immunoreactivity. Three categories of neurons were analysed - control patient neurons (Ctrl), C9orf72 FTD 
patient neurons without a poly(GR) inclusion (C9 GR-), and C9orf72 FTD patient neurons with a poly(GR) 
inclusion (C9 GR+). Each point represents the median nucleolar volume for a single patient. Grey lines show 
pairing between the same C9orf72 FTD individuals in poly(GR)-inclusion-positive and poly(GR)-inclusion-
negative groups. Empty circle represents homozygous C9orf72 FTD patient, not included in mean calculation or 
statistical analyses. Black lines show the mean of patient medians for each group. Error bars represent standard 
error of mean (SEM). *p<0.05, ***p<0.0001 
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inclusion-negative neurons in C9orf72 FTD patients. To do this we carried out a paired 
regression analysis on these two groups. Use of a regression analysis incorporating all 
individual nucleolar measurements accounts for the unequal variability and error 
associated with the poly(GR)-inclusion-positive and inclusion-negative median nucleolar 
volumes in C9orf72 FTD patients, due to the fact that poly(GR) inclusions are only present 
in a minority of cells. Additionally, paired analysis accounts for the fact that the poly(GR)-
inclusion-positive and poly(GR)-inclusion-negative neurons are derived from the same 
C9orf72 FTD patients, and a paired relationship therefore exists between nucleolar volumes 
derived from the same patient. This relationship is apparent when we examine the 
difference in median nucleolar volume for each individual C9orf72 FTD patient: for all 
patients, median nucleophosmin volume is higher in poly(GR)-inclusion-positive than 
inclusion-negative neurons, while median nucleolin volume is higher in inclusion-positive 
than inclusion-negative neurons in all patients except one. A statistically significant 
increase was observed in both nucleophosmin and nucleolin volume in C9orf72 FTD patient 
neurons with poly(GR) inclusions compared to those without poly(GR) inclusions (mean ± 
SEM: nucleophosmin: 15.5 ± 2.0 µm3 vs 8.7 ± 1.0 µm3, p < 0.0001;  nucleolin: 9.0 ± 0.9 µm3 
vs 5.2 ± 0.5 µm3;  p < 0.0001). 
5.2.4 Nucleolar size relative to nuclear size 
As a lower median nucleophosmin volume was observed in C9orf72 FTD patient poly(GR)-
inclusion-negative cells compared to control cells, this raises the possibility that poly(GR) 
inclusions are present within a subset of the neuronal population with larger nucleoli. It is 
also possible that the increase in nucleolar volume observed is part of a more generic 
increase in cell size. To help determine whether these factors might be driving the 
observed differences in nucleolar volume, we examined nuclear volume in each of the cell 
populations. Cells with a larger nucleus might be expected to also have a larger nucleolus. 
To examine this possibility, we correlated neuronal nuclear volume against nucleophosmin  
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Figure 5.7 Correlation of nucleolar volume with nuclear volume 
 
DAPI nuclear volume was plotted against nucleophosmin volume (A-D) or nucleolin volume (E-H) for each 
neuron measured. Linear regressions were carried out on control neurons (A,E), C9orf72 FTD patient poly(GR)-
inclusion-negative neurons (C9 GR-; B,F), C9orf72 FTD patient poly(GR)-inclusion-positive neurons (C9 GR+; 
C,G), and neurons pooled from all three populations (D,H). Linear regressions were carried out on each 
comparison. Red lines show line of best fit. All regression lines were found to have a significantly non-zero slope 
p < 0.0001.  r
2
 values represent the goodness of fit of the data to the regression line.  
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Figure 5.8 Median neuronal nuclear volume in post-mortem frontal cortex 
  
Quantification of neuronal nuclear volume as determined by DAPI staining in (a) nucleophosmin stained slides 
or (b) nucleolin stained slides. Three categories of neurons were analysed - control patient neurons (Ctrl),  
C9orf72 FTD patient poly(GR)-inclusion-negative neurons (C9 GR-), and  C9orf72 FTD patient poly(GR)-inclusion-
positive neurons (C9 GR+). Each point represents the median nuclear volume for a single patient. Grey lines 
show pairing between the same C9FTD individuals in C9 GR- and C9 GR+ groups. Empty circle represents C9 
homozygous patient, not included in mean calculation or statistical analyses. Black lines show the mean of 
patient medians for each group. Error bars represent standard error of mean (SEM).  
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Figure 5.9 Pooled frequency distribution of nucleolar proportion of nucleus in post-mortem patient cortex 
 
Histograms displaying nucleolar volume as a proportion of nuclear volume, pooled from all control patients 
(ctrl; blue), poly(GR)-inclusion-negative neurons from all C9orf72 FTD patients (C9 GR-; orange) and poly(GR)-
inclusion-positive neurons from all C9orf72 FTD patients (C9 GR+; red) for either A) nucleoophosmin stained or 
B) nucleolin stained sections from each individual C9orf72 FTD patients. 
 
or nucleolin volume (Figure 5.7). Linear regressions revealed that nuclear volume is weakly 
positively correlated against nucleolar volume in neurons. Lines of best fit plotted for these 
populations had a significantly non-zero slope (p < 0.001) with low r2 values ranging 
between 0.038 and 0.202 for the different sub groups signifying weak correlation.  
Next, we examined whether there was a difference in median nuclear size between control 
patient neurons, C9orf72 FTD patient poly(GR)-inclusion-negative neurons and C9orf72 FTD 
patient poly(GR)-inclusion-positive neurons (Figure 5.8). No significant difference in nuclear 
volume was observed between C9orf72 FTD patient poly(GR)-inclusion-negative and 
C9orf72 FTD patient poly(GR)-inclusion-positive neurons by paired regression analysis for 
either nucleophosmin (p = 0.963) or nucleolin (p = 0.168) stained sections. Similarly, no 
significant difference was observed in nuclear volume between control patient neurons and 
C9orf72 FTD patient poly(GR)-inclusion-negative neurons by unpaired t-test for either 
nucleophosmin (p = 0.491) or nucleolin (p = 0.781) stained sections.  
Finally, we examined whether the nucleolus occupies a larger proportion of total nuclear 
volume in C9orf72 FTD patient poly(GR)-inclusion-positive neurons compared to C9orf72 
FTD patient poly(GR)-inclusion-negative neurons and control patient neurons. To do this, 
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total nucleolar volume was divided by total nuclear volume for each neuron in both 
nucleophosmin and nucleolin stained sections. Frequency histograms were plotted for the 
distributions of the nuclear proportion of nucleophosmin and nucleolin in C9orf72 FTD 
patient poly(GR)-inclusion-positive, C9orf72 FTD patient poly(GR)-inclusion-negative and 
control patient neurons pooled from all patients (Figure 5.9). As was observed for absolute 
nucleolar volume, C9orf72 FTD patient poly(GR)-inclusion-positive neurons had a positive 
shift in both nucleophosmin and nucleolin proportion of the nucleus compared to C9orf72 
FTD patient poly(GR)-inclusion-negative neurons and control neurons.  
Next we looked to see if there was a statistically significant increase in nucleolar proportion 
of the nucleus in C9orf72 FTD patient poly(GR)-inclusion-positive cells compared to C9orf72 
FTD patient poly(GR)-inclusion-negative cells and median values were plotted for each 
patient (Figure 5.10). Nucleophosmin occupied a significantly larger proportion of the 
nucleus in C9orf72 FTD patient poly(GR)-inclusion-positive neurons compared to C9orf72 
FTD patient poly(GR)-inclusion-negative neurons when assessed by paired regression 
analysis (p < 0.01), however while a trend for a larger nuclear proportion was observed for 
nucleolin, paired regression analysis showed that this was not significant (p = 0.122). No 
significant difference was observed in nucleolar proportion of the nucleus between C9orf72 
FTD patient poly(GR)-inclusion-negative neurons and control patient neurons as assessed 
by unpaired t-test for either nucleophosmin (p = 0.144) or nucleolin (p = 0.681).   
Therefore while an increase in nucleolar volume in proportion to nuclear volume is 
observed in C9orf72 FTD patient poly(GR)-inclusion-positive neurons compared to C9orf72 
FTD patient poly(GR)-inclusion-negative neurons, this trend is less robust compared to the 
increase in absolute nuclear volume observed.  
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Figure 5.10 Median neuronal nucleolar proportion of nucleus in post-mortem frontal cortex 
 
Quantification of neuronal nucleolar proportion of nucleus as determined by (a) nucleophosmin or (b) nucleolin 
immunoreactivity. Three categories of neurons were analysed - control patient neurons (Ctrl), C9orf72 FTD 
neurons without a poly(GR) inclusion (C9 GR-), and C9orf72 FTD neurons with a poly(GR) inclusion (C9 GR+). 
Nucleolar volume was divided by nuclear volume (as determined by DAPI staining) in each neuron. Each point 
represents the median nucleolar proportion of nucleus for a single patient. Grey lines show pairing between the 
same C9orf72 FTD individuals in C9 GR- and C9 GR+ groups. Empty circle represents homozygous C9orf72 FTD 
patient, not included in mean calculation or statistical analyses. Black lines show the mean of patient medians 
for each group. Error bars represent standard error of mean (SEM). **p<0.01 
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5.2.5 Nucleolar dispersal and fragmentation 
We next examined whether C9orf72 FTD patient neurons exhibit a diffuse or fragmented 
localisation of nucleolar markers, as has been observed in C9orf72 cell models and patient 
lymphoblasts (Haeusler et al., 2014; Tao et al., 2015). When nucleophosmin staining was 
examined, no signal above background intensity could be observed outside of defined 
nucleoli (Figure 5.1). Conversely, nucleolin staining was observed to consist of both a 
defined nucleolar compartment and a fainter, more diffuse signal within the nucleus 
(Figure 5.3). To determine whether there is a difference in the volume of diffuse nucleolin 
signal, a lower threshold intensity was used to identify staining in the green 488 channel 
than was used to measure the defined nucleolar structures. The nucleolar population was 
then subtracted from the diffuse nucleolin population to leave only low threshold staining. 
Median volume of diffuse staining per neuron was plotted for control patient neurons, 
C9orf72 FTD patient poly(GR)-inclusion-positive neurons and C9orf72 FTD patient poly(GR)-
inclusion-positive (Figure 5.11a). No difference was observed between control patient 
neurons and C9orf72 FTD patient poly(GR)-inclusion-negative neuron, or between C9orf72 
FTD patient poly(GR)-inclusion-positive neurons and C9orf72 FTD patient poly(GR)-
inclusion-negative neurons. As the volume of diffuse nucleolin may be associated with the 
nuclear volume of each neuron, we next examined the proportion of each nucleus 
occupied by diffuse nucleolar staining, but similarly, no difference was observed between 
control patient neurons and C9orf72 FTD patient poly(GR)-inclusion-negative neurons, or 
between C9orf72 FTD patient poly(GR)-inclusion-positive neurons and C9orf72 FTD patient 
poly(GR)-inclusion-negative neurons (Figure 5.11b). 
To investigate whether a nucleolar fragmentation phenotype is exhibited by nucleolin and 
nucleophosmin, we next examined the number of nucleolar puncta per neuron. The 
number of distinct nucleophosmin stained or nucleolin stained objects in each neuron was 
analysed. Control patient neurons, and C9orf72 FTD patient poly(GR)-inclusion-positive  
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Figure 5.11 Median diffuse nucleolin volumes in post-mortem frontal cortex 
 
Quantification of (a) diffuse nucleolin volume and (b) difuse nucleolin volume as a proportion of DAPI nuclear 
volume. Three categories of neurons were analysed - control patient neurons (Ctrl), C9orf72 FTD neurons 
without a poly(GR) inclusion (C9 GR-), and C9orf72 FTD neurons with a poly(GR) inclusion (C9 GR+). Each point 
represents (a) the median diffuse nucleolin volume for a single patient or (b) the median diffuse nucleolin 
proportion of the nucleus for a single patient. Grey lines show pairing between the same C9orf72 FTD 
individuals in poly(GR)-inclusion-positive and poly(GR)-inclusion-negative groups. Empty circle represents 
homozygous C9orf72 FTD patient, not included in mean calculation or statistical analyses. Black lines show the 
mean of patient medians for each group. Error bars represent standard error of mean (SEM). 
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Figure 5.12 Frequency distribution of number of distinct nucleolar objects per neuron in post-mortem patient 
frontal cortex 
Histograms displaying the proportion of the population exhibiting a given number of defined nucleolar objects 
per cell, pooled from all control patients (Ctrl; blue), poly(GR)-inclusion-negative neurons from all heterozygous 
C9orf72 FTD patients (C9 GR-; orange,) poly(GR)-inclusion-positive neurons from all heterozygous C9orf72 FTD 
patients (C9 GR+; red) poly(GR)-inclusion-negative neurons for the single homozygous C9orf72 FTD patient (C9 
Hom GR-; grey) , and poly(GR)-inclusion-positive neurons for the single homozygous C9orf72 FTD patient (C9 
Hom GR+; black) for either A) nucleophosmin stained or B) nucleolin stained sections. 
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Figure 5.13 Mean number of distinct nucleolar objects per neuron in post-mortem patient frontal cortex 
 
Quantification of distinct nucleolar objects per neuron as determined by (a) nucleophismin or (b) nucleolin 
immunoreactivity. Three categories of neurons were analysed - control patient neurons (Ctrl), C9orf72 FTD 
neurons without a poly(GR) inclusion (C9 GR-), and C9orf72 FTD neurons with a poly(GR) inclusion (C9 GR+). 
Each point represents the mean number of objects for a single patient. Empty circle represents C9 homozygous 
patient, not included in mean calculation or statistical analyses. Black lines show the grand mean of patient 
means for each group. Error bars represent standard error of mean (SEM). 
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neurons and C9orf72 FTD patient poly(GR)-inclusion-negative neurons were pooled from all 
patients, and a histogram was plotted displaying the proportion of the neuronal population 
containing a given number of nucleolar structures in nucleophosmin and nucleolin stained 
slides (Figure 5.12). No difference in the number of nucleoli between control patient 
neurons, and C9orf72 FTD patient poly(GR)-inclusion-negative neurons or and C9orf72 FTD 
patient poly(GR)-inclusion-positive neurons was observed in cells stained with nucleolin or 
nucleophosmin, with over 60 % of each population containing one nucleolus. This was 
further confirmed by plotting the mean number of nucleoli per cell for each patient, with 
no difference observed between control patient neurons, C9orf72 FTD patient poly(GR)-
inclusion-positive neurons or C9orf72 FTD patient poly(GR)-inclusion-negative neurons 
(Figure 5.13). 
5.2.6 Nucleolar dysfunction and disease course 
Finally, we investigated the potential for a correlation between increased nucleolar volume 
in C9orf72 FTD patient poly(GR)-inclusion-positive neurons and age of disease onset or 
disease duration in each C9orf72 FTD patient. Two values were used to examine nucleolar 
volume for both nucleolin and nucleophosmin immunostained nucleoli in each C9orf72 FTD 
patient: 1) median nucleolar volume in C9orf72 FTD patient poly(GR)-inclusion-positive 
neurons, and 2) the difference in median nucleolar volume between C9orf72 FTD patient 
poly(GR)-inclusion-negative and C9orf72 FTD patient poly(GR)-inclusion-positive neurons. 
These measurements of nucleolar volume were each plotted against age of disease onset 
and disease duration of each patient to give eight total comparisons (Figure 5.1.4). A linear 
regression analysis was carried out on each pair of factors, however, no significant 
correlation was observed for any of the comparisons.  
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Figure 5.14 Correlation of nucleolar volume with patient disease course 
 
Difference in median nucleolar volume between poly(GR)-inclusion-positive and negative neurons was plotted 
against patient age of disease onset for (A) nucleophosmin and (B) nucleolin stained sections. Difference in 
median nucleolar volume between poly(GR)-inclusion-positive and negative neurons was also plotted against 
patient disease duration for (C) nucleophosmin and (D) nucleolin stained sections. Median nucleolar volume in 
poly(GR)-inclusion-positive neurons was plotted against patient age of disease onset for (E) nucleophosmin and 
(F) nucleolin stained sections. Median nucleolar volume in poly(GR)-inclusion-positive was also plotted against 
patient disease duration for (G) nucleophosmin and (H) nucleolin stained sections. Linear regressions were 
pereformed on all comparisons. r
2
 values are shown as a measure of goodness of fit. p values shown denote the 
statistical probability of a linear trend with a non-zero slope. Red lines indicate line of best fit. Dashed black 
lines represent 95% confidence band for line of best fit. 
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5.3  Discussion 
5.3.1 Summary of results 
In this chapter, we found that the nucleolar dysfunction reported in C9orf72 cell models is 
also evident in C9orf72 FTD post-mortem patient brains. Furthermore, increased neuronal 
nucleolar volume was found to be associated with the presence of a poly(GR) inclusion, in 
support of a toxic role for arginine-containing DPR proteins in C9orf72 FTD. 
We examined nucleolar morphology and poly(GR) aggregate formation in immunostained 
C9orf72 FTD and control patient brains by developing a 3D volumetric image analysis 
protocol. In C9orf72 FTD patients, neurons containing a poly(GR) inclusion were found to 
have a larger volume of both nucleophosmin and nucleolin staining compared to poly(GR)-
inclusion-negative neurons. C9orf72 FTD neurons without a poly(GR) inclusion also had a 
significantly lower volume of nucleophosmin than control patient neurons, however 
nucleolin volume was similar between these populations. Nucleophosmin was additionally 
found to occupy a larger proportion of the nucleus in poly(GR)-inclusion-positive neurons 
than in  C9orf72 FTD neurons without a poly(GR) inclusion. No difference in nuclear volume 
was observed between control neurons or C9orf72 FTD neurons with or without a poly(GR) 
inclusion, suggesting that the observed differences in nucleolar volume are specific to the 
nucleolus and are not the result of generic cellular swelling. 
However, while nucleolar segregation and dispersal of nucleolar proteins has been 
reported in cell models of C9orf72, evidence for these phenomena could not be observed 
in C9orf72 post-mortem brain. No significant difference in the volume of diffuse nucleolin 
outside of a defined nucleolar compartment was observed between control neurons and 
C9orf72 FTD neurons with or without a poly(GR) inclusion. Additionally, no difference in the 
number of distinct nucleolar objects were observed for nucleophosmin or nucleolin 
staining for any of the groups examined.    
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Finally, we examined whether the severity of nucleolar phenotype correlates with C9orf72 
FTD patient age of disease onset or disease duration, but found no significant correlation 
for any of the comparisons tested.  
5.3.2 Confirmation of a nucleolar morphological change in post-mortem C9orf72 
FTD patient brain 
Contrary to the previous study by Schludi et al. (2015), we observed a significant increase in 
nucleolar volume in poly(GR)-inclusion-positive neurons compared to poly(GR)-inclusion-
negative neurons in C9orf72 FTD patient frontal cortex. This disparity may be for a number 
of reasons. Firstly, while the previous study examined two control and two C9orf72 patient 
cases, we assessed a larger patient cohort of eight controls, eight heterozygous C9orf72 
FTD patients, and one homozygous C9orf72 FTD patient, with a larger number of neurons 
also examined per case, lending greater power to our analysis. Secondly, while the first 
study examined single plane images and estimated nucleolar volume using feret diameter, 
we undertook a 3D volumetric approach by taking z-stack images in 20 µm thick brain 
sections to more accurately assess nucleolar volume. Use of a 2D approach risks erroneous 
estimation of nucleolar volume if the image plane does not intersect with the widest 
portion of the nucleolus.    
To fully characterise any changes in nucleolar morphology, we measured the volumes of 
two different nucleolar markers: nucleophosmin, a nuclear chaperone that mainly localises 
to the granular component of the nucleolus (Frehlick et al., 2007), and nucleolin, a 
multifunctional protein involved in ribosomal synthesis and maturation that primarily 
localises to the dense fibrilar centres of the nucleolus (Mongelard and Bouvet, 2007). An 
increased volume of both of these markers was observed in poly(GR) positive cells. This 
supports the findings of previous C9orf72 cell model studies, which have observed 
increased volume of both nucleolin and nucleophosmin in response to over-expression of 
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poly(GR) or poly(PR) (Tao et al., 2015; Wen et al., 2014). The increase in nucleolar volume 
in poly(GR)-inclusion-positive cells in this study is also approximately equal to that seen in 
studies of C9orf72 cell models and patient derived cell lines, with nucleolar volume in 
poly(GR) positive cells found to be between 1.5 and 2 times greater than in poly(GR)-
negative cells (Haeusler et al., 2014; Tao et al., 2015; Wen et al., 2014), suggesting a similar 
effect on nucleoli in C9orf72 patients compared to cell models. Additionally, we observed a 
significantly lower volume of nucleophosmin staining in C9orf72 neurons lacking a poly(GR) 
inclusion compared to control patient neurons, but the same was not observed for 
nucleolin volume in these cells. Differential regulation of these two markers could reflect 
disparate effects of poly(GR) on the granular component and dense fibrilar centres of the 
nucleolus in C9orf72 FTD, however further investigation with additional nucleolar markers 
would be required to determine if this is the case. 
5.3.3 Absence of the translocation or fragmentation of nucleolar markers in 
C9orf72 FTD post mortem brain  
Nucleolar stress is known to promote stabilisation of p53, promoting cell death. This 
pathway usually involves the disruption of nucleolar integrity and translocation of nucleolar 
proteins into the nucleoplasm (Boulon et al., 2010). Nucleolin and nucleophosmin were 
reported to exhibit a more dispersed localisation in C9orf72 ALS patient B lymphocyte cells 
compared to control lymphocytes, while nucleolin was also more dispersed in C9orf72 ALS 
patient derived iPS neurons and in (GGGGCC)21 transfected HEK293T cells compared to 
controls (Haeusler et al., 2014). In addition, nucleophosmin was observed to translocate 
into the nucleoplasm in HEK293T cells transfected with (GR)30 or (PR)30 DNA constructs (Tao 
et al., 2015). Conversely, in this chapter we did not detect evidence for a change in the 
volume of diffuse nucleolar proteins outside of a defined nucleolar localisation. No 
nucleophosmin staining above background signal was detected outside of the nucleolus in 
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either control or C9orf72 FTD patient neurons. Nucleolin signal above background 
fluorescence levels was detected in some cells from both control and C9orf72 FTD patient 
neurons, but no significant difference in the volume of this staining was detected between 
control neurons, C9orf72 FTD poly(GR)-inclusion-positive neurons or C9orf72 FTD poly(GR)-
inclusion-negative neurons, regardless of whether absolute volume or volume as a 
proportion of DAPI nuclear volume was measured. However, measuring the volume of 
diffuse immunostaining assumes a uniform concentration of nucleolin within the measured 
region, and so does not necessarily reflect the exact amount of nucleolin present outside of 
the nucleolus in each neuron. A more accurate estimate of the quantity of nucleolin 
outside of the nucleolus might be obtained by also considering the intensity of the extra-
nucleolar signal, which would require a more sophisticated analysis protocol to be designed 
to quantify this and to account for the patient to patient staining variability. It was also 
reported that nucleolin exhibited a more “fractured” morphology in B-lymphocytes 
(Haeusler et al., 2014), suggestive of the nucleolar fragmentation observed in response to 
some forms of nucleolar stress (Boulon et al., 2010). However, when we examined the 
number of defined nucleophosmin or nucleolin stained objects per neuron, no significant 
difference was observed between control or C9orf72 FTD patient neurons, regardless of the 
presence or absence of a poly(GR) inclusion, with the majority of neurons containing one 
nucleolus. Therefore, while we did observe a difference in nucleolar volume, we did not 
observe nucleolar dispersal or fragmentation in C9orf72 FTD patient post-mortem cortex in 
contrast to the observations made in C9orf72 cell models or patient derived cell lines. This 
suggests that while current cell models recapitulate the nucleolar dysfunction seen in 
C9orf72 FTD patients in some respects, the mechanisms at work in these two systems may 
still differ, therefore caution should be taken to confirm the relevance of any dysfunction 
identified in cell models to human disease.  
212 
 
5.3.4 Potential impact of increased nucleolar volume in C9orf72 FTD 
Disruption of normal ribosomal RNA transcription and onset of nucleolar stress has 
previously been shown to trigger neuronal apoptosis (Kalita et al., 2008; Parlato et al., 
2008). Increased nucleolar volume, as was detected in poly(GR) inclusion positive neurons 
in this chapter, is usually associated with increased ribosomal production and aberrant cell 
growth, and is observed in cancer cells (Montanaro et al., 2008) as well as in cardiac 
hypertrophy (Hariharan and Sussman, 2014). Conversely, in neurodegenerative diseases 
such as Parkinson’s Disease (PD) and Alzheimer’s disease (AD), nucleolar stress and decline 
in rRNA synthesis is usually associated with a decrease in nucleolar volume (Mann and 
Yates, 1982; Mann et al., 1981; Parlato and Kreiner, 2013). Nucleolar shrinkage and 
decreased nucleolar activity is similarly associated with normal aging (Garcıá Moreno et al., 
1997). Interestingly, one study found that while nucleolar size is decreased in AD patients 
in comparison to control patients, it is increased in patients with asymptomatic AD, who 
exhibit Aβ plaques and neurofibrillary tangles but normal cognitive function (Iacono et al., 
2009), suggesting that increased nucleolar volume could represent a protective 
mechanism. Moreover, while neurons are post-mitotic, larger nucleoli and increased 
nucleolar activity have been associated with growth with regards to cellular regeneration 
and outgrowth of axons following injury (Hetman and Pietrzak, 2012). In response to the 
lack of a correlation observed between DPR inclusion burden and affected brain regions in 
C9orf72 FTD/ALS, it has been hypothesised that DPR inclusions could exert a protective role 
by sequestering soluble DPR species and preventing them from exerting their toxic effect. 
An increase in nucleolar volume could therefore be interpreted as a mechanism promoting 
the growth and recovery of cells in which soluble poly(GR) has been sequestered into an 
inclusion. This theory would also be consistent with the decreased nucleophosmin volume 
observed in C9orf72 FTD neurons without a poly(GR) inclusion in comparison to control 
neurons, if these cells were to harbour a heightened level of soluble poly(GR). However, 
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while human astrocytes treated with synthetic (PR)20 produced increased levels of rRNA 
and snoRNAs, the levels of mature 18S, 5.8S and 28S ribosomal subunits were decreased 
(Kwon et al., 2014). A second study also showed that overexpression of (GR)30 and (PR)30 in 
HEK293T cells caused increased nucleolar volume but a reduction in mature 18S and 28S 
transcripts (Tao et al., 2015). Cell models treated with arginine-containing DPR proteins 
therefore appear to contradict the positive correlation usually observed between nucleolar 
volume and rate of ribosomal subunit production. Furthermore, decreased maturation of 
the 28S ribosomal subunit was observed in C9orf72 ALS patient motor cortex (Haeusler et 
al., 2014). Increased rRNA production in the context of fewer mature ribosomes may 
suggest an uncoupling in the chain of ribosomal production and an increase in immature 
rRNA transcription as an attempted compensation mechanism by the affected neuron. 
Therefore, the increase in nucleolar volume in C9orf72 FTD is likely to be pathological and 
not protective.   
While a clear nucleolar enlargement was observed in C9orf72 poly(GR)-inlcusion-positive 
neurons, neither the median size of nucleoli in these neurons, nor the difference in median 
nucleolar size between C9orf72 poly(GR)-inlcusion-positive and poly(GR)-inclusion-negative 
neurons were observed to correlate with either patient age of disease onset, or disease 
duration. It is possible that increasing the statistical power of the analysis by examining 
nucleolar volume in a larger cohort of patients could reveal the existence of a weak 
correlation. However, considering the multitude of different disease mechanisms known to 
be involved in C9orf72 FTD/ALS, it is likely that nucleolar dysfunction plays a small role in a 
more complicated overarching process, and therefore a correlation may not be seen due to 
the dependency of age of onset or duration on a multitude of other factors. 
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5.3.5 Isolating a causal relationship between poly(GR) inclusion burden and 
nucleolar dysfunction 
While work in this chapter established an association between poly(GR) inclusion presence 
and increased nucleolar volume, more work is required before a causal relationship can be 
established between poly(GR) aggregates and nucleolar dysfunction, due to the large 
number of confounding variables inherently present in patient tissue. As a weak but 
significant positive correlation was observed between nucleolar volume and nuclear 
volume, we examined nuclear volume in control, C9orf72 FTD poly(GR)-inclusion-positive 
and C9orf72 FTD poly(GR)-inclusion-negative neurons to ensure that a larger nucleolar 
volume was not being driven by 1) the presence of poly(GR) inclusions in a sub-population 
of larger neurons, 2) a generic increase in whole cell size in response to poly(GR) inclusion 
presence, or 3) greater ease of poly(GR) inclusion detection in larger neurons due to 
inclusions frequently being larger in these cells. However, no difference in DAPI size was 
observed, indicating a specific nucleolar enlargement in poly(GR) inclusion positive cells. 
We also examined nucleolar volume as a proportion of nuclear volume in each neuron. 
Nucleophosmin was found to occupy a significantly higher proportion of the nucleus in 
poly(GR)-inclusion-positive neurons compared to negative neurons, however while a trend 
was observed for a higher nucleolin proportion of the nucleus in poly(GR)-inclusion-positive 
neurons, this was not found to be significant. This could reflect the very weak correlation 
between nuclear size and nucleolar volume, meaning that dividing nucleolar volume by 
DAPI volume would introduce a great deal of noise and therefore limit how informative this 
comparison is with the current sample size.  
It is also important to consider that poly(GR) is known to co-aggregate with other DPR 
proteins, and therefore further work is needed to determine whether or not these proteins 
also contribute to nucleolar dysfunction. In conjunction with our work in human post-
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mortem brain, we have also been continuing to collaborate with Prof. Linda Partridge’s 
group at the UCL Institute of Heathy Aging and the Max Plank Institute for Biology of Aging 
to use our protein-only Drosophila models to dissect the impact of different DPR proteins 
on nucleolar morphology. In recent unpublished work, (GR)100 or (GA)100 repeats were 
individually expressed using non-GGGGCC, protein-only DNA constructs in Drosophila adult 
neurons under an inducible ELAV-GeneSwitch promoter. Drosophila in which the (GR)100 or 
(GA)100 transgene had been induced by administration of an RU486 activator were 
compared against flies that harboured a transgene, but that had received no induction. 
Nucleoli in poly(GR)-inclusion-positive cells in induced (GR)100  expressing flies were found 
to be significantly larger than those in poly(GR)-negative cells, with an over ten-fold 
increase in average volume observed. No significant difference was observed in nucleolar 
volume between poly(GR)-inclusion-negative cells in induced or uninduced (GR)100 flies.  In 
contrast, poly(GA)-inclusion-positive cells in induced (GA)100 expressing flies underwent a 
modest but significant 50% increase in volume compared to cells lacking a poly(GA) 
inclusion. The extensive nucleolar enlargement observed in (GR)100 expressing flies, which 
are known to experience a marked reduction in viability as was detailed in section 4.2.3, 
strongly implicates poly(GR) in nucleolar dysfunction.  
However, more work is still required in C9orf72 post-mortem brain to compliment work 
carried out in our Drosophila models and determine the relative contributions of different 
DPR proteins to changes in nucleolar morphology. Furthermore, the small increase in 
nucleolar volume observed in fly cells bearing a poly(GA) inclusion requires further 
investigation. To determine the relative contributions of different DPR proteins in human 
post-mortem brain, co-immunostaining could be carried out using antibodies against 
poly(GR), a second DPR protein such as poly(GA), and a nucleolar marker. Neurons 
containing poly(GR)-only inclusions could then be distinguished from those bearing 
inclusions comprised of both poly(GR) and poly(GA), or poly(GA)-only inclusions, and the 
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nucleolar volumes could be compared across these populations. It would also be of interest 
to co-immunostain for poly(PR) inclusions and poly(GR) inclusions, to assess whether both 
arginine containing dipeptides are similarly associated with an increase in nucleolar 
volume. 
The potential effect of repeat RNA on nucleolar dysfunction should also be taken into 
account. Both nucleolin and nucleophosmin are known to bind RNA G-quadruplexes, and a 
previous study associated aborted GGGGCC repeat expansion RNA transcripts with 
nucleolar dysfunction (Haeusler et al., 2014).  In order to examine the contribution of RNA 
mechanisms of toxicity to nucleolar dysfunction in human C9orf72 patient brain, RNA FISH 
could be carried out to detect sense or antisense RNA foci in conjunction with 
immunofluorescent staining for nucleolar markers to examine how the presence of these 
different entities might differentially affect nucleolar volume.  
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Chapter 6:  Discussion 
6.1  Final Summary 
The primary aim of this project was to dissect the different gain-of-function mechanisms in 
C9orf72 FTD/ALS, to help understand which pathways are important in disease 
pathogenesis. To do this, genetic constructs were synthesised to recapitulate the RNA 
and/or DPR protein gain-of-function aspects of C9orf72 repeat pathology. The effect of 
these constructs was then examined in cell culture and Drosophila models to understand 
how these individual components of repeat pathology might initiate disease. This work was 
coupled with studies in human C9orf72 FTD post-mortem brain tissue in order to 
understand whether the effects seen in our model systems are relevant to patients with 
the disease.    
Three types of DNA constructs were generated to produce a genetic toolkit for dissecting 
gain-of-function mechanisms of pathology: 1) pure repeats which yield both repeat RNA 
and DPR proteins were generated in a range of lengths from 3 to 103 repeats, 2) RNA-only 
repeats which produce repeat RNA, but not DPR proteins were generated from 36 to 1152 
repeats in length and 3) protein-only repeats that code individually for the five different 
DPR proteins were produced in lengths of 36 repeats or 100 repeats, with short constructs 
of 6 or 7 repeats generated with a GFP tag. Together these tools allow the dissection of 
RNA and protein gain-of-function mechanisms, and the range of repeat lengths generated 
additionally enables the study of these phenomena in a dose-dependent manner.  
These repeat constructs were then transiently transfected into immortalised cell lines to 
study RNA foci formation and the subcellular localisation of DPR protein aggregates. RNA-
only and pure repeat constructs made both sense and antisense foci in cells, and repeat 
length was found to be positively correlated with the proportion of RNA foci-positive cells, 
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but not with the number of foci per cell. When protein-only constructs were transfected 
into cells, poly(GA) of 36 and 100 repeats in length formed star-like cytoplasmic inclusions 
reminiscent of those seen in C9orf72 FTD/ALS patient brain with more extensive inclusion 
formation observed in GA100 transfected cells. Short GFP-tagged poly(GR) and poly(PR) 
peptides and untagged PR36 peptides produced in protein-only construct transfected cells 
were observed to aggregate within the nucleus, while longer PR100 protein aggregated in 
the cytoplasm, suggesting a repeat length dependent effect on poly(PR) localisation. Lastly, 
poly(AP) and short GFP-tagged poly(GP) peptides were found to exhibit a diffuse 
localisation throughout the cell. 
In collaboration with Prof. Linda Partridge’s group, transgenic fly lines were generated 
using the pure, RNA-only and protein-only repeat constructs that I produced. Pure repeat 
constructs caused degeneration when expressed in the fly eye and a loss of viability when 
expressed in adult neurons; however no detectable toxicity was caused by RNA-only 
constructs, implicating DPR proteins in toxicity (Mizielinska et al., 2014). When protein-only 
constructs were expressed in flies, arginine-containing DPR proteins poly(GR) and poly(PR) 
were sufficient to cause severe toxicity, implicating an important toxic role for these 
molecular species in C9orf72 FTD/ALS, while poly(GA) also caused a modest reduction in 
viability. 
Human post-mortem C9orf72 FTD patient brain was then examined to investigate the 
frequency of inclusion formation by different DPR proteins. To do this, an automated image 
analysis protocol was designed and tested in the cerebellum. Poly(GA) inclusions were 
found to be the most frequent, with poly(GP) and (GR) less frequent, and poly(AP) and 
poly(PR) found only rarely. Some disparity was found in the inclusion burden between the 
different regions of the cerebellum and between different patients, which calls for further 
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study to determine what impact DPR protein burden in this area might have on patient 
disease course. 
Finally, as the arginine-containing DPR proteins that were toxic in our Drosophila model 
were reported to bind to nucleoli and cause changes in nucleolar morphology and function 
in cell model systems (Kwon et al., 2014; May et al., 2014; Schludi et al., 2015; Tao et al., 
2015; Wen et al., 2014; Yamakawa et al., 2014; Zu et al., 2013), nucleolar volume was 
examined in human post mortem C9orf72 FTD patient brain to determine whether 
evidence for poly(GR) mediated nucleolar dysfunction could be observed patients with the 
disease. Neurons in C9orf72 FTD patients that contained a poly(GR) inclusion were found to 
have a significantly larger median nucleolar volume compared to neurons in C9orf72 FTD 
patients without a poly(GR) inclusion, which is a hallmark of nucleolar stress.  
6.2  The role of RNA and DPR protein gain-of-function mechanisms in 
C9orf72 FTD/ALS 
C9orf72 FTD/ALS is a complex and multifaceted pathology that involves a wide range of 
different molecular processes, and results in a striking variance in symptoms, pathological 
subtype and disease onset. This thesis provides some initial experiments and tools to begin 
to untangle the array of different pathways at work. The results of these experiments 
implicate a potentially important toxic role for arginine-containing DPR proteins in C9orf72 
FTD/ALS, however this does not necessarily rule out a contribution for RNA gain-of-function 
mechanisms, toxicity mediated by other DPR proteins, or loss of C9orf72 protein function. 
6.2.1 Further investigation of potential RNA gain-of-function disease mechanisms 
While RNA-only constructs of up to 288 repeats were not observed to yield a toxic 
phenotype in our transgenic Drosophila model, further experiments are needed to 
determine whether or not RNA gain-of-function disease mechanisms are important in 
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patients with C9orf72 FTD/ALS. Generation of Drosophila expressing longer 576 or 1152 
RNA-only repeats would be interesting to determine whether a longer repeat length is an 
important factor in the initiation of repeat RNA mediated toxicity, however the propensity 
for these longer constructs to undergo deletion due to instability has thus far precluded 
this option. Expression of pure or RNA-only repeats in an intronic context more akin to that 
of the repeats found in patients might also be necessary to observe RNA mediated toxicity: 
sequence surrounding the repeats may affect their expression and pathogenicity, and 
dispensing with the use of a polyadenylation sequence directly after the repeats would 
promote their retention within the cell nucleus and therefore allow more extensive RNA 
foci formation. 160 GGGGCC repeats have previously been expressed within an intronic 
context in a transgenic Drosophila model, which resulted in abundant nuclear sense RNA 
foci formation, however this had little effect on the survival of these flies (Tran et al., 2015). 
This suggests that even when expressed within an intronic context, this repeat length is not 
sufficient to cause RNA-mediated toxicity in flies. The generation of flies expressing 
antisense orientation RNA-only repeats would also be of interest, as expression of 
antisense repeat RNA transcripts was absent in the Drosophila generated in our study 
(Mizielinska et al., 2014). Both pure and RNA-only constructs were found to produce the 
same number of RNA foci and were both similarly able to form a G-quadruplex secondary 
structure, suggesting that these constructs are equally suitable for modelling RNA gain-of-
function mechanisms. However, it might additionally be informative to compare 
sequestration of RNA-binding proteins in RNA foci formed by pure or RNA-only repeat 
transcripts in cell culture or Drosophila models, in case the presence of the stop codon 
containing interruptions in the RNA-only repeats disrupts the binding of any proteins 
crucial to pathogenesis. 
When interpreting the lack of RNA toxicity in this model, it is also important to consider 
that the phylogenic distance between humans and Drosophila may mean that some 
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proteins that bind repeat RNA in human brain and play an important role in disease 
progression in humans may not be present in flies. Another important next step may 
therefore be to generate an RNA-only mouse to study RNA gain-of-function mechanisms in 
a mammalian system (see section 6.4 for further discussion of C9orf72 mouse models). 
Additional analysis of C9orf72 FTD/ALS patient brain may also assist in our understanding of 
the role of repeat RNA in pathogenesis. While studies have observed a correlation between 
RNA foci burden and age of onset in C9orf72 FTD or ALS patients (Cooper-Knock et al., 
2015b; Mizielinska et al., 2013), a more in depth characterisation of the distribution of 
sense and antisense RNA foci formation in larger patient cohorts, across multiple 
pathological subtypes, and in a greater range of different brain regions will help to 
determine how well RNA foci burden correlates with degeneration and disease type. 
Coupling this type of study with immunofluorescent counterstaining for different RNA-
binding proteins to examine variation in sequestration into sense and antisense RNA foci 
across different brain regions and between patients might also reveal some informative 
differences. Presently these types of studies are limited by the technical challenges posed 
by the small size of RNA foci, which are difficult to clearly visualise in human brain and 
require painstaking analysis by eye in large numbers of high magnification confocal 
fluorescence z-stack images. Automation of this process would make analysis of much 
larger data sets possible: this might be done by employing the use of a high throughput 
confocal fluorescence microscope to collect images, and by designing a more sophisticated 
image analysis protocol similar to the Definiens protocol used for DPR inclusion 
quantification in this study. However, even when automated, the image capture process 
required to generate a large data set of different patients and brain regions counterstained 
for different RNA-binding proteins would be very time consuming, and analysis of the large 
number resulting high resolution images would require an exceptional amount of 
processing power. It may therefore be that a large scale study such as this is not presently 
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feasible for most individual lab groups with the currently available equipment, but would 
make an interesting collaborative project. 
6.2.2 The consequences of DPR protein expression in model systems and C9orf72 
FTD/ALS patient brain.  
The work in this thesis supports a toxic role for DPR proteins within C9orf72 FTD/ALS 
patients. The degree of toxicity exhibited by the arginine-containing poly(GR) and poly(PR) 
DPR proteins in our Drosophila model is so severe that for them to be completely benign in 
human C9orf72 FTD/ALS patients seems improbable. However, it is true that regional DPR 
protein inclusion burden does not correlate well with neurodegeneration in C9orf72 
FTD/ALS patients (Davidson et al., 2014; Mackenzie et al., 2015, 2013) and that these 
aggregates are conspicuously sparse in some important areas of degeneration such as in 
the spinal cord and motor neurons of C9orf72 ALS patients (Gomez-Deza et al., 2015). 
However, it is possible that soluble DPR protein species may instead be responsible for 
toxicity. Initial studies have identified the presence of soluble poly(GP) and poly(GA) in 
C9orf72 FTD/ALS patient brain, which have so far been found to correlate with poly(GP) or 
poly(GA) inclusion burden in different brain regions (Gendron et al., 2015; Mackenzie et al., 
2015). However, analysis of the quantities of soluble poly(GR) and poly(PR) has yet to be 
carried out. Development of an immunoassay for the detection of soluble poly(GR) and 
poly(PR) will therefore be important to determine whether soluble levels of these proteins 
might correlate with the degree of degeneration in different brain regions, despite  
absence of a correlation between poly(GR) or poly(PR) inclusion burden and degeneration.  
It is also true that while poly(GR) and poly(PR) localise to the nucleolus in the cell culture 
model studied in this thesis, as well as in cell culture models generated by other groups 
(Kwon et al., 2014; May et al., 2014; Schludi et al., 2015; Tao et al., 2015; Wen et al., 2014; 
Yamakawa et al., 2014; Zu et al., 2013), within patients these proteins are primarily 
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detected within star-like inclusions similarly to poly(GA) and p62, or as para-nucleolar 
inclusions within the nucleus (Schludi et al., 2015), indicating a difference in localisation 
between cell models and patients. Sequestration of these peptides into inclusions could 
therefore be predicted to prevent them from interacting with nucleolar factors. However, 
as the work in this thesis shows an association between poly(GR) inclusion burden and an 
increase in nucleolar volume in C9orf72 FTD patient cortex, it may be that neurons with a 
poly(GR) inclusion also have a high soluble poly(GR) burden, which could be the species 
that interacts with the nucleolus to cause dysfunction. It may therefore be useful to 
determine not only the global quantities of soluble poly(GR), but also how soluble levels of 
this peptide differ in inclusion-bearing and non-inclusion-bearing cells, which would require 
the microdissection of individual cells and the analysis of the different soluble and insoluble 
fractions. 
There are a number of potential reasons for a difference in DPR protein toxicity in cell 
culture and Drosophila models compared to human C9orf72 FTD/ALS patients, such as the 
differences in the genetic context of expression between these systems. The repeat 
constructs expressed in our transgenic Drosophila lines were expressed as a part of poly-
adenylated mRNA transcripts, which facilitates the nuclear export and translation of these 
transcripts (Tran et al., 2015; Weill et al., 2012). Additionally, translation of our protein-only 
repeats was driven by an ATG start codon allowing canonical translation to occur. These 
factors may result in a high DPR protein burden in pure repeat and protein-only repeat 
expressing Drosophila in comparison to those produced from the intronic repeats within 
human C9orf72 FTD/ALS patients. In patients the accumulation of DPR proteins by the 
inefficient process of RAN translation is likely to be more gradual, with protein degradation 
mechanisms potentially serving to reduce levels of these proteins until proteolysis begins 
to decline in old age (Martinez-Vicente et al., 2005). While slow onset of DPR protein 
burden in patients will potentially limit their toxicity, these peptides will have a lifetime in 
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which to gradually inflict damage. Study of patients in the early phases of C9orf72 FTD/ALS 
has already shown that DPR protein aggregation pre-dates TDP-43 deposition (Baborie et 
al., 2014; Proudfoot et al., 2014), implying that these proteins may be the initiators of 
disease, while TDP-43 mislocalisation may be the final actuator of cell death, or may simply 
be a consequence of disrupted cell function. An “amyloid-like cascade hypothesis” has 
been proposed, in which DPR proteins may be responsible for the initiation of disease 
processes in an analogous fashion to soluble Aβ and amyloid plaques in Alzheimer’s 
disease, which then leads to a snowballing effect of increasing inflammatory response and 
cell damage that eventually leads to deposition of tau neurofibrillary tangles, or in the case 
of C9orf72 FTD/ALS, TDP-43 aggregation (Edbauer and Haass, 2015). Additional detailed 
quantification of DPR protein aggregation in different brain regions and in different 
pathological subtypes of early-phase C9orf72 FTD/ALS patients would help to determine 
whether DPR proteins do play this type of role in disease initiation, for which the DPR 
protein aggregate image analysis protocol developed in this thesis could be used. Equally, 
analysis of soluble species in these patients would also allow us to understand more about 
the relative roles of insoluble aggregates and soluble monomers or oligomers that may be 
formed by DPR proteins.    
6.2.3 Contribution of different pathological mechanisms to disease heterogeneity 
Rather than considering C9orf72 FTD/ALS to be a pathology for which one key disease 
causing factor initiates symptom onset, it is likely that all of the molecular mechanisms that 
arise from the repeat expansion play a role in pathogenesis. The large number of 
potentially toxic factors caused by the repeat expansion raises the possibility that different 
mechanisms are more or less important in different patients or brain regions, and thus lead 
to the degeneration of different cell populations, which might explain the high 
heterogeneity of this disease.  
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There are a huge number of different factors potentially affecting disease course in C9orf72 
FTD/ALS patients (summarised in Figure 6.1), which include: 1) differential reduction in the 
levels of three different C9orf72 transcripts and two C9orf72 protein isoforms, 2) 
expression of sense GGGGCC and antisense CCCCGG RNA transcripts, their subsequent 
aggregation to form sense and antisense RNA foci, the formation of different secondary 
RNA conformations and the potential sequestration of an array of RNA binding factors, 3) 
RAN translation of five different DPR proteins which exist in soluble form and as 
cytoplasmic or nuclear aggregates, some of which may disrupt nucleolar function and 
nucleocytoplasmic transport (see section 6.3 below), 4) modulation of all of the above 
processes according to exact repeat length harboured by a particular patient, as well as by 
other genetic and environmental risk factors. When all of these factors are taken into 
account, the clinical heterogeneity of this disease seems unsurprising.  
Neurons are thought to be particularly susceptible to cellular stress and damage, especially 
as the brain ages, as they are post-mitotic cells with a high metabolic demand which can 
result in the build-up of damage caused by physiological stress and excitotoxicity (Saxena 
and Caroni, 2011). However, which population of neurons are affected first in C9orf72 
FTD/ALS may be dependent on all of the factors listed above, with certain mechanisms or 
risk factors perhaps favouring damage or TDP-43 accumulation in one cell type over 
another. One study examined the survival of cultured rat cortical, motor and hippocampal 
neurons transfected with 42 GGGGCC repeats, and found that cortical and motor neurons 
exhibited a significant reduction in survival compared to controls, while no significant 
difference was observed in hippocampal neurons, suggesting that cortical and motor 
neurons are distinctly sensitive to toxicity mediated by the repeats (Wen et al., 2014). 
Further cell culture or mouse model studies could be carried out using the RNA-only and 
protein-only constructs generated in this thesis to determine whether motor neurons or 
cortical neurons are more susceptible to one gain-of-function mechanism or the other, to 
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examine if a predominance of one mechanism or the other might promote either an FTD or 
an ALS disease onset.  Some studies in C9orf72 FTD/ALS patient brain have also highlighted 
some differences in DPR protein burden in different patients, with a lower poly(GP) burden 
detected in the cerebellum of C9orf72 ALS patients compared to FTD or FTD/ALS patients 
(Gendron et al., 2015), and a higher poly(GA) inclusion burden in the cerebellum of C9orf72 
FTD patients compared to ALS or FTD/ALS patients (Schludi et al., 2015). However these 
findings were not replicated by another study (Mackenzie et al., 2015), and therefore 
further research in patient tissue is required to confirm what differences exist between 
different C9orf72 disease subtypes.  
 
 
 
Figure 6.1 C9orf72 FTD/ALS disease mechanisms. 
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6.3  Dissecting RNA-mediated and DPR protein-mediated disruption of 
nucleocytoplasmic transport in C9orf72 FTD/ALS 
Components of the nuclear pore complex (NPC) are known to be extremely long lived in 
post-mitotic cells, and can become damaged during aging (D’Angelo et al., 2009). 
Mutations in several nuclear pore components and nucleocytoplasmic transport factors are 
also associated with nervous system impairment in several rare diseases (Dickmanns et al., 
2015). Therefore, the process of nucleocytoplasmic transport may be an important focus 
for neurodegeneration research. Recently, a number of studies have implicated the 
disruption of protein and RNA transport between the nucleus and the cytoplasm as a 
pathological mechanism in C9orf72 FTD/ALS (Freibaum et al., 2015; Jovičić et al., 2015; 
Zhang et al., 2015), adding to the number of cellular processes thought to be disrupted by 
the repeats, however it is unclear what the relative contributions of RNA and DPR protein 
gain-of-function mechanisms to this process are. The genetic constructs generated in this 
thesis could therefore also be used to dissect the contributions of RNA and DPR protein 
gain-of-function mechanisms to the disruption of nucleocytoplasmic transport in C9orf72 
FTD/ALS in future. 
6.3.1 Discovery of a GGGGCC repeat mediated disruption of nucleocytoplasmic 
transport  
Three reports were published that undertook genetic modifier screens in transgenic 
C9orf72 repeat expressing yeast and fruit fly models to assess whether mutations in other 
genes causing their gain or loss of function resulted in the suppression or enhancement of 
repeat toxicity.  
One group crossed transgenic flies expressing 30 GGGGCC repeats with other fly lines 
harbouring mutations in genes previously found to interact with GGGGCC repeat RNA 
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(Zhang et al., 2015). A second group carried out an unbiased genetic screen in Drosophila 
expressing 58 GGGGCC repeats (Freibaum et al., 2015). Finally, a third group specifically 
examined the effect of DPR protein expression by carrying out a genetic modifier screen in 
PR50 expressing Saccharomyces cerevisiae strains, which were observed to have a 
dramatically reduced viability. 
All three groups found that mutations in genes encoding components of the Ran GTPase 
nuclear transport cycle modulated toxicity in these different models. Maintenance of a high 
ratio of GDP-bound Ran to GTP-bound Ran between the cytoplasm and nucleus is critical 
for normal functioning of nucleocytoplasmic transport. In the cytoplasm, Ran GTPase 
activating protein (RanGAP) induces Ran to hydrolyse its bound GTP to GDP, while in the 
nucleus the Ran guanine exchange factor (GEF) RCC1 catalyses the conversion of Ran-GDP 
to Ran-GTP. A dominant-negative mutation of Ran was found to enhance toxicity in one 
Drosophila  model (Freibaum et al., 2015). Additionally, overexpression of RanGAP, 
promoting nuclear import, suppressed toxicity in the other fly model (Zhang et al., 2015). 
However, overexpression of RCC1, promoting nuclear export, enhanced toxicity in PR50 
expressing yeast (Jovičić et al., 2015), suggesting that toxicity in these models is mediated 
by a deficit in nuclear import. A number of other components of nucleocytoplasmic 
transport were also found to modulate toxicity, including components of the nuclear pore 
complex and several karyopherin nuclear transport proteins (Freibaum et al., 2015; Jovičić 
et al., 2015). Furthermore, the nuclear envelope was observed to have an aberrant 
wrinkled morphology in flies, and some nucleocytoplasmic transport proteins were 
additionally observed to form perinuclear aggregates in neurons differentiated from 
C9orf72 ALS patient derived iPSCs. 
In accordance with these observed defects in nucleocytoplasmic transport machinery, a 
functional deficit in nuclear import was also observed in these models as well as in C9orf72 
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ALS iPSC derived neurons, with fluorescent marker proteins conjugated to a nuclear 
localisation signal and a nuclear export signal found to be enriched in the cytoplasm and 
depleted from the nucleus (Freibaum et al., 2015; Zhang et al., 2015). RNA export was 
additionally found to be disrupted, with an accumulation of newly synthesised RNA 
observed in the nuclei of C9orf72 ALS iPSC derived neurons (Freibaum et al., 2015). These 
studies therefore implicate the disruption of nuclear protein import and RNA export as 
potentially important disease mechanisms induced by the C9orf72 repeat expansion  
6.3.2 Determining the cause of nucleocytoplasmic transport defects in C9orf72 
FTD/ALS 
The three studies discussed above approached their respective genetic screens with 
different preconceptions regarding the toxic species at work in C9orf72 FTD/ALS, but 
arrived at the same conclusion of the disruption of nucleocytoplasmic transport within this 
disease. Zhang et al. proposed an RNA-gain-of function mechanism of toxicity, based on the 
observed interaction of RanGAP with G-quadruplex forming GGGGCC RNA. As RanGAP 
localises to the cytoplasm and not the nucleus, this would preclude an interaction between 
RanGAP and nuclear RNA foci, and instead implicate the soluble repeat RNA species or 
infrequent RNA foci present within the cytoplasmic compartment. While this group were 
unable to detect DPR proteins within their fly model, this does not preclude their presence 
at concentrations below the sensitivity threshold of the assay used. Additionally, while the 
disruption of GGGGCC RNA and G-quadruplex formation was observed to rescue nuclear 
transport defects, this could equally be predicted to abolish subsequent RAN translation 
from these repeats. To confirm the involvement of RNA gain-of-function mechanisms, it 
may be interesting to examine nucleocytoplasmic transport in cell culture or fly models 
expressing our RNA-only constructs to determine whether a transport defect can still be 
observed.  
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Current evidence is more supportive of a DPR protein gain-of-function mechanism 
mediating a defect in nucleocytoplasmic transport, as Jovicic et al. used protein-only PR50 
repeats that do not produce repetitive GGGGCC RNA in their yeast and primary neuron 
studies, which were sufficient to yield a defect in nucleocytoplasmic transport. It would be 
interesting to also investigate nucleocytoplasmic transport in cell or fly models expressing 
different protein-only constructs to determine whether DPR proteins other than poly(PR) 
disrupt nuclear transport. Ascertaining whether or not poly(GR) plays a role in 
nucleocytoplasmic transport disruption would be of particular importance to determine 
whether both arginine-containing DPR proteins exert the same effect. Jovicic et al. showed 
that deletion of many of the same targets that suppressed PR50 toxicity also suppress GR100 
toxicity in yeast, however none of the targets that were effective at suppressing GR100 
toxicity were confirmed to be involved with nucleocytoplasmic transport, and GR100 toxicity 
was not severe enough in this model to enable the overexpression screen to be carried out. 
Examination of nucleocytoplasmic transport in cell lines and transgenic fly models 
expressing poly(GR) in isolation from other DPR proteins or GGGGCC repeat RNA could 
therefore be carried out to further investigate the involvement of this protein.  
Intriguingly, recent research has also found that the short isoform of the C9orf72 protein 
localises to the nuclear envelope (Xiao et al., 2015), suggesting that a loss-of-function 
mechanism may also be involved in the disruption of nucleocytoplasmic transport. 
However, further studies are required to determine whether downregulation of C9orf72 
results in a functional nuclear trafficking deficit. Nevertheless, it is fascinating that all three 
of the proposed mechanisms of repeat expansion pathogenesis appear to converge on the 
same functional defect.  
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6.3.3 Nucleocytoplasmic transport defects and protein aggregation  
A breakdown in nuclear import could be fundamentally important to C9orf72 FTD/ALS 
pathogenesis. Previous studies have shown that knocking down components of the nuclear 
import machinery in a cell culture model results in the cytoplasmic aggregation of TDP-43 
(Nishimura et al., 2010), and disruption of nucleocytoplasmic transport has previously been 
observed to be associated with TDP-43 aggregation in non-C9orf72 forms of FTD 
(Nishimura et al., 2010; Ward et al., 2014), suggesting that this defect could be a point of 
convergence in different TDP-43 proteinopathies. Indeed, Zhang et al. note that nuclear 
import defects correlate with aberrant localisation of TDP-43 or its Drosophila homolog 
TBPH in their C9orf72 ALS iPSC neurons and GGGGCC repeat expressing flies respectively, 
raising the possibility that TDP-43 aggregation could result from a defect in 
nucleocytoplasmic transport induced by the C9orf72 repeat expansion. However a robust 
causal effect still remains to be demonstrated.  
Recent research found that cytoplasmic inclusion formation by a range of different 
aggregate-prone proteins, including several synthetic proteins with no biological function, 
inhibit nucleocytoplasmic transport (Woerner et al., 2015), suggesting that it is a general 
pathological mechanism initiated by aggregating proteins. It may be that DPR protein 
aggregates also inhibit nucleocytoplasmic transport in the same way. However, cytoplasmic 
aggregate formation by TDP-43 C-terminal fragments were also specifically found to inhibit 
nucleocytoplasmic transport in this study (Woerner et al., 2015), which makes it unclear 
whether the observed defects in nucleocytoplasmic transport in C9orf72 repeat expansion 
models are the cause or the consequence of TDP-43 mislocalisation and aggregation. One 
possibility is that RNA or DPR protein gain-of-function mechanisms of toxicity could cause 
an initial reduction in nucleocytoplasmic transport, leading to some TDP-43 deposition, 
which could then produce a positive feedback loop further inhibiting nucleocytoplasmic 
transport and leading to further TDP-43 and DPR protein aggregation. Interestingly, while 
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cytoplasmic aggregates caused nucleocytoplasmic defects, nuclear aggregates were not 
found to disrupt nuclear transport (Woerner et al., 2015), indicating that the compartment 
that aggregation occurs in is important in determining their pathogenicity. It was noted 
that in the nuclear compartment these proteins co-immunoprecipitated with the nucleolar 
protein nucleophosmin, which the authors suggest may chaperone the proteins within the 
nucleus and block the toxicity of the aggregates (Woerner et al., 2015). This draws some 
interesting parallels with the findings in this thesis and in other publications which 
implicate a role for arginine-containing DPR proteins in nucleolar dysfunction. An 
interesting possibility would be if disruption of normal nucleolar function by poly(GR) and 
poly(PR) prevents nucleophosmin from carrying out a protective role against nuclear 
aggregates. However, as Woerner et al. only showed co-localisation of nucleophosmin with 
aggregating proteins, more functional work is needed to confirm whether it is playing a 
protective role. One potential experiment could be to examine the effect of nuclear 
aggregates in a cell culture model with or without the knock-down of nucleophosmin using 
siRNA to determine whether a difference in aggregate toxicity is observed. However as 
nucleophosmin is a multifunctional protein, determining whether any increased toxicity 
caused by nuclear inclusions is due specifically to the loss of nucleophosmin aggregate 
chaperoning activity or due to a more generic reduction in cell viability caused by a loss of 
other nucleophosmin functions could be problematic. More work is also required to 
determine if and how nucleocytoplasmic transport defects and nucleolar dysfunction in 
repeat expressing cells may be interrelated: this might be investigated by rescuing 
nucleocytoplasmic transport in a C9orf72 cell model or iPSC-derived neurons and 
examining whether nucleolar morphology is also rescued as a result, or conversely rescuing 
nucleolar function and examining whether nucleocytoplasmic transport is restored.     
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6.4  Mouse models for C9orf72 FTD/ALS 
While modelling disease in cell culture systems and simple organisms such as fruit fly, 
nematode worm and zebrafish provide useful tools for understanding basic pathological 
mechanisms, transgenic mouse models allow disease to be studied in a more complex 
mammalian nervous system and facilitate more sophisticated behavioural tests. This not 
only makes a more detailed dissection of disease mechanisms possible, but also allows 
preclinical testing of promising therapeutics. Development of C9orf72 FTD/ALS mouse 
models that mirror disease progression observed in human patients is therefore important. 
6.4.1  Current C9orf72 repeat expansion mouse models 
A number of C9orf72 loss-of-function and gain-of-function mouse models have been 
generated to date. In the loss-of-function models produced so far, no neurodegenerative 
features have been observed. Treatment of mice with antisense oligonucleotides against 
C9orf72, causing a reduction in transcript levels, was not found to cause any signs of 
neurodegeneration or behavioural changes (Lagier-Tourenne et al., 2013). More recently, 
Nestin-Cre+/−;C9orf72fl/fl mice were generated with a conditional knock-out of C9orf72 in 
neurons and glia. These mice exhibit a reduced body weight, but no reduction in viability, 
neurodegeneration or motor defects (Koppers et al., 2015). A deficit of C9orf72 protein 
therefore does not appear to cause any phenotypes characteristic of C9orf72 FTD/ALS. 
The first published gain-of-function mouse model for C9orf72 FTD/ALS expresses 80 
GGGGCC repeats under an inducible tetracycline promotor (Hukema et al., 2014). These 
mice exhibit ubiquitin positive inclusions, but neither poly(GA) inclusions or TDP-43 
inclusions could be detected after 12 weeks of doxycycline treatment. Additionally, the 
authors do not report the presence of any RNA foci, and no behavioural deficits or 
neurodegeneration were observed, therefore the recapitulation of C9orf72 FTD/ALS 
pathology by this mouse is limited.  
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A mouse with 66 GGGGCC repeats overexpressed in the CNS by adeno-associated virus 
(AAV) mediated transduction was the first rodent model for C9orf72 FTD/ALS that 
recapitulated elements of repeat RNA and DPR protein pathology (Chew et al., 2015). Sense 
RNA foci and sense DPR proteins poly(GA), poly(GP) and poly(GR) were detected in the 
brain and spinal cord of these mice at 6 months of age, but the presence of antisense RNA 
foci, or antisense DPR protein aggregates was not investigated. TDP-43 was also found to 
mislocalise in these mice, demonstrating that repeat gain-of-function in the absence of a 
C9orf72 protein loss-of-function can induce this important hallmark of ALS and FTD. These 
mice additionally exhibited neuronal loss in the cortex and cerebellum, along with motor 
defects and behavioural problems such as anxiety, antisocial behaviour and hyperactivity, 
drawing parallels with some of the symptoms observed in FTD and ALS patients (Chew et 
al., 2015). However, two more recent transgenic mouse models expressing much longer 
repeat expansions using a bacterial artificial chromosome (BAC) were not able to replicate 
the functional deficits or neurodegeneration observed in this model (O’Rourke et al., 2015; 
Peters et al., 2015), indicating that the overexpression in the (GGGGCC)66 mouse may be 
driving the phenotypes seen. One of these models expressed the first six exons of the 
human C9orf72 gene containing approximately 500 GGGGCC repeats within the first intron 
and around 140 kb of upstream genomic sequence (Peters et al., 2015). Mice exhibited 
sense and antisense RNA foci in neurons as well as both soluble poly(GP) and poly(GP) 
inclusions, however, the presence or absence of other DPR proteins was not reported. No 
reduction in survival, and no behavioural or cognitive deficits were noted in repeat 
expressing mice comparison to non-transgenic littermates. Furthermore, no TDP-43 
pathology was observed. The second BAC transgenic mice exhibit an array of transgenes 
with between 100 and 1000 hexanucleotide repeats within the first intron of a complete 
human C9orf72 gene (O’Rourke et al., 2015). Again both sense and antisense RNA foci were 
observed in neurons, as well as both soluble poly(GP) and poly(GP) inclusions, which were 
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found to be most abundant in the cerebellum and least frequent in the spinal cord, 
mirroring the distribution pattern observed in C9orf72 FTD/ALS patients (Schludi et al., 
2015). However, the presence or absence of other DPR proteins was again not reported 
(O’Rourke et al., 2015). This group also observed an increase in neuronal nucleolin staining 
area in repeat expansion expressing mice, in accord with the similar increase in nucleolar 
volume observed in C9orf72 FTD/ALS patients in this thesis, suggesting that these mice 
successfully model this aspect of the disease. Conversely, this group did not detect a 
difference in the levels of any ribosomal RNA in 8 month old mice, suggesting this 
morphological change in nucleoli is not linked to a nucleolar dysfunction; however it may 
be of interest to examine older mice to determine whether a reduction in ribosomal RNA 
maturation develops with age. Once more, no neurodegeneration, behavioural defects or 
reduction in survival were noted in this model, with no TDP-43 pathology observed. 
Interestingly, no sequestration of Pur α, hnRNP A3, hnRNP A2/ B1, or hnRNP H was 
observed by RNA foci in these animals, as had previously been noted in human C9orf72 
FTD/ALS patient tissue, bringing into question what factors might affect binding of these 
proteins to the repeat RNA (O’Rourke et al., 2015).  
6.4.2 Future research prospects for C9orf72 FTD/ALS mouse models 
The lack of neurodegeneration in the current C9orf72 BAC transgenic mouse models 
despite the presence of RNA foci and DPR protein aggregate formation is very interesting, 
especially in the light of reports from recent conferences that other soon to be published 
gain-of-function and loss-of-function C9orf72 mouse models do exhibit neurodegeneration 
and a reduction in survival (Dance, 2015). Examination of differences in in these mice may 
help to unravel what factors lead from the presence of the histopathological hallmarks of 
disease to the onset of neurodegeneration. For example, upstream or downstream 
sequences surrounding the C9orf72 gene may affect the pathogenicity of the repeats in 
some way. The regional or cell type expression pattern of the transgene in various mouse 
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models may also affect disease onset, as well as the expression level of the repeat 
expansion. Furthermore, the BAC mouse models published so far express part or the entire 
human C9orf72 gene in addition to endogenous levels of the mouse C9orf72 homolog: it 
would therefore be interesting to determine whether overexpression of C9orf72 protein is 
protective in these models, or whether a partial loss of C9orf72 function is required for 
disease onset. To determine this, these gain-of-function mouse models could perhaps be 
crossed with the existing mice with a conditional C9orf72 knock-out in neurons and glia 
(Koppers et al., 2015). While neither these loss-of-function mice or the gain-of-function 
BAC transgenic mice individually show a neurodegenerative phenotype, it is possible that a 
phenotype could be observed in the resulting cross. 
There are also clearly many differences between mice and patients that could affect the 
toxicity of the repeats. Mice do not undergo spontaneous neurodegeneration in old age as 
humans and some higher mammals do and therefore may not be as susceptible to 
neurodegeneration. This could be one reason that a number of existing neurodegenerative 
mouse models fail to accurately recapitulate the symptoms of human disease despite the 
expression of disease relevant mutations. Lifespan may be an important factor as disease 
onset in C9orf72 FTD/ALS patients most often only occurs after many decades, while mice 
only live for up to two years. In a non-overexpression system this may not give the repeat 
expansion sufficient time to cause neurodegeneration in a mouse during its shorter life 
time.  
Due to the lack of complete penetrance and the high variability in disease onset seen in 
human C9orf72 expansion carriers, a “two hit hypothesis” has also been suggested in which 
one or more additional environmental stressors or genetic risk factors are required in 
combination with the presence of the repeat expansion in order to initiate disease 
(Edbauer and Haass, 2015), which may not be present in inbred mouse lines housed in a 
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very safe and artificial environment mostly free from stress. It might therefore be 
interesting to investigate whether introducing pharmacological or environmental stressors 
to these mouse models induces a neurodegenerative phenotype. 
The RNA-only and protein-only DNA constructs developed in this thesis would be 
interesting candidates for generation of C9orf72 mouse models. In theory, expression of 
our stop codon containing RNA-only repeats could be used to make a mouse that produces 
sense and antisense RNA foci, but not DPR proteins. This could be compared with mice 
made to express our protein-only repeats coding individually for each of the different DPR 
proteins to examine whether a difference in phenotype can be observed between mice in 
an analogous fashion to the observations made in our Drosophila studies (Mizielinska et al., 
2014). It would be of great interest to determine whether poly(GR) or poly(PR) are 
sufficient to cause toxicity in a mammalian system, and whether any RNA mediated toxicity 
could be observed in an RNA-only mouse, which would indicate an important biological 
difference between these two organisms. Nucleolar morphology and function could also be 
studied in RNA-only and protein-only mice to clarify whether poly(GR) or poly(PR)  
expression is necessary and sufficient to cause nucleolar dysfunction.  
6.5  Treatment prospects for C9orf72 FTD/ALS 
6.5.1 Development of potential therapies for C9orf72 FTD/ALS 
A better understanding of the pathological mechanisms at work in C9orf72 FTD/ALS will 
hopefully yield new treatment prospects, which are sorely needed for these patients. One 
promising treatment option is the use of antisense oligonucleotides (ASOs), short nucleic 
acid sequences that bind to complimentary RNA transcripts within the cell, which either 
sterically inhibit their interaction with other binding partners, or promote their degradation 
by RNase H (Dias and Stein, 2002). ASOs have previously been shown to reduce RNA foci 
formation and normalise aberrant splicing in a mouse model of myotonic dystrophy 
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(Mulders et al., 2009), and are now being tested in models of C9orf72 FTD/ALS. Several 
groups administered ASOs targeted against the C9orf72 locus in neurons differentiated 
from C9orf72 ALS patient derived iPSCs, which were found to reduce sense RNA foci 
formation and partially reversed transcriptome changes observed in C9orf72 iPSCs 
(Donnelly et al., 2013; Sareen et al., 2013). One study found that ASOs prevented the 
induction of glutamate excitotoxicity in C9orf72 iPSC-derived neurons, and reduced the 
interaction between sense RNA foci and the RNA binding protein ADARB2 (Donnelly et al., 
2013). Additionally, ASO treatment restored the disrupted Ran gradient between the 
nucleus and cytoplasm in C9orf72 ALS iPSC-derived neurons, and rescued the nuclear mis-
localisation of TDP-43 (Zhang et al., 2015). In another study, ASOs targeted similarly against 
the C9orf72 locus were administered to fibroblasts derived from C9orf72 ALS patients and 
were found to reduce sense RNA foci formation, however did not correct the aberrant RNA 
transcript expression profile in these cells (Lagier-Tourenne et al., 2013). This may be due 
to the influence of antisense RNA transcripts within C9orf72 FTD/ALS patient cells, which 
may need to be independently targeted with a second ASO in order to substantively 
reverse transcript changes in patients.  
Bioactive small molecules have also been designed that bind to GGGGCC repeats, and 
affect secondary structure formation. One study found a particular compound that binds 
GGGGCC repeats reduced RNA foci formation and poly(GP) inclusion formation in neurons 
differentiated from C9orf72 patient fibroblasts, with no significant effect on C9orf72 
transcript levels detected (Su et al., 2014). The porphyrin molecule TMPyP4, which is 
known to bind and distort RNA G-quadruplexes (Morris et al., 2012), was also found to 
result in the disruption of GGGGCC RNA binding to the proteins hnRNPA1 and SF2 (Zamiri 
et al., 2014). These small molecule compounds could therefore also be developed as new 
therapeutic interventions for C9orf72 FTD/ALS.  
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While the above ASOs and small molecules target RNA transcripts and therefore disrupt 
RNA gain-of-function disease mechanisms, they may also affect downstream RAN 
translation of the transcripts and therefore simultaneously disrupt DPR protein gain-of-
function disease mechanisms. This could be beneficial if both RNA gain-of-function and DPR 
protein gain-of-function disease mechanisms are eventually found to be important to the 
progression of C9orf72 FTD/ALS. One study found that immunostaining of poly(GP) was not 
changed in C9orf72 iPSC-derived neurons before or after ASO treatment despite disruption 
of sense RNA foci formation (Donnelly et al., 2013), however this could be attributed to a 
slow turnover of poly(GP), so additional characterisation may be required. As other studies 
investigating ASO treatment have not examined the effect of these molecules on RAN 
translation (Lagier-Tourenne et al., 2013; Sareen et al., 2013), it remains to be determined 
how this treatment affects DPR protein expression. 
As ASOs and RNA targeted small molecules may result in the reduction or loss of normal 
C9orf72 protein function due to degradation or steric hindrance of the C9orf72 RNA 
transcripts, the potential of a detrimental C9orf72 loss-of-function effect in patients should 
be investigated. While it was found that use of ASOs to reduce C9orf72 transcript levels in 
mice for 18 weeks was well tolerated and did not produce any characteristic behavioural or 
pathological features characteristic of neurodegeneration (Lagier-Tourenne et al., 2013), it 
is not yet understood how loss-of-function effects might contribute to the disease in 
humans, and whether this may exacerbate symptoms. Future treatment development 
therefore should aim to minimise the impact these molecules have on native C9orf72 
protein in C9orf72 FTD/ALS patients. 
While directly targeting C9orf72 repeats may present a promising strategy for treating 
patients with this mutation, it would not be effective for patients with other sporadic or 
familial forms of FTD or ALS. Future research into the disease mechanisms involved in 
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C9orf72 FTD/ALS and other forms of FTD or ALS may start to uncover points of convergence 
in these pathologies that can then be targeted in order to develop interventions for a much 
larger number of patients. 
6.5.2 Biomarkers for C9orf72 FTD/ALS 
The development of effective treatments for FTD and ALS patients not only requires the 
identification of suitable targets for pharmacological interventions, but also early disease 
detection in patients, and effective monitoring of treatment efficacy in clinical trials. To 
achieve this, clear biomarkers are required to indicate the disease progression in a patient, 
which can take the form of changes in brain imaging, or in a molecular profile in patient 
biological samples. The presence of the C9orf72 repeat expansion can be detected in 
patients using techniques such as repeat-primed PCR or Southern blotting against the 
repeats in patient tissue samples, which will allow patients with a family history of FTD or 
ALS to be screened and treated early in the disease course, providing an opportunity to halt 
disease progression before extensive neurodegeneration occurs.  
To determine the extent of disease progression in a patient and the efficacy of a treatment 
intervention, several markers are available. Brain imaging techniques such as magnetic 
resonance imaging (MRI) or positron emission tomography (PET) can be used to assess the 
degree and pattern of cortical or subcortical grey matter loss. RNA foci formation can also 
be assessed in fibroblast or blood samples from patients with the use of fluorescence in situ 
hybridisation, which may provide a read out of the efficacy of system wide interventions. 
To give a readout of disease progression in the nervous system, a number of secreted 
molecular disease indicators within the CNS are also being investigated: one group found 
that poly(GP) protein can be detected by ELISA assay in the cerebrospinal fluid (CSF) (Su et 
al., 2014). An immunoassay for the detection of poly(GA) has also been developed 
(Gendron et al., 2015; van Blitterswijk et al., 2015) which could be used to determine 
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whether changes in the level of this DPR protein can also be detected in the CSF of C9orf72 
FTD/ALS patients. Additional potentially useful biomarkers have been highlighted by 
another group in the form of secreted CNS proteins found to be upregulated in C9orf72 ALS 
iPSC-derived neurons (Donnelly et al., 2013), however further investigation is required to 
confirm whether the upregulation of these markers can be detected in human patients. As 
work in this thesis implicates arginine-containing DPR proteins as toxic species in C9orf72 
FTD/ALS pathology, these proteins could provide a helpful marker of disease progression, 
therefore future development of immunoassays for quantifying the levels of poly(GR) and 
poly(PR) in patient CSF may be beneficial. 
6.6  Conclusion 
The discovery of the C9orf72 repeat expansion has revolutionised our understanding of 
both ALS and FTD, and has provided a host of interesting new research avenues that will 
not only enhance our understanding of disease course in patients with the repeat 
expansion, but also of all ALS and FTD cases, and of neurodegeneration in general.  This 
project focussed on dissecting RNA and DPR protein gain-of-function mechanisms in 
C9orf72 FTD/ALS, and has highlighted arginine-containing DPR protein toxicity as a 
potentially important mechanism in C9orf72 FTD/ALS, which could be mediated in part by 
disruption of nucleolar function. A range of different DNA constructs and image analysis 
tools have also been produced in this work that can be adapted and repurposed in future 
for further dissection of RNA and DPR protein gain-of-function mechanisms in model 
organisms and in patient tissue. A great number of questions still remain to be answered 
about the pathological mechanisms at work in C9orf72 FTD/ALS and new discoveries often 
seem to lead to more questions than answers. However, in this fast moving field, 
breakthroughs in our understanding are sure to be imminent, moving us closer towards the 
ultimate goal of developing effective treatments for ALS and FTD. 
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